Bispecific antibody targeting 4-1BB and PD-L1 and medical application thereof
By developing bispecific antibodies targeting 4-1BB and PD-L1, the problem of insufficient hepatotoxicity and efficacy of 4-1BB antibody drugs when activate the 4-1BB signaling pathway is solved, and the immune response and tumor suppression is achieved. Effect.
Patent Information
- Application Number
- CN202410697343.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The existing 4-1BB antibody drugs are prone to hepatotoxicity when activating the 4-1BB signaling pathway, and insufficient activation of the signaling pathway leads to limited tumor killing effect, and lack of drugs that can ensure both safety and efficacy.
A bispecific antibody targeting 4-1BB and PD-L1 was developed to promote T cell proliferation and release of IL-2 and IFNγ through its bispecific binding against 4-1BB and PD-L1, thereby enhancing immunity. Response, inhibit the occurrence and development of tumors.
This bispecific antibody significantly promotes T cell proliferation and immune response, has good thermal stability and affinity, can effectively inhibit the occurrence and development of tumors, and reduce the risk of hepatotoxicity.
Smart Images

Figure CN119060192A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application is based on an application with CN application number 202310647240.X and filing date June 1, 2023, and claims priority. The entire contents of the CN application are hereby introduced as a whole into this application. Technical Field
[0003] The present invention belongs to the field of biomedicine and relates to a bispecific antibody. Specifically, the present invention relates to a bispecific antibody targeting tumor necrosis factor receptor superfamily 9 (TNFRSF9 / 4-1BB) and programmed death protein ligand-1 (PD-L1), a polynucleotide encoding the bispecific antibody of the present invention, a vector and a host cell for expressing the bispecific antibody of the present invention, and the use of the bispecific antibody of the present invention in the treatment, prevention and / or diagnosis of diseases related to 4-1BB activity and PD-L1 activity. Background Art
[0004] Cancer immunotherapy is a treatment approach that restores or enhances the body's natural defenses against tumors through the body's immune system. This treatment is often targeted to specific biomolecules on the surface of cancer cells, such as tumor-associated antigens (TAAs). Anti-tumor activity is achieved by directing the host immune system to TAAs, thereby establishing or inducing an adaptive immune response against cancer cells. Over the past few decades, the use of monoclonal antibodies (MAbs) to treat cancer has achieved great success, and many of them have been approved for cancer treatment or are in clinical trials.
[0005] Immune checkpoints are a type of inhibitory signaling molecules in the immune system that prevent tissue damage by regulating the persistence and intensity of immune responses in peripheral tissues and participate in maintaining tolerance to self-antigens. Studies have found that one of the reasons why tumor cells can evade the body's immune system and proliferate uncontrollably is that they utilize the inhibitory signaling pathway of immune checkpoints, thereby inhibiting the activity of T lymphocytes, making it impossible for T lymphocytes to effectively kill tumors.
[0006] Programmed cell death protein ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7homolog1, B7-H1), belongs to the tumor necrosis factor superfamily. It is a type I transmembrane glycoprotein composed of 290 amino acid residues, including an IgV-like region, an IgC-like region, a transmembrane hydrophobic region and a 30-amino acid intracellular tail, with a complete molecular weight of 40kDa1. PD-L1mRNA is expressed in almost all tissues, but PD-L1 protein is only continuously expressed in a few tissues, including liver, lungs, tonsils, and immune-specialized tissues such as eyes and placenta. PD-L1 is also expressed in activated T cells, B cells, monocytes, dendritic cells, macrophages, etc. The receptor of PD-L1 is PD-1, which is mainly expressed on the surface of immune cells such as CD4+T cells, CD8+T cells, NKT cells, B cells and activated monocytes. PD-1 / PD-L1 is a very common group of immune checkpoint molecules, and PD-1 / PD-L1 pathway inhibitors can block the binding of PD-1 and PD-L1, block negative regulatory signals, restore T cell activity, and thus enhance immune response. Therefore, immune regulation targeting PD-1 / PD-L1 is of great significance for tumor suppression.
[0007] 4-1BB (CD137 / TNFRSF9) is a transmembrane protein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). 4-1BB is expressed on the cell surface as a monomer or dimer. After binding to its ligand (4-1BBL), it conducts downstream pathway signaling through trimerization, triggering the secretion of IL-2 and IFN-γ, enhancing the immune response of T cells; at the same time, it upregulates the activity of Bcl-2 family proteins to reduce the partial death of T cells due to activation.
[0008] At present, there are many 4-1BB antibody drugs under development around the world. In existing 4-1BB antibody drug studies, it is common to overactivate the 4-1BB signaling pathway, leading to enrichment of CD8+T cells in the liver and causing reports of liver toxicity; in some studies, despite good safety, the 4-1BB signaling pathway is not activated enough, resulting in limited tumor killing effects. Therefore, on the basis of ensuring the appropriateness of the 4-1BB signaling pathway, there is still an urgent need to reduce the systemic toxicity of 4-1BB antibody drugs, especially liver toxicity, in order to obtain 4-1BB antibody drugs with both safety and efficacy. Bispecific antibodies are an effective way to reduce toxicity. Currently, the world's fastest-progressing 4-1BB and PD-L1 bispecific antibody GEN1046 (Genmab, clinical number NCT03917381) has been used in a Phase I / II clinical trial to treat solid tumors with positive results, and the disease control rate (DCR) reached 65.6%. Summary of the invention
[0009] After in-depth research and creative work, the inventors have obtained a bispecific antibody against 4-1BB and PD-L1. The inventors were surprised to find that the bispecific antibody has good anti-tumor potential. Furthermore, the inventors have also prepared a pharmaceutical composition comprising the bispecific antibody. The following invention is provided:
[0010] One aspect of the present invention relates to a bispecific antibody comprising a first protein functional region and a second protein functional region, wherein:
[0011] The first protein functional region is an anti-4-1BB antibody or an antigen-binding fragment thereof,
[0012] The second protein functional region is an antibody or an antigen-binding fragment thereof that targets a target different from 4-1BB,
[0013] Wherein, the anti-4-1BB antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 with an amino acid sequence as shown in SEQ ID NO: 1, HCDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and HCDR3 with an amino acid sequence as shown in SEQ ID NO: 3, and the light chain variable region comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 4, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 5, and LCDR3 with an amino acid sequence as shown in SEQ ID NO: 6.
[0014] In some embodiments of the present invention, the bispecific antibody, wherein
[0015] The amino acid sequence of the heavy chain variable region of the anti-4-1BB antibody is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.
[0016] In some embodiments of the present invention, in the bispecific antibody, the second protein functional region is an anti-PD-L1 antibody or an antigen-binding fragment thereof, or an anti-PD-1 antibody or an antigen-binding fragment thereof.
[0017] In some embodiments of the present invention, the bispecific antibody, the anti-PD-L1 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO:31, HCDR2 as shown in SEQ ID NO:32, and HCDR3 as shown in SEQ ID NO:33, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO:34, LCDR2 as shown in SEQ ID NO:35, and LCDR3 as shown in SEQ ID NO:36.
[0018] In some embodiments of the present invention, the bispecific antibody, wherein
[0019] The amino acid sequence of the heavy chain variable region of the anti-PD-L1 antibody is shown in SEQ ID NO:37, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:38.
[0020] In some embodiments of the present invention, the bispecific antibody, wherein the anti-4-1BB antibody and / or the antibody targeting a target different from 4-1BB further independently comprises a human heavy chain constant region and a human light chain constant region, and the human heavy chain constant region is independently selected from the heavy chain constant region of human IgG1, human IgG2, human IgG3 or human IgG4;
[0021] Preferably, the human light chain constant region is independently selected from the light chain constant region of a lambda light chain or a kappa light chain;
[0022] Preferably, the human heavy chain constant region is the heavy chain constant region of human IgG4 and has the following mutations:
[0023] (1) S267A or S267C; and
[0024] (2) L328A or L328N;
[0025] Preferably, it further has any one, two, three or four mutations selected from the following (3):
[0026] (3) S268A, S268Q, D270C, P329S and S330T.
[0027] In some embodiments of the present invention, the bispecific antibody, wherein the anti-4-1BB antibody and / or the antibody targeting a target different from 4-1BB further independently comprises an Fc domain of human IgG1, human IgG2, human IgG3 or human IgG4. In some embodiments of the present invention, the bispecific antibody, wherein the amino acid sequence of the Fc domain is as shown in any one of SEQ ID NO: 9 to SEQ ID NO: 17, and SEQ ID NO: 67 to SEQ ID NO: 75;
[0028] Preferably, the amino acid sequence of the heavy chain of the anti-4-1BB antibody is as shown in any one of SEQ ID NO: 18 to SEQ ID NO: 26, and SEQ ID NO: 76 to SEQ ID NO: 84.
[0029] In some embodiments of the present invention, in the bispecific antibody, the antigen-binding fragment is independently selected from VHH, Fab, scFv and sdAb.
[0030] In some embodiments of the present invention, the bispecific antibody, wherein the first protein functional region and the second protein functional region are directly connected or connected through a first connecting fragment;
[0031] Preferably, the first connecting fragment is (GGGGS)n, where n is 1, 2, 3, 4 or 5.
[0032] In some embodiments of the present invention, the bispecific antibody, wherein the heavy chain variable region and the light chain variable region in the scFv (single chain antibody) are directly connected or connected through a second connecting fragment;
[0033] Preferably, the second connecting fragment is (GGGGS)n, where n is 1, 2, 3, 4 or 5.
[0034] In some embodiments of the present invention, the bispecific antibody, wherein the first protein functional region and the second protein functional region are independently 1, 2 or more than 2.
[0035] In some embodiments of the present invention, the bispecific antibody, wherein
[0036] The first protein functional region is an anti-4-1BB antibody, and the second protein functional region is a VHH, Fab, scFv or sdAb targeting PD-L1; or
[0037] The first protein functional region is a VHH, Fab, scFv or sdAb targeting 4-1BB, and the second protein functional region is an anti-PD-L1 antibody.
[0038] In some embodiments of the present invention, the bispecific antibody, wherein
[0039] The bispecific antibody is in the form of IgG-scFv.
[0040] In some embodiments of the present invention, the bispecific antibody, wherein
[0041] The first protein functional region is a scFv targeting 4-1BB, and the second protein functional region is an anti-PD-L1 antibody.
[0042] The number of the first protein functional regions is 2, and the number of the second protein functional region is 1;
[0043] The scFv comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, and HCDR3 as shown in SEQ ID NO: 3, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6;
[0044] The anti-PD-L1 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO:31, HCDR2 as shown in SEQ ID NO:32, and HCDR3 as shown in SEQ ID NO:33, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO:34, LCDR2 as shown in SEQ ID NO:35, and LCDR3 as shown in SEQ ID NO:36;
[0045] The scFv is respectively connected to the C-termini of the two heavy chains of the anti-PD-L1 antibody;
[0046] Preferably, the first protein functional region and the second protein functional region are connected via a first connecting fragment;
[0047] Preferably, the heavy chain variable region and the light chain variable region of the scFv are connected by a second connecting fragment;
[0048] Preferably, the first connecting fragment and the second connecting fragment are independently (GGGGS)n, where n is 1, 2, 3, 4 or 5. GGGGS is represented by SEQ ID NO: 67.
[0049] In some embodiments of the present invention, the bispecific antibody, wherein
[0050] The first protein functional region is a scFv targeting 4-1BB, and the second protein functional region is an anti-PD-L1 antibody.
[0051] The number of the first protein functional regions is 2, and the number of the second protein functional region is 1;
[0052] The scFv comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 8;
[0053] The anti-PD-L1 antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 37, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 38;
[0054] The scFv is respectively connected to the C-termini of the two heavy chains of the anti-PD-L1 antibody;
[0055] Preferably, the first protein functional region and the second protein functional region are connected via a first connecting fragment;
[0056] Preferably, the heavy chain variable region and the light chain variable region of the scFv are connected by a second connecting fragment;
[0057] Preferably, the first connecting fragment and the second connecting fragment are independently (GGGGS)n, and n is 1, 2, 3, 4 or 5.
[0058] In some embodiments of the present invention, the bispecific antibody, wherein
[0059] The first protein functional region is a scFv targeting 4-1BB, and the second protein functional region is an anti-PD-L1 antibody.
[0060] The number of the first protein functional regions is 2, and the number of the second protein functional region is 1;
[0061] The amino acid sequence of the heavy chain variable region of the scFv is shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region of the scFv is shown in SEQ ID NO: 8;
[0062] The amino acid sequence of the heavy chain variable region of the anti-PD-L1 antibody is shown in SEQ ID NO: 37, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 38;
[0063] The scFv is respectively connected to the C-termini of the two heavy chains of the anti-PD-L1 antibody;
[0064] Preferably, the first protein functional region and the second protein functional region are connected via a first connecting fragment;
[0065] Preferably, the heavy chain variable region and the light chain variable region of the scFv are connected by a second connecting fragment;
[0066] Preferably, the first connecting fragment is (GGGGS)n, where n is 2;
[0067] Preferably, the second connecting fragment is (GGGGS)n, where n is 4.
[0068] In the present invention, the "first" (e.g., the first protein functional region, the first connecting fragment) or "second" (e.g., the second protein functional region, the second connecting fragment), unless otherwise specified, is merely for the purpose of distinguishing between references and does not have a particular meaning of order.
[0069] Another aspect of the present invention relates to an isolated polynucleotide encoding the bispecific antibody according to any one of the present invention.
[0070] Another aspect of the present invention relates to a recombinant expression vector, which comprises the isolated polynucleotide of the present invention; preferably, the recombinant expression vector is a recombinant eukaryotic expression vector.
[0071] Another aspect of the present invention relates to a recombinant host cell, which comprises the isolated polynucleotide of the present invention or the recombinant expression vector of the present invention; preferably, the recombinant host cell is a recombinant mammalian cell.
[0072] Another aspect of the present invention relates to the use of the bispecific antibody described in any one of the present invention in the preparation of a medicament for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity; preferably, the disease or condition is cancer.
[0073] In some embodiments of the present invention, the use, wherein the cancer is selected from one or more of lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer and blood cancer.
[0074] Another aspect of the present invention relates to a pharmaceutical composition comprising the bispecific antibody according to any one of the present invention, and a pharmaceutically acceptable carrier or excipient.
[0075] In some embodiments of the present invention, the pharmaceutical composition, wherein the concentration of the bispecific antibody is 0.1 to 100 mg / mL, preferably 0.2 to 50 mg / mL, more preferably 0.5 to 30 mg / mL, more preferably 5 to 25 mg / mL, more preferably 10 to 20 mg / mL.
[0076] In some embodiments of the present invention, the pharmaceutical composition, wherein the pH of the pharmaceutical composition is 4.5 to 7.5, preferably 4.8 to 6.0, and more preferably 5.0 to 5.5.
[0077] In some embodiments of the present invention, the pharmaceutical composition, wherein the osmotic pressure of the pharmaceutical composition is in the range of 250 to 350 mOsm / kg; preferably in the range of 260 to 320 mOsm / kg, and more preferably in the range of 290 to 310 mOsm / kg.
[0078] In some embodiments of the present invention, the pharmaceutical composition comprises a buffer, and the buffer is selected from one or more of acetate buffer, histidine buffer, citrate buffer and phosphate buffer; preferably, the buffer is acetate buffer or citrate buffer; preferably, the buffer is citrate buffer; preferably, the concentration of the buffer is 5-50mM; more preferably, the concentration of the buffer is 10-30mM; preferably, the pH of the buffer is 4.5-7.5, preferably 4.8-6.0, more preferably 5.0-5.8, more preferably 5.2-5.5.
[0079] In some embodiments of the present invention, the pharmaceutical composition, wherein the pharmaceutical composition further comprises a stabilizer, wherein the stabilizer is any one of sodium chloride, arginine hydrochloride, mannitol, sucrose and trehalose, or the stabilizer is a combination of multiple ones of sodium chloride, arginine hydrochloride, mannitol, sucrose and trehalose; preferably, the concentration of the stabilizer is 10-300mM, preferably 20-295mM, 50-290mM, 80-285mM or 120-280mM, more preferably 20-280mM or 120-250mM.
[0080] In some embodiments of the present invention, in the pharmaceutical composition, the stabilizer is selected from any one of the following (1) to (8):
[0081] (1) sodium chloride, at a concentration of 120 to 280 mM, preferably at a concentration of 120 to 160 mM;
[0082] (2) arginine hydrochloride at a concentration of 120 to 280 mM, preferably 120 to 160 mM;
[0083] (3) mannitol, at a concentration of 120 to 280 mM, preferably at a concentration of 200 to 250 mM;
[0084] (4) sucrose, at a concentration of 120 to 280 mM, preferably, at a concentration of 200 to 250 mM;
[0085] (5) trehalose, at a concentration of 120 to 280 mM, preferably, at a concentration of 200 to 250 mM;
[0086] (6) A combination of sucrose and mannitol, wherein the concentration of sucrose is 100-180 mM, and the concentration of mannitol is 60-120 mM; preferably, wherein the concentration of sodium chloride is 120-160 mM, and the concentration of mannitol is 80-100 mM.
[0087] In some embodiments of the present invention, the pharmaceutical composition further comprises a surfactant, and the surfactant is selected from one or more of polysorbate 80, polysorbate 20 and poloxamer 188; preferably, calculated on a w / v basis, the concentration of the surfactant is 0.005% to 0.1%, more preferably, the concentration of the surfactant is 0.01% to 0.08%, more preferably, the concentration of the surfactant is 0.01% to 0.04%.
[0088] In some embodiments of the present invention, the pharmaceutical composition comprises the components shown in any one of the following (1) to (25):
[0089] (1) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or
[0090] (2) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or
[0091] (3) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM histidine buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or
[0092] (4) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM phosphate buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or
[0093] (5) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 200-250 mM sucrose; and (d) 0.01%-0.04% polysorbate 80; or
[0094] (6) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 200-250 mM trehalose; and (d) 0.01%-0.04% polysorbate 80; or
[0095] (7) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 120-200 mM sodium chloride; and (d) 0.01%-0.04% polysorbate 80; or
[0096] (8) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 120-200 mM arginine hydrochloride; and (d) 0.01%-0.04% polysorbate 80; or
[0097] (9) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 200-250 mM sucrose; and (d) 0.01%-0.04% polysorbate 80; or
[0098] (10) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 200-250 mM trehalose; and (d) 0.01%-0.04% polysorbate 80; or
[0099] (11) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 120-200 mM sodium chloride; and (d) 0.01%-0.04% polysorbate 80; or
[0100] (12) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 120-200 mM arginine hydrochloride; and (d) 0.01%-0.04% polysorbate 80; or
[0101] (13) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or
[0102] (14) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM sucrose; and (d) 0.04% polysorbate 80; or
[0103] (15) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM trehalose; and (d) 0.02% polysorbate 80; or
[0104] (16) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 150 mM sodium chloride; and (d) 0.02% polysorbate 80; or
[0105] (17) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 150 mM arginine hydrochloride; and (d) 0.02% polysorbate 80; or
[0106] (18) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or
[0107] (19) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM trehalose; and (d) 0.02% polysorbate 80; or
[0108] (20) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 150 mM sodium chloride; and (d) 0.02% polysorbate 80; or
[0109] (21) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 150 mM arginine hydrochloride; and (d) 0.02% polysorbate 80; or
[0110] (22) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or
[0111] (23) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or
[0112] (24) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or
[0113] (25) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10 mM citric acid buffer, pH 5.3-5.7; (c) 140 mM sucrose; (d) 90 mM mannitol; and (e) 0.02% polysorbate 80.
[0114] Another aspect of the present invention relates to a lyophilized preparation of the pharmaceutical composition.
[0115] The present invention also relates to a reconstituted preparation obtained by reconstituted the lyophilized preparation.
[0116] Another aspect of the present invention relates to a liquid preparation, characterized in that the liquid preparation contains the pharmaceutical composition according to any one of the present invention, or contains a glucose solution or a sodium chloride solution and the reconstituted preparation according to the present invention; preferably, the concentration of the sodium chloride solution is 0.85-0.9% (w / v), and the concentration of the glucose solution is 5-25% (w / v); preferably, in the liquid preparation, the concentration of the bispecific antibody is 0.1-50 mg / mL, more preferably 0.2-20 mg / mL; more preferably 0.2-5 mg / mL; preferably, the pH of the liquid preparation is 5.0-7.0; preferably, the liquid preparation is an injection.
[0117] The pharmaceutical composition of the present invention is a highly stable pharmaceutical composition containing an antibody that specifically binds to 4-1BB and / or PD-L1, comprising: (1) a buffer; and (2) a bispecific antibody targeting 4-1BB and PD-L1.
[0118] The bispecific antibody targeting 4-1BB and PD-L1 in the pharmaceutical composition of the present invention is as described in any embodiment of the “Bispecific antibody targeting 4-1BB and PD-L1” section of the present application.
[0119] The concentration of the bispecific antibody targeting 4-1BB and PD-L1 in the pharmaceutical composition of the present invention is about 0.1-100 mg / mL, preferably about 0.2-50 mg / mL, more preferably about 0.5-30 mg / mL, more preferably about 10-20 mg / mL; preferably, the concentration of the bispecific antibody targeting 4-1BB and PD-L1 is about 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, 9 mg / mL, 10mg / mL, 11mg / mL, 12mg / mL, 13mg / mL, 14mg / mL, 15mg / mL, 16mg / mL, 17mg / mL, 18mg / mL, 19mg / mL, 20mg / mL, 25mg / mL, 30mg / mL, 35mg / mL, 40mg / mL, 45mg / mL or 50mg / mL, more preferably 1 mg / mL, 5mg / mL, 10mg / mL, 15mg / mL, 20mg / mL, 25mg / mL or 30mg / mL.
[0120] The buffer in the pharmaceutical composition of the present invention is selected from one or more of acetate buffer, citrate buffer, phosphate buffer and histidine buffer; preferably, the buffer is acetate buffer or citrate buffer; preferably, the buffer is citrate buffer. Preferably, the buffer is acetate buffer or citrate buffer; preferably, the buffer is citrate buffer; preferably, the concentration of the buffer is about 5 to 50 mM; more preferably, the concentration of the buffer is about 10 to 30 mM; preferably, the pH of the buffer is about 4.5 to 7.5, preferably about 4.8 to 6.0, more preferably about 5.0 to 5.8, more preferably about 5.2 to 5.5. Herein, non-limiting examples of the pH of the buffer are about 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4 and 7.5, preferably about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7 or 5.8.
[0121] Therefore, the pharmaceutical composition of the present invention may contain: a citric acid buffer having a pH of about 4.8 to 6.0, the concentration of which in the pharmaceutical composition is about 10 to 30 mM; and about 0.2 to 50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1 described in any of the above embodiments. Preferably, the heavy chain amino acid sequence of the humanized antibody is as shown in SEQ ID NO: 37, and the light chain amino acid sequence is as shown in SEQ ID NO: 38.
[0122] Therefore, the pharmaceutical composition of the present invention may contain: a citric acid buffer having a pH of about 4.8 to 6.0, the concentration of which in the pharmaceutical composition is about 10 to 30 mM; and about 0.2 to 50 mg / mL of a bispecific antibody targeting 4-1BB and PD-L1 as described in any of the above embodiments; and about 10 to 300 mM of a stabilizer, preferably, the stabilizer is selected from one or more of arginine, arginine salt, sodium chloride, mannitol, sorbitol, sucrose, glycine and trehalose. Preferably, the stabilizer is sucrose or trehalose. Preferably, the stabilizer is sucrose or trehalose at a concentration of about 120 to 280 mM; preferably, the stabilizer is a combination of sucrose and mannitol. Preferably, the stabilizer is sucrose at a concentration of about 100 to 180 mM and mannitol at a concentration of about 60 to 120 mM.
[0123] In some embodiments, the pharmaceutical composition further comprises a surfactant, and the surfactant is selected from one or more of polysorbate 80, polysorbate 20 and poloxamer 188. Preferably, the concentration of the surfactant is about 0.001% to 0.1%, preferably about 0.005% to 0.1%, more preferably about 0.01% to 0.08%, more preferably about 0.01% to 0.04%, more preferably about 0.01% to 0.02%, and most preferably about 0.02%, calculated by w / v.
[0124] Therefore, the pharmaceutical composition of the present invention may contain: a citric acid buffer having a pH of about 5.0 to 7.0, the concentration of which in the pharmaceutical composition is about 10 to 30 mM; about 0.2 to 50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1 as described in any of the foregoing embodiments; and about 0.01% to 0.04% polysorbate 80 on a w / v basis.
[0125] In some embodiments, the pharmaceutical composition as described above comprises a histidine buffer, and the histidine buffer is a histidine-histidine hydrochloride buffer. In some embodiments, the above-mentioned histidine-histidine hydrochloride buffer is made of histidine and histidine hydrochloride, preferably L-histidine and L-histidine monohydrochloride. In some embodiments, the histidine buffer is made of 1 to 30 mM L-histidine and 1 to 30 mM L-histidine monohydrochloride. In some embodiments, the histidine buffer is made of histidine and histidine hydrochloride in a molar ratio of 1:1 to 1:4. In some embodiments, the histidine buffer is made of histidine and histidine hydrochloride in a molar ratio of about 1:1. In some embodiments, the histidine buffer is made of histidine and histidine hydrochloride in a molar ratio of about 1:3. In some embodiments, the histidine preparation is: a histidine buffer with a pH of about 5.5 made of about 4.5 mM L-histidine and about 15.5 mM L-histidine monohydrochloride. In some embodiments, the histidine preparation is a histidine buffer having a pH of about 5.5 made from about 7.5 mM L-histidine and about 22.5 mM L-histidine monohydrochloride. In some embodiments, the histidine preparation is a histidine buffer having a pH of about 6.0 made from about 10 mM histidine and about 10 mM histidine hydrochloride. In some embodiments, the histidine preparation is a histidine buffer having a pH of about 6.5 made from about 14.7 mM L-histidine and about 5.3 mM L-histidine monohydrochloride.
[0126] In some embodiments, the pharmaceutical composition as described above comprises an acetate buffer, preferably, the acetate buffer is an acetate-sodium acetate buffer or an acetate-potassium acetate buffer, preferably an acetate-sodium acetate buffer. In some embodiments, the acetate buffer is made of 1 to 30 mM acetic acid and 1 to 30 mM sodium acetate. In some embodiments, the acetate buffer is made of acetic acid and sodium acetate in a molar ratio of about 1:2.1. In some embodiments, the acetate buffer is made of acetic acid and sodium acetate in a molar ratio of about 1:3.8. In some embodiments, the acetate buffer is made of acetic acid and sodium acetate in a molar ratio of about 1:5.7. In some embodiments, the acetate buffer is: an acetate buffer with a pH of about 5.0 made of about 6.5 mM acetic acid and about 13.5 mM sodium acetate. In some embodiments, the acetate buffer is: an acetate buffer with a pH of about 5.1 made of about 4.3 mM acetic acid and about 16.2 mM sodium acetate. In some embodiments, the acetate buffer is an acetate buffer with a pH of about 5.5 made from about 3 mM acetic acid and about 17 mM sodium acetate. In some embodiments, the acetate buffer is an acetate buffer with a pH of about 4.7 made from about 11 mM acetic acid and about 9 mM sodium acetate. In some embodiments, the acetate buffer is an acetate buffer with a pH of about 5.3 made from about 5.7 mM acetic acid and about 14.3 mM sodium acetate. In some embodiments, the acetate buffer is an acetate buffer with a pH of about 5.2 made from about 5.0 mM acetic acid and about 15.0 mM sodium acetate.
[0127] In some embodiments, the pharmaceutical composition as described above comprises a citric acid buffer, preferably, the citric acid buffer is a citric acid-sodium citrate buffer. In some embodiments, the citric acid buffer is made of 1 to 30 mM citric acid and 1 to 30 mM sodium citrate. In some embodiments, the citric acid buffer is made of citric acid and sodium citrate in a molar ratio of about 1:1 to 1:4. In some embodiments, the citric acid buffer is: a citric acid buffer with a pH of about 6.5 made from about 5.0 mM citric acid and about 15.0 mM sodium citrate. In some embodiments, the citric acid buffer is: a citric acid buffer with a pH of about 6.0 made from about 10 mM citric acid and about 10 mM sodium citrate. In some embodiments, the citric acid buffer is: a citric acid buffer with a pH of about 5.0 made from about 7.6 mM citric acid and about 12.4 mM sodium citrate. In some embodiments, the citrate buffer is a citrate buffer having a pH of about 5.5 made from about 5.3 mM citric acid and about 14.7 mM sodium citrate.
[0128] In some embodiments, the pharmaceutical composition as described above comprises a buffer, and the concentration of the buffer is about 1-100 mM, preferably about 5-50 mM, preferably about 10-30 mM; preferably about 15-25 mM; non-limiting examples of the above buffer concentration are about 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM or a range formed by any two values within these ranges as endpoints, preferably about 5 mM, 10 mM, 15 mM, 20 mM or 25 mM.
[0129] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, wherein the concentration of the stabilizer is about 10-300 mM, preferably about 20-295 mM, 50-290 mM, 80-285 mM or 120-280 mM, more preferably about 20-280 mM or 120-250 mM; non-limiting examples of the concentration of the stabilizer are about 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 150 mM, 160 mM, 170 mM, 175 mM, 180 mM, 180 mM, 190 mM, 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM, 280 mM, 290 mM, 300 mM, 310 mM, 320 mM, 330 mM, 340 mM, 350 mM, 360 mM, 370 mM, 380 mM, 390 mM, 400 mM, 410 mM, 420 mM, 430 mM, 440 mM, 450 mM, 460 mM, 470 mM, 480 mM, 490 mM, 500 mM, 510 mM, 520 mM, 530 mM, 540 mM, 550 mM, 560 mM, 570 mM, 580 mM, 590 mM, 610 mM, 620 mM, 630 mM, 640 The present invention relates to a range of about 100 mM, 150 mM, 160 mM, 170 mM, 180 mM, 185 mM, 190 mM, 195 mM, 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM or a range formed by any two values within these ranges as endpoints, preferably about 135 mM, 140 mM, 145 mM, 150 mM, 155 mM, 200 mM, 210 mM, 220 mM, 230 mM, 240 mM or 250 mM.
[0130] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, and the stabilizer is trehalose. In some embodiments, the above stabilizer is trehalose at a concentration of about 100 to 300 mM, preferably about 120 to 280 mM, and more preferably about 200 to 250 mM; non-limiting examples of the above trehalose concentration are about 180 mM, 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM or 280 mM, preferably about 220 mM or 230 mM or 240 mM. Preferably, the above pharmaceutical composition further comprises (a) about 10 to 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 to 20 mM citric acid buffer, pH of about 5.4 to 5.6; (c) about 0.02% polysorbate 80.
[0131] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, and the stabilizer is sucrose. In some embodiments, the above-mentioned stabilizer is sucrose with a concentration of about 100-300mM, and the concentration of the above-mentioned sucrose is preferably about 120-280mM, and more preferably 200-250mM; non-limiting examples of the above-mentioned sucrose concentration are about 180mM, 200mM, 210mM, 220mM, 230mM, 240mM, 250mM, 260mM, 270mM or 280mM, preferably about 220mM or 230mM or 240mM. Preferably, the above-mentioned pharmaceutical composition also includes (a) about 10-20mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10-20mM citric acid buffer, pH of about 5.4-5.6; (c) about 0.02% polysorbate 80.
[0132] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, and the stabilizer is arginine or an arginine salt; preferably, the arginine salt is arginine hydrochloride. In some embodiments, the stabilizer is arginine or an arginine salt at a concentration of about 100 to 300 mM, preferably about 120 to 280 mM, more preferably about 120 to 160 mM; non-limiting examples of the concentration of the arginine or arginine salt are about 110 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 150 mM, 155 mM, 160 mM, 170 mM and 180 mM, preferably about 140 mM, 145 mM, 150 mM or 155 mM. Preferably, the above-mentioned pharmaceutical composition further comprises (a) about 10 to 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 to 20 mM citric acid buffer with a pH of about 5.4 to 5.6; and (c) about 0.02% polysorbate 80.
[0133] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, and the stabilizer is sodium chloride. In some embodiments, the stabilizer is sodium chloride with a concentration of about 100-300 mM, preferably about 120-280 mM, more preferably 120-160 mM, and non-limiting examples of the sodium chloride concentration are about 110 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 150 mM, 155 mM, 160 mM, 170 mM and 180 mM, preferably about 140 mM, 145 mM, 150 mM or 155 mM. Preferably, the above-mentioned pharmaceutical composition further comprises (a) about 10 to 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 to 20 mM citric acid buffer with a pH of about 5.4 to 5.6; and (c) about 0.02% polysorbate 80.
[0134] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, and the stabilizer is mannitol. In some embodiments, the above-mentioned stabilizer is mannitol with a concentration of about 100-300mM, and the concentration of the above-mentioned mannitol is preferably about 120-280mM, more preferably 200-250mM; non-limiting examples of the above-mentioned mannitol concentration are about 180mM, 200mM, 210mM, 220mM, 230mM, 240mM, 250mM, 260mM, 270mM or 280mM, preferably about 220mM or 230mM or 240mM. Preferably, the above-mentioned pharmaceutical composition further comprises (a) about 10 to 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 to 20 mM citric acid buffer with a pH of about 5.4 to 5.6; and (c) about 0.02% polysorbate 80.
[0135] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, and the stabilizer is sorbitol. In some embodiments, the stabilizer is sorbitol at a concentration of about 100 to 300 mM, preferably about 120 to 280 mM, more preferably 200 to 250 mM; non-limiting examples of the sorbitol concentration are about 180 mM, 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM or 280 mM, preferably about 220 mM, 230 mM or 240 mM. Preferably, the above-mentioned pharmaceutical composition further comprises (a) about 10 to 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 to 20 mM citric acid buffer with a pH of about 5.4 to 5.6; and (c) about 0.02% polysorbate 80.
[0136] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, which is a combination of sucrose and mannitol. In some embodiments, the stabilizer is a combination of about 20 to 280 mM sucrose and about 20 to 280 mM mannitol, preferably a combination of about 100 to 180 mM sucrose and about 60 to 120 mM mannitol, preferably a combination of about 120 to 160 mM sucrose and about 80 to 100 mM mannitol, and a non-limiting example of the stabilizer is about 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM or 150 mM sucrose and about 80 mM, 85 mM, 90 mM, 95 mM or 100 mM mannitol. Preferably, the above-mentioned pharmaceutical composition further comprises (a) about 5 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 mM acetate buffer with a pH of about 5.4 to 5.6; and (c) about 0.02% polysorbate 80.
[0137] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, which is a combination of sucrose and sodium chloride. In some embodiments, the stabilizer is a combination of about 20-280mM sucrose and about 20-280mM sodium chloride, preferably a combination of about 100-180mM sucrose and about 60-120mM sodium chloride, preferably a combination of about 120-160mM sucrose and about 80-100mM sodium chloride, and a non-limiting example of the stabilizer is about 120mM, 125mM, 130mM, 135mM, 140mM, 145mM or 150mM sucrose and about 80mM, 85mM, 90mM, 95mM or 100mM sodium chloride. Preferably, the above-mentioned pharmaceutical composition further comprises (a) about 5 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 mM acetate buffer with a pH of about 5.4 to 5.6; and (c) about 0.02% polysorbate 80.
[0138] In some embodiments, the pharmaceutical composition as described above comprises a stabilizer, and the stabilizer is a combination of trehalose and mannitol. In some embodiments, the stabilizer is a combination of about 20 to 280 mM trehalose and about 20 to 280 mM mannitol, preferably a combination of about 100 to 180 mM trehalose and about 60 to 120 mM mannitol, preferably a combination of about 120 to 160 mM trehalose and about 80 to 100 mM mannitol, and a non-limiting example of the stabilizer is about 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM or 150 mM trehalose and about 80 mM, 85 mM, 90 mM, 95 mM or 100 mM mannitol. Preferably, the above-mentioned pharmaceutical composition further comprises (a) about 5 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) about 10 mM acetate buffer with a pH of about 5.4 to 5.6; and (c) about 0.02% polysorbate 80.
[0139] Another aspect of the present invention relates to an anti-4-1BB antibody or an antigen-binding fragment thereof, wherein:
[0140] The anti-4-1BB antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO:1, HCDR2 as shown in SEQ ID NO:2, and HCDR3 as shown in SEQ ID NO:3, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO:4, LCDR2 as shown in SEQ ID NO:5, and LCDR3 as shown in SEQ ID NO:6;
[0141] The anti-4-1BB antibody comprises a human heavy chain constant region and a human light chain constant region, wherein the human heavy chain constant region is selected from the heavy chain constant region of human IgG1, human IgG2, human IgG3 or human IgG4;
[0142] Preferably, the human light chain constant region is independently selected from the light chain constant region of a lambda light chain or a kappa light chain;
[0143] Preferably, the human heavy chain constant region is the heavy chain constant region of human IgG4 and has the following mutations:
[0144] (1) S267A or S267C; and
[0145] (2) L328A or L328N;
[0146] Preferably, it further has any one, two, three or four mutations selected from the following (3):
[0147] (3) S268A, S268Q, D270C, P329S and S330T.
[0148] In some embodiments of the present invention, the anti-4-1BB antibody or antigen-binding fragment thereof, wherein:
[0149] The amino acid sequence of the heavy chain variable region of the anti-4-1BB antibody is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.
[0150] In some embodiments of the present invention, the anti-4-1BB antibody or antigen-binding fragment thereof, wherein the anti-4-1BB antibody comprises the Fc domain of human IgG1, human IgG2, human IgG3 or human IgG4;
[0151] The amino acid sequence of the Fc domain is shown in any one of SEQ ID NO: 9 to SEQ ID NO: 17, and SEQ ID NO: 67 to SEQ ID NO: 75.
[0152] In some embodiments of the present invention, the anti-4-1BB antibody or antigen-binding fragment thereof, wherein:
[0153] The amino acid sequence of the heavy chain of the anti-4-1BB antibody is shown in any one of SEQ ID NO: 18 to SEQ ID NO: 26, and SEQ ID NO: 76 to SEQ ID NO: 84.
[0154] In some embodiments of the present invention, the anti-4-1BB antibody or its antigen-binding fragment, wherein the antigen-binding fragment is independently selected from VHH, Fab, scFv and sdAb.
[0155] Another aspect of the present invention relates to an isolated polynucleotide encoding the anti-4-1BB antibody or antigen-binding fragment thereof according to any one of the present invention.
[0156] Another aspect of the present invention relates to a recombinant expression vector, which comprises the isolated polynucleotide of the present invention; preferably, the recombinant expression vector is a recombinant eukaryotic expression vector.
[0157] Another aspect of the present invention relates to a recombinant host cell, which comprises the isolated polynucleotide of the present invention or the recombinant expression vector of the present invention; preferably, the recombinant host cell is a recombinant mammalian cell.
[0158] Another aspect of the present invention relates to the use of the anti-4-1BB antibody or antigen-binding fragment thereof according to any one of the present invention in the preparation of a medicament for treating and / or preventing a disease or condition associated with 4-1BB activity; preferably, the disease or condition is cancer.
[0159] In some embodiments of the present invention, the use, wherein the cancer is selected from one or more of lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer and blood cancer.
[0160] Another aspect of the present invention relates to a pharmaceutical composition comprising the anti-4-1BB antibody or antigen-binding fragment thereof according to any one of the present invention, and a pharmaceutically acceptable carrier or excipient.
[0161] The present invention also relates to at least one of the following aspects:
[0162] The present invention provides a bispecific antibody targeting tumor necrosis factor receptor superfamily-9 (4-1BB / CD137 / TNFRSF9) and programmed death protein ligand-1 (PD-L1) and its use in the treatment, prevention and / or diagnosis of diseases associated with 4-1BB activity and PD-L1 activity. The bispecific antibody provided by the present invention can be used as an independent therapy or in combination with other therapies / or other anticancer agents for the treatment of cancer.
[0163] In another aspect, the present invention provides a bispecific antibody or an antigen-binding fragment thereof targeting 4-1BB and PD-L1, comprising
[0164] (a) 4-1BB antigen binding fragment,
[0165] (b) an immunoglobulin Fc domain, and
[0166] (c) PD-L1 antigen binding fragment.
[0167] In some embodiments, the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 described in the present invention, wherein the 4-1BB antigen-binding fragment comprises HCDR1, HCDR2 and HCDR3 whose amino acid sequences are respectively identical to the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, or have one mutation selected from deletion, insertion or substitution, and LCDR1, LCDR2 and LCDR3 whose amino acid sequences are respectively identical to the amino acid sequences shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, or have one mutation selected from deletion, insertion or substitution.
[0168] In some embodiments, the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 described in the present invention, wherein the 4-1BB antigen-binding fragment comprises a heavy chain variable region that is identical to the amino acid sequence shown in SEQ ID NO:7 or has 1, 2 or 3 mutations selected from deletion, insertion or substitution, and a light chain variable region that is identical to the amino acid sequence shown in SEQ ID NO:8 or has 1, 2 or 3 mutations selected from deletion, insertion or substitution.
[0169] In some embodiments, in the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 described in the present invention, the Fc domain is of IgG1 type, IgG2 type or IgG3 type.
[0170] In some embodiments, in the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 described in the present invention, the Fc domain is of IgG4 type.
[0171] In some embodiments, the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 described in the present invention, wherein the immunoglobulin Fc domain is selected from an amino acid sequence that is identical to SEQ ID NO: 9-18 or has 1, 2, 3, 4 or 5 mutations selected from deletion, insertion or substitution.
[0172] In some embodiments, the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 described in the present invention, wherein the PD-L1 antigen-binding fragment comprises HCDR1, HCDR2 and HCDR3, which are respectively identical to the amino acid sequences shown in SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33, or have one mutation selected from deletion, insertion or substitution, and LCDR1, LCDR2 and LCDR3, whose amino acid sequences are respectively identical to the amino acid sequences shown in SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36, or have one mutation selected from deletion, insertion or substitution.
[0173] In some embodiments, the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 described in the present invention, wherein the PD-L1 antigen-binding fragment comprises a heavy chain variable region that is identical to the amino acid sequence shown in SEQ ID NO: 37 or has 1, 2 or 3 mutations selected from deletion, insertion or substitution and a light chain variable region that is identical to the amino acid sequence shown in SEQ ID NO: 38 or has 1, 2 or 3 mutations selected from deletion, insertion or substitution.
[0174] In some embodiments, the bispecific antibody or antigen-binding fragment thereof targeting 4-1BB and PD-L1 of the present invention comprises
[0175] (a) 4-1BB antigen binding fragment;
[0176] (b) an immunoglobulin Fc domain; and
[0177] (c) PD-L1 antigen binding fragment;
[0178] The connection sequence from N-terminus to C-terminus is N'-(a)-(b)-(c)-C' or N'(c)-(b)-(a)-C'; preferably, the 4-1BB antigen-binding fragment and the PD-L1 antigen-binding fragment are independently selected from VHH, Fab, scFv or sdAb.
[0179] In some embodiments, the antibody or antigen-binding fragment thereof targeting 4-1BB of the present invention comprises a heavy chain and a light chain, wherein the heavy chain is an amino acid sequence identical to SEQ ID NO: 28 or SEQ ID NO: 29 or having 1, 2, 3, 4 or 5 mutations selected from deletion, insertion or substitution, and the light chain is an amino acid sequence identical to SEQ ID NO: 30 or having 1, 2, 3, 4 or 5 mutations selected from deletion, insertion or substitution.
[0180] In some embodiments, the antibodies or antigen-binding fragments thereof described herein have one or more of the following characteristics:
[0181] (1) Specific binding to 4-1BB;
[0182] (2) Specific binding to PD-L1;
[0183] (3) blocking the PD-1 / PD-L1 interaction;
[0184] (4) Strong endocytic activity;
[0185] (5) Promote the release of IL-2 and / or IFNγ.
[0186] In another aspect, the present invention provides a polynucleotide encoding the antibody or antigen-binding fragment thereof as described above.
[0187] In another aspect, the present invention provides an expression vector comprising the polynucleotide as described above, preferably, the expression vector is a eukaryotic expression vector.
[0188] In another aspect, the present invention provides a host cell comprising the polynucleotide or expression vector as described above. Preferably, the host cell is a mammalian cell.
[0189] In another aspect, the present invention provides a method for preparing the antibody or antigen-binding fragment thereof as described above, the method comprising expressing the antibody or antigen-binding fragment thereof in the host cell described above under conditions suitable for the expression of the antibody or antigen-binding fragment thereof, and recovering the expressed antibody or antigen-binding fragment thereof from the host cell.
[0190] In another aspect, the present invention provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, and a pharmaceutically acceptable carrier or excipient as described above.
[0191] In another aspect, the present invention provides the use of the antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, or pharmaceutical composition as described above in the preparation of a medicament for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity; preferably, the disease or condition is cancer; more preferably, the cancer is selected from lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer, and blood cancer.
[0192] In another aspect, the present invention provides an antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, or a pharmaceutical composition as described above, for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity, preferably the disease or condition is cancer; preferably, the disease or condition is cancer; more preferably, the cancer is selected from lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer, and blood cancer.
[0193] In another aspect, the present invention provides a method for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity, comprising administering to a subject in need thereof an antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, or a pharmaceutical composition as described above; preferably, the disease or condition is cancer; more preferably, the cancer is selected from lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer, and blood cancer.
[0194] In another aspect, the present invention provides a kit comprising the antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, or pharmaceutical composition as described above.
[0195] In another aspect, the present invention also provides an immunoconjugate comprising the antibody or antigen-binding fragment thereof described herein conjugated to a therapeutic agent or a diagnostic agent.
[0196] In another aspect, the present invention provides a combination product comprising an antibody or antigen-binding fragment thereof as described herein, an immunoconjugate as described herein, or a pharmaceutical composition as described herein, and one or more additional therapeutic agents.
[0197] In another aspect, the present invention provides a method for detecting the presence of 4-1BB or PD-L1 in a sample using the antibody or antigen-binding fragment thereof as described herein.
[0198] The bispecific antibody of the present invention has a strong affinity to the 4-1BB protein and the PD-L1 protein, has good thermal stability, and can significantly promote T cell proliferation and the release of IL-2 and IFNγ, thereby enhancing the immune response and inhibiting the occurrence and development of tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0199] Figure 1 : Schematic diagram of the molecular structure of the bispecific antibodies K2 or K2F targeting 4-1BB or PD-L1.
[0200] Figure 2 : Confirmation of disulfide bond formation of human IgG4 Fc-mutated bispecific antibodies targeting 4-1BB or PD-L1.
[0201] Figure 3 : The luciferase reporter gene system was used to detect the signal transduction activity of human IgG4Fc mutated 4-1BB antibody in CHO FcGR2B4G6 / Jurkat NFKB 4-1BB dual cells.
[0202] Figure 4 : The luciferase reporter gene system was used to detect the signaling activity of bispecific antibodies K2 and K2F targeting 4-1BB and PD-L1 in CHO FcGR2B 4G6 / Jurkat NFKB 4-1BB dual cells.
[0203] Figure 5 : The luciferase reporter gene system was used to detect the signaling activity of bispecific antibodies K2 and K2F targeting 4-1BB and PD-L1 in CHO PD-L1 / Jurkat NFKB 4-1BB dual cells.
[0204] Figure 6 : Bispecific antibodies targeting 4-1BB or PD-L1 bind to human 4-1BB on the surface of Jurkat NFKB 4-1BB cells.
[0205] Figure 7 : Bispecific antibodies targeting 4-1BB or PD-L1 bind to human PD-L1 on the surface of Jurkat NFKB 4-1BB cells.
[0206] Figure 8 : Bispecific antibodies targeting 4-1BB or PD-L1 block the PD-1 / PD-L1 interaction activity of CHO PD-L1 cells.
[0207] Fig. 9 : The luciferase reporter gene system was used to detect the 4-1BB signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in CHOPD-L1 / Jurkat NFKB 4-1BB dual cells, MC38PD-L1 / Jurkat NFKB 4-1BB dual cells, HCC827PD-L1 / Jurkat NFKB 4-1BB dual cells or MDA-MB-231 / Jurkat NFKB 4-1BB dual cells.
[0208] FIG. 10A to FIG. 10F: The luciferase reporter gene system was used to detect the 4-1BB signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in 6 dual-cell systems. Fig. 10A : The luciferase reporter gene system was used to detect the 4-1BB signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in CHO PD-L1 / Jurkat NFKB 4-1BB dual cells. Fig. 10B : The luciferase reporter gene system was used to detect the signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in MC38PD-L1 / Jurkat NFKB 4-1BB dual cells. Fig. 10C : The luciferase reporter gene system was used to detect the 4-1BB signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in HCC827PD-L1 / Jurkat NFKB 4-1BB dual cells. Fig. 10D : The luciferase reporter gene system was used to detect the 4-1BB signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in CHOPD-L1 / Jurkat NFKB 4-1BB-SP dual cells. Fig. 10E : The luciferase reporter gene system was used to detect the signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in MC38PD-L1 / Jurkat NFKB 4-1BB-SP dual cells. Fig.10F : The luciferase reporter gene system was used to detect the 4-1BB signaling activity of bispecific antibodies targeting 4-1BB or PD-L1 in HCC827PD-L1 / Jurkat NFKB 4-1BB-SP dual cells.
[0209] FIG. 11A to FIG. 11D : Bispecific antibodies targeting 4-1BB or PD-L1 promote the secretion of IL-2 and IFNγ by human lymphocytes.
[0210] Fig.12 : Bispecific antibodies targeting 4-1BB or PD-L1 inhibit the growth of MC3-B7H1 tumors transplanted into mice with humanized 4-1BB and PD-L1.
[0211] Fig.13 : Bispecific antibodies targeting 4-1BB or PD-L1 inhibit the growth of MC3-B7H1 tumors transplanted into mice with humanized 4-1BB and PD-L1.
[0212] Fig.14 : Effects of bispecific antibodies targeting 4-1BB or PD-L1 on the cytokine release activity of human PBMCs.
[0213] Fig.15: Binding activity of a pharmaceutical composition comprising a bispecific antibody targeting 4-1BB or PD-L1 to human 4-1BB.
[0214] Fig.16 : Binding activity of a pharmaceutical composition comprising a bispecific antibody targeting 4-1BB or PD-L1 to human PD-L1.
[0215] Fig.17 : Activation effect of a pharmaceutical composition comprising a bispecific antibody targeting 4-1BB or PD-L1 on T cells.
[0216] Fig.18 : The binding ability test results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application with human 4-1BB.
[0217] Fig.19 : The binding ability test results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application with mouse 4-1BB.
[0218] Fig. 20 : The binding ability test results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls with Jurkat NFKB 4-1BB cells.
[0219] Fig.21 : Test results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls blocking the binding of 4-1BBL to Jurkat NFKB 4-1BB cells.
[0220] Fig. 22 : Activity detection results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls in the luciferase reporter gene system (CHO FCGR2B 4G6 / Jurkat NFKB 4-1BB dual cells).
[0221] Fig.23 : Activity detection results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls in the luciferase reporter gene system (THP-1 / Jurkat NFKB 4-1BB dual cells).
[0222] Fig.24: Activity detection results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls in the luciferase reporter gene system (Raji / Jurkat NFKB 4-1BB dual cells).
[0223] Fig.25 : Activity detection results of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 and related controls prepared in Experimental Example 2 of the present application in the luciferase reporter gene system (Raji / Jurkat NFKB dual cells).
[0224] FIG. 26A to FIG. 26F : Changes in the release of cytokines IL-2, IL-4, IL-6, IL-10, TNFα and IFNγ caused by the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls.
[0225] Fig. 27 : Tumor growth inhibition effects of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls.
[0226] Fig.28 : Effects of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls on the spleen weight of tumor-bearing mice on the 14th day after administration.
[0227] Fig.29A : The effects of the anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and related controls on the number of total lymphocytes per unit weight in the liver of tumor-bearing mice on the 14th day after administration.
[0228] FIG. 29B to FIG. 29E : The anti-4-1BB antibodies JS011-phage 3 and JS011-phage 6 prepared in Experimental Example 2 of the present application and the related controls showed an effect on CD3 + CD4 + T cell ratio, CD3 + CD8 + T cell ratio, CD3 + CD8 + CD11c + T cell ratio and CD3 - NK1.1 + The influence of NK cell ratio.
[0229] The partial sequence involved in the present invention is as follows:
[0230] SEQ ID NO:1
[0231] G JZ
[0232] SEQ ID NO:2
[0233] WINPQSGGTNYAQKFQG
[0234] SEQ ID NO:3
[0235] EGGEWLAIPFDY
[0236] SEQ ID NO:4
[0237] SADKLGDKYAS
[0238] SEQ ID NO:5
[0239] EDSKRPS
[0240] SEQ ID NO:6
[0241] QTWDTNTVL
[0242] SEQ ID NO:7
[0243] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0244] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0245] WGQGTLVTVSS
[0246] SEQ ID NO:8
[0247] ELELTQPPSVSVSPGQTASITCSADKLGDKYASWYQQKPGQSPVLVLYEDSKRPSG
[0248] IPERISGSNSGNTATLTIRGTQPMDEADYYCQTWDTNTVLFGGGTRLTVL
[0249] SEQ ID NO:9
[0250] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0251] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0252] GGPSVFLFPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPRE
[0253] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTL
[0254] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0255] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0256] SEQ ID NO:10
[0257] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0258] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0259] GGPSVFLFPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVHNAKTKPRE
[0260] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQPREPQVYTL
[0261] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0262] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0263] SEQ ID NO:11
[0264] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0265] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0266] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVHNAKTKPRE
[0267] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQPREPQVYTL
[0268] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0269] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0270] SEQ ID NO:12
[0271] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0272] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0273] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVHNAKTKPRE
[0274] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQPREPQVYTL
[0275] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0276] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0277] SEQ ID NO:13
[0278] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0279] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0280] GGPSVFLFPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVHNAKTKPRE
[0281] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPTSIEKTISKAKGQPREPQVYTL
[0282] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0283] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0284] SEQ ID NO:14
[0285] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0286] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0287] GGPSVFLFPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVHNAKTKPRE
[0288] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQPREPQVYTL
[0289] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0290] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0291] SEQ ID NO:15
[0292] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0293] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0294] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVHNAKTKPRE
[0295] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQPREPQVYTL
[0296] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0297] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0298] SEQ ID NO:16
[0299] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0300] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0301] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVHNAKTKPRE
[0302] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQPREPQVYTL
[0303] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0304] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0305] SEQ ID NO:17
[0306] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0307] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0308] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVHNAKTKPRE
[0309] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQPREPQVYTL
[0310] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0311] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0312] SEQ ID NO:18
[0313] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0314] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0315] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0316] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0317] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH
[0318] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP
[0319] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0320] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0321] SEQ ID NO:19
[0322] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0323] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0324] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0325] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0326] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVH
[0327] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQP
[0328] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0329] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0330] SEQ ID NO:20
[0331] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0332] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0333] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0334] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0335] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVH
[0336] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQP
[0337] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0338] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0339] SEQ ID NO:21
[0340] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0341] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0342] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0343] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0344] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVH
[0345] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQP
[0346] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0347] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0348] SEQ ID NO:22
[0349] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0350] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0351] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0352] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0353] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVH
[0354] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPTSIEKTISKAKGQP
[0355] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0356] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0357] SEQ ID NO:23
[0358] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0359] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0360] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0361] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0362] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVH
[0363] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQP
[0364] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0365] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0366] SEQ ID NO:24
[0367] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0368] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0369] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0370] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0371] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVH
[0372] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQP
[0373] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0374] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0375] SEQ ID NO:25
[0376] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0377] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0378] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0379] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0380] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVH
[0381] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQP
[0382] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0383] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0384] SEQ ID NO:26
[0385] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0386] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0387] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0388] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0389] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVH
[0390] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQP
[0391] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0392] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0393] SEQ ID NO:27
[0394] ELELTQPPSVSVSPGQTASITCSADKLGDKYASWYQQKPGQSPVLVLYEDSKRPSG
[0395] IPERISGSNSGNTATLTIRGTQPMDEADYYCQTWDTNTVLFGGGTRLTVLGQPKAAPSV
[0396] TLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYA
[0397] ASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0398] SEQ ID NO:28
[0399] QGQLQESGPSLVKPSQTLSLTCTVSGDSITRGYWNWIRKHPGKGLEYIGYISYTGS
[0400] TYSNLSLKSRVTISRDTSKNQYYLKLSSVTAADTAVYYCATSTGWLDPVDYWGQGTL
[0401] VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
[0402] AVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPE
[0403] FLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
[0404] REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY
[0405] TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
[0406] RLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGSGGGGSELELTQPPSVS
[0407] VSPGQTASITCSADKLGDKYASWYQQKPGQSPVLVLYEDSKRPSGIPERISGSNSGNTA
[0408] TLTIRGTQPMDEADYYCQTWDTNTVLFGCGTRLTVLGGGGSGGGGSGGGGSGGGGSQ
[0409] VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGWINPQSG
[0410] GTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDYWGQ
[0411] GTLVTVSS
[0412] SEQ ID NO:29
[0413] QGQLQESGPSLVKPSQTLSLTCTVSGDSITRGYWNWIRKHPGKGLEYIGYISYTGS
[0414] TYSNLSLKSRVTISRDTSKNQYYLKLSSVTAADTAVYYCATSTGWLDPVDYWGQGTL
[0415] VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP
[0416] AVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPE
[0417] FLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVHNAKTKP
[0418] REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQPREPQVY
[0419] TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
[0420] RLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGGGGSGGGGSELELTQPPSVS
[0421] VSPGQTASITCSADKLGDKYASWYQQKPGQSPVLVLYEDSKRPSGIPERISGSNSGNTA
[0422] TLTIRGTQPMDEADYYCQTWDTNTVLFGCGTRLTVLGGGGSGGGGSGGGGSGGGGSQ
[0423] VQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGWINPQSG
[0424] GTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDYWGQ
[0425] GTLVTVSS
[0426] SEQ ID NO:30
[0427] DIVMTQSPDSLAVSLGERATINCKASQNVDTSVAWFQQKPGQPPKALIYSASFRYS
[0428] GVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQYYGYPFTFGQGTKLEIKRTVAAPSV
[0429] <h2 style=";text-align:left;direction:ltr">FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0430] <h2 style=";text-align:left;direction:ltr"> SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVVTKSFNRGEC<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0431] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:31<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0432] <h2 style=";text-align:left;direction:ltr"> RGYWN<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0433] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:32<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0434] <h2 style=";text-align:left;direction:ltr"> YISYTGSTYSNLSLKS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0435] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:33<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0436] <h2 style=";text-align:left;direction:ltr"> TSTGWLDPVDY<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0437] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:34<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0438] <h2 style=";text-align:left;direction:ltr"> KASQNVDTSVA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0439] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:35<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0440] <h2 style=";text-align:left;direction:ltr"> SASFRYS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0441] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:36<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0442] <h2 style=";text-align:left;direction:ltr"> QQYYGYPFT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0443] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:37<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0444] <h2 style=";text-align:left;direction:ltr"> QGQLQESGPSLVKPSQTLSLTCTVSGDSITRGYWNWIRKHPGKGLEYIGYISYTGS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0445] <h2 style=";text-align:left;direction:ltr"> TYSNLSLKSRVTISRDTSKNQYYLKLSSVTAADTAVYYCATSTGWLDPVDYWGQGTL<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0446] <h2 style=";text-align:left;direction:ltr"> VTVSS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0447] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:38<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0448] <h2 style=";text-align:left;direction:ltr"> DIVMTQSPDSLAVSLGERATINCKASQNVDTSVAWFQQKPGQPPKALIYSASFRYS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0449] <h2 style=";text-align:left;direction:ltr"> GVPDRFSGSGSGTDFLTLTISSLQAEDVAVYFCQQYYGYPFTFGQGTKLEIK
[0450] SEQ ID NO:39
[0451] EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMSWVRQAPGKGLEWVSGFSGSG
[0452] GFTFYADSVRGRFTISRDSSKNTLFLQMSSLRAEDTAVYYCAIPARGYNYGSFQHWGQ
[0453] GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH
[0454] TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP
[0455] PCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVH
[0456] NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
[0457] REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0458] GSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0459] SEQ ID NO:40
[0460] SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPS
[0461] GLPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGQPKA
[0462] APSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNN
[0463] KYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0464] SEQ ID NO:41
[0465] EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDV
[0466] GGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQG
[0467] TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT
[0468] FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP
[0469] CPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHN
[0470] AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
[0471] EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
[0472] FFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0473] SEQ ID NO:42
[0474] DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLAS
[0475] GVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIKGQPKAA
[0476] PSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNK
[0477] YAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
[0478] SEQ ID NO:43
[0479] CAGGGCCAGCTGCAGGAGAGCGGCCCCAGCCTGGTGAAGCCCAGCCAGACCC
[0480] TGAGCCTGACCTGCACCGTGAGCGGCGACAGCATCACCAGAGGCTACTGGAACTG
[0481] GATCAGAAAGCACCCCGGCAAGGGCCTGGAGTACATCGGCTACATCAGCTACACC
[0482] GGCAGCACCTACAGCAACCTGAGCCTGAAGTCCAGAGTGACCATCAGCAGAGACA
[0483] CCAGCAAGAACCAGTACTACCTGAAGCTGAGCAGCGTGACCGCCGCCGACACCGC
[0484] CGTGTACTACTGCGCCACCAGCACCGGCTGGCTGGACCCCGTGGACTACTGGGGCC
[0485] AGGGCACCCTGGTGACCGTGAGCAGCGCTAGCACCAAGGGCCCCAGCGTGTTCCCC
[0486] CTGGCCCCTTGCAGCAGAAGCACCAGCGAGAGCACAGCCGCCCTGGGCTGCCTGGT
[0487] GAAGGACTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGCGCTCTGACCA
[0488] GCGGCGTGCATACCTTCCCCGCCGTGCTCCAGAGCAGCGGACTGTACTCCCTGAGC
[0489] AGCGTGGTGACCGTGCCTTCCAGCAGCCTGGGCACCAAGACCTACACCTGCAACGT
[0490] GGACCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTGGAGAGCAAGTACGG
[0491] CCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCTAGCGTGTTCCT
[0492] GTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCT
[0493] GCGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCAGTTTAATTGGTACGTG
[0494] GACGGCGTGGAAGTGCATAACGCCAAGACCAAGCCCAGAGAGGAGCAGTTCAACA
[0495] GCACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGC
[0496] AAGGAATACAAGTGCAAGGTCTCCAACAAGGCCTGCCTAGCAGCATCGAGAAGA
[0497] CCATCAGCAAGGCCAAGGGCCAGCCACGGGAGCCCCAGGTCTACACCCTGCCACCC
[0498] TAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGTGAAAGGC
[0499] TTCTATCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACA
[0500] ACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACTCC
[0501] AGACTGACCGTGGACAAGTCCAGATGGCAGGAGGGCAACGTCTTCAGCTGCTCCGT
[0502] GATGCACGAGGCCCTGCCACAACCACTACACCCGAAGTCCCTGAGCCTGAGCCTGG
[0503] GAGGCGGAGGCAGCGGCGGAGGCGGATCCGAGCTGGAGCTGACCCAGCCTCCTAG
[0504] CGTGAGCGTGAGCCCTGGTCAGACCGCCAGCATCACCTGCAGCGCGACAAGCTG
[0505] GGAGACAAGTACGCCAGCTGGTACCAGCAGAAGCCTGGACAGAGCCCTGTGCTGG
[0506] TGCTGTACGAGGACAGCAAGAGACCTAGCGGAATCCCTGAGAGAATCAGCGGGAAG
[0507] CAACAGCGGAAACACCGCCACCCTGACCATCAGAGGAACCCAGCCTATGGACGAG
[0508] GCCGACTACTACTGCCAGACCTGGGACACCAACACCGTGCTGTTCGGATGCGGAAC
[0509] CAGACTGACCGTGCTGGGAGGCGGAGGCAGCGGCGGAGGCGGAAGCGGAGGCGG
[0510] AGGCAGCGGAGGCGGAGGCAGCCAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGT
[0511] GAAGAAGCCTGGAGCCAGCGTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTC
[0512] ACCGGATACTACATGCACTGGGTGAGACAGGCCCCTGGACAGTGCCTGGAGTGGA
[0513] TGGGATGGATCAACCCTCAGAGCGGAGGAACCAACTACGCCCAGAAGTTCCAGGG
[0514] AAGAGTGACCATGACCAGAGACACCAGCATCAGCACCGCCTACATGGAGCTGAGC
[0515] AGACTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCAGAGAGGGAGGAGAGT
[0516] GGCTGGCCATCCCTTTCGACTACTGGGGCCAGGGAACCCTGGTGACCGTGAGCAGC
[0517] TGA
[0518] SEQ ID NO:44
[0519] GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCCTGGGCGAGA
[0520] GAGCCACCATCAACTGCAAGGCCAGCCAGAACGTGGACACCAGCGTGGCCTGGTT
[0521] CCAGCAGAAGCCCGGCCAGCCCCCCAAGGCCCTGATCTACAGCGCCAGCTTCAGAT
[0522] ACAGCGGCGTGCCCGACAGATTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCT
[0523] GACCATCAGCAGCCTGCAGGCCGAGGACGTGGCCGTGTACTTCTGCCAGCAGTACT
[0524] ACGGCTACCCCTTCACCTTCGGCCAGGGCACCAAGCTGGAGATCAAGCGAACTGTG
[0525] GCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT
[0526] GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTG
[0527] GAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAG
[0528] GACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAG
[0529] ACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTC
[0530] GCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
[0531] SEQ ID NO:45
[0532] CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAG
[0533] TGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACTGGCTACTATATGCACTGG
[0534] GTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTCAGA
[0535] GTGGTGGCACAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGA
[0536] CACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACG
[0537] GCCGTGTATTACTGTGCGAGAGAGGGGGGGGAGTGGCTGGCCATCCCGTTTGACTA
[0538] CTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCCAGCG
[0539] TGTTCCCCCTGGCCCCTTGCAGCAGAAGCACCAGCGAGAGCACAGCCGCCCTGGGC
[0540] TGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGCGGCGC
[0541] TCTGACCAGCGGCGTGCATACCTTCCCCGCCGTGCTCCAGAGCAGCGGACTGTACT
[0542] CCCTGAGCAGCGTGGTGACCGTGCCTTCCAGCAGCCTGGGCACCAAGACCTACACC
[0543] TGCAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTGGAGAGCA
[0544] AGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCTAGC
[0545] GTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGAACCCCCGA
[0546] GGTGACCTGCGTGGTGGTGGACGTGTGCCAGGAGTGCCCCGAGGTCCAGTTTAATT
[0547] GGTACGTGGACGGCGTGGAAGTGCATAACGCCAAGACCAAGCCCAGAGAGGAGCA
[0548] GTTCAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGC
[0549] TGAACGGCAAGGAATACAAGTGCAAGGTCTCCAACAAGGGCGCTCCTAGCAGCAT
[0550] CGAGAAGACCATCAGCAAGGCCAAGGGCCAGCCACGGGAGCCCCAGGTCTACACC
[0551] CTGCCACCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTGGT
[0552] GAAAGGCTTCTATCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCC
[0553] GAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTCCT
[0554] GTACTCCAGACTGACCGTGGACAAGTCCAGATGGCAGGAGGGCAACGTCTTCAGCT
[0555] GCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTG
[0556] AGCCTGGGAGGCGGAGGCAGCGGCGGAGGCGGATCCGAGGTGCAGCTGCTGGAGA
[0557] GCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGACTGAGCTGCGCCGCCAG
[0558] CGGCGCCGCCCCCTGCATGGCCTGGTTCAGACAGGCCCCCGGCAAGGGCCTGGAG
[0559] GGCGTGGCCGCCAGCGTGAGAGGCGGCCTGAGCCCCTACTACGCCGACAGCGTGA
[0560] AGGGCAGATTCACCATCAGCCACGACATCCCCAAGAACACCATGTACCTGCAGATG
[0561] AACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGCGCCGCCAGAGCCACCTT
[0562] CTACAGATGCGAGGGCGACGCCAGCAGCTACACCTACTGGGGCCAGGGCACCCTG
[0563] GTGACCGTGAGCAGCTGA
[0564] SEQ ID NO:46
[0565] GACATCGTGATGACCCAGAGCCCCGACAGCCTGGCCGTGAGCCTGGGCGAGA
[0566] GAGCCACCATCAACTGCAAGGCCAGCCAGAACGTGGACACCAGCGTGGCCTGGTT
[0567] CCAGCAGAAGCCCGGCCAGCCCCCCAAGGCCCTGATCTACAGCGCCAGCTTCAGAT
[0568] ACAGCGGCGTGCCCGACAGATTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCT
[0569] GACCATCAGCAGCCTGCAGGCCGAGGACGTGGCCGTGTACTTCTGCCAGCAGTACT
[0570] ACGGCTACCCCTTCACCTTCGGCCAGGGCACCAAGCTGGAGATCAAGCGAACTGTG
[0571] GCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT
[0572] GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTG
[0573] GAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAG
[0574] GACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAG
[0575] ACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTC
[0576] GCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
[0577] SEQ ID NO:67
[0578] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0579] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0580] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPRE
[0581] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTL
[0582] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0583] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0584] SEQ ID NO:68
[0585] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0586] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0587] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVHNAKTKPRE
[0588] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQPREPQVYTL
[0589] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0590] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0591] SEQ ID NO:69
[0592] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0593] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0594] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVHNAKTKPRE
[0595] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQPREPQVYTL
[0596] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0597] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0598] SEQ ID NO:70
[0599] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0600] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0601] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVHNAKTKPRE
[0602] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQPREPQVYTL
[0603] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0604] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0605] SEQ ID NO:71
[0606] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0607] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0608] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVHNAKTKPRE
[0609] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPTSIEKTISKAKGQPREPQVYTL
[0610] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0611] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0612] SEQ ID NO:72
[0613] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0614] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0615] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVHNAKTKPRE
[0616] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQPREPQVYTL
[0617] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0618] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0619] SEQ ID NO:73
[0620] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0621] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0622] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVHNAKTKPRE
[0623] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQPREPQVYTL
[0624] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0625] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0626] SEQ ID NO:74
[0627] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0628] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0629] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVHNAKTKPRE
[0630] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQPREPQVYTL
[0631] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0632] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0633] SEQ ID NO:75
[0634] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
[0635] LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
[0636] GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVHNAKTKPRE
[0637] EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQPREPQVYTL
[0638] PPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
[0639] TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0640] SEQ ID NO:76
[0641] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0642] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0643] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0644] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0645] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH
[0646] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP
[0647] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0648] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0649] SEQ ID NO:77
[0650] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0651] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0652] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0653] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0654] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVH
[0655] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQP
[0656] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0657] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0658] SEQ ID NO:78
[0659] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0660] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0661] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0662] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0663] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVH
[0664] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQP
[0665] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0666] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0667] SEQ ID NO:79
[0668] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0669] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0670] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0671] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0672] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVH
[0673] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQP
[0674] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0675] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0676] SEQ ID NO:80
[0677] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0678] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0679] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0680] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0681] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAAEDPEVQFNWYVDGVEVH
[0682] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPTSIEKTISKAKGQP
[0683] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0684] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0685] SEQ ID NO:81
[0686] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0687] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0688] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0689] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0690] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVAQEDPEVQFNWYVDGVEVH
[0691] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQP
[0692] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0693] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0694] SEQ ID NO:82
[0695] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0696] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0697] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0698] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0699] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVH
[0700] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNPSSIEKTISKAKGQP
[0701] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0702] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0703] SEQ ID NO:83
[0704] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0705] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0706] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0707] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0708] PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVH
[0709] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGNSTSIEKTISKAKGQP
[0710] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0711] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL
[0712] SEQ ID NO:84
[0713] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWIN
[0714] PQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDY
[0715] WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
[0716] GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP
[0717] PCPAPEFLGGGSVFLFPPKPKDTLMISRTPEVTCVVVDVCQECPEVQFNWYVDGVEVH
[0718] NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGAPSSIEKTISKAKGQP
[0719] REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD
[0720] GSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL DETAILED DESCRIPTION
[0721] definition
[0722] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art.
[0723] In order to make it easier to understand the present invention, some scientific and technological terms are specifically defined as follows. Unless otherwise clearly defined in other parts of this article, the scientific and technological terms used herein have the meanings commonly understood by ordinary technicians in the field to which the present invention belongs. Regarding the definitions and terms in this area, professionals can specifically refer to Current Protocols in Molecular Biology (Ausubel). The abbreviations of amino acid residues are standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids. The singular form used herein (including the claims) includes its corresponding plural form, unless otherwise clearly specified in the text.
[0724] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.
[0725] The term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.
[0726] "Programmed death receptor-1 (PD-1)" refers to an immunoinhibitory receptor belonging to the CD28 family. PD-1 is mainly expressed on previously activated T cells in vivo and binds two ligands, PD-L1 and PD-L2. The term "PD-1" as used herein includes human PD-1 (hPD-1), variants, isoforms and species homologs of hPD-1, and analogs having at least one common epitope with hPD-1.
[0727] "Programmed cell death protein ligand 1 (PD-L1)", also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7 homolog 1, B7-H1), belongs to the tumor necrosis factor superfamily. The term "PD-L1" used herein includes human PD-L1 (hPD-L1), variants, isoforms and species homologs of hPD-L1, and analogs having at least one common epitope with hPD-L1.
[0728] "Tumor necrosis factor receptor superfamily-9 (TNFRSF9 or 4-1BB or CD137)" is a transmembrane protein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). 4-1BB is expressed on the cell surface as a monomer or dimer. After binding to its ligand (4-1BBL), it trimers and recruits TRAF1 and TRAF2. It mainly transmits downstream signals through NF-κB and MAPKs, and triggers the secretion of IL-2 and IFN-γ through a mechanism independent of the CD28 family, thereby enhancing the immune response of T cells. At the same time, it upregulates the anti-apoptotic activity of Bcl-2 family proteins to reduce the partial death of T cells due to activation.
[0729] The term "percent (%) amino acid sequence identity" or simply "identity" is defined as the percentage of amino acid residues in a candidate amino acid sequence that are identical to the amino acid residues in a reference amino acid sequence, after the amino acid sequences are aligned (and gaps introduced where necessary) to obtain the maximum percent sequence identity, and any conservative substitutions are not considered part of the sequence identity. Sequence alignments can be performed using various methods in the art to determine percent amino acid sequence identity, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGN (DNASTAR) software. One skilled in the art can determine appropriate parameters for measuring alignments, including any algorithm required to achieve maximum alignment over the entire length of the compared sequences.
[0730] The term "immune response" refers to the actions of, for example, lymphocytes, antigen presenting cells, phagocytes, granulocytes, and soluble macromolecules produced by the above cells or the liver (including antibodies, cytokines and complement), which result in the selective damage, destruction or elimination from the human body of invading pathogens, cells or tissues infected with pathogens, cancer cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues.
[0731] The term "signal transduction pathway" or "signal transduction activity" refers to a biochemical cause-effect relationship, usually initiated by protein-protein interactions such as the binding of a growth factor to a receptor, that results in the transmission of a signal from one part of a cell to another part of the cell. Typically, the transmission involves specific phosphorylation of one or more tyrosine, serine or threonine residues on one or more proteins in a series of reactions that lead to signal transduction. The penultimate process usually involves nuclear events, resulting in changes in gene expression.
[0732] The terms "activity" or "biological activity", or the terms "biological property" or "biological characteristic" are used interchangeably herein and include, but are not limited to, epitope / antigen affinity and specificity, the ability to neutralize or antagonize PD-1 activity in vivo or in vitro, IC50, in vivo stability of the antibody, and the immunogenic properties of the antibody. Other identifiable biological properties or characteristics of antibodies known in the art include, for example, cross-reactivity (i.e., cross-reactivity with non-human homologs of the targeted peptide, or with other proteins or tissues in general), and the ability to maintain high expression levels of the protein in mammalian cells. The aforementioned properties or characteristics are observed, measured or evaluated using techniques known in the art, including but not limited to ELISA, FACS or BIACORE plasma resonance analysis, unrestricted in vitro or in vivo neutralization assays, receptor binding, production and / or secretion of cytokines or growth factors, signal transduction, and immunohistochemistry of tissue sections from different sources (including humans, primates or any other source).
[0733] The term "antibody" refers to any form of antibody having the desired biological activity. Therefore, it is used in the broadest sense, specifically including but not limited to monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (such as bispecific antibodies), humanized antibodies, fully human antibodies, chimeric antibodies and camelized single domain antibodies.
[0734] The term "isolated antibody" refers to the purified state of the binding compound, and in this case means that the molecule is substantially free of other biomolecules, such as nucleic acids, proteins, lipids, sugars, or other substances such as cell debris and growth medium. The term "isolated" does not imply the complete absence of such substances or the absence of water, buffers, or salts unless they are present in amounts that significantly interfere with the experimental or therapeutic use of the binding compound described herein.
[0735] The term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically include a large number of antibodies directed against (or specific for) different epitopes. The modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies, and is not to be construed as requiring production of the antibody by any particular method.
[0736] The term "full-length antibody" refers to an immunoglobulin molecule that contains four peptide chains when naturally present: two heavy (H) chains (about 50-70 kDa at full length) and two light (L) chains (about 25 kDa at full length) connected to each other by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH). The heavy chain constant region consists of three domains CH1, CH2 and CH3. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain CL. The VH and VL regions can be further subdivided into highly variable complementary determining regions (CDRs) and regions separated by more conservative framework regions (FRs). Each VH or VL region consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of antibodies mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0737] The term "antigen-binding fragment" of an antibody ("parent antibody") includes fragments or derivatives of an antibody, typically including at least one fragment of an antigen-binding region or variable region (e.g., one or more CDRs) of a parent antibody that retains at least some of the binding specificity of the parent antibody. Examples of antibody binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, such as sc-Fv; nanobodies and multispecific antibodies formed from antibody fragments. When the binding activity of the antigen is expressed on a molar basis, the binding fragment or derivative typically retains at least 10% of its antigen-binding activity. Preferably, the binding fragment or derivative retains at least 20%, 50%, 70%, 80%, 90%, 95%, or 100% or more of the antigen-binding affinity of the parent antibody. It is also contemplated that the antigen-binding fragment of an antibody may include conservative or non-conservative amino acid substitutions that do not significantly change its biological activity (referred to as "conservative variants" or "functional conservative variants" of antibodies). The term "binding compound" refers to both antibodies and their binding fragments.
[0738] The term "single-chain Fv" or "scFv" antibody refers to an antibody fragment comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. The Fv polypeptide generally also comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.
[0739] The term "Fc" or "Fc region" or "Fc fragment" or "Fc domain" is used herein to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. A native immunoglobulin "Fc domain" comprises two or three constant domains, namely a CH2 domain, a CH3 domain, and an optional CH4 domain. For example, in a native antibody, an immunoglobulin Fc domain comprises the second and third constant domains (CH2 domain and CH3 domain) of two heavy chains derived from IgG, IgA, and IgD class antibodies; or comprises the second, third, and fourth constant domains (CH2 domain, CH3 domain, and CH4 domain) of two heavy chains derived from IgM and IgE class antibodies. The Fc region herein may comprise a hinge region.
[0740] The term "hinge region" refers to the proline-rich, easily stretchable and bendable polypeptide chain located between CH1 and CH2 in an antibody.
[0741] The term "domain antibody" is an immunologically functional immunoglobulin fragment containing only the variable region of the heavy chain or the variable region of the light chain. In some cases, two or more VH regions are covalently linked with a peptide linker to form a bivalent domain antibody. The two VH regions of a bivalent domain antibody can target the same or different antigens.
[0742] The term "immunoglobulin" refers to a protein having the structure of a naturally occurring antibody. For example, the IgG class immunoglobulin is a heterotetrameric glycoprotein of about 150,000 daltons consisting of two light chains and two heavy chains bound by disulfide bonds. From the N-terminus to the C-terminus, each immunoglobulin heavy chain has a variable region (VH), also referred to as a variable heavy chain domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also referred to as a heavy chain constant region. Similarly, from the N-terminus to the C-terminus, each immunoglobulin light chain has a variable region (VL), also referred to as a variable light chain domain or a light chain variable domain, followed by a constant light chain (CL) domain, also referred to as a light chain constant region. The heavy chains of immunoglobulins can be assigned to one of five classes, called α (IgA), δ (IgD), ε (IgE), γ (IgG) or μ (IgM), some of which can be further divided into subclasses, such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chains of immunoglobulins can be divided into one of two types, called κ and λ, based on the amino acid sequence of their constant domains.
[0743] Methods and techniques for identifying CDRs in heavy chain variable region and light chain variable region amino acid sequences are known in the art and can be used to identify CDRs in the amino acid sequences of specific heavy chain variable regions and / or light chain variable regions disclosed herein. Exemplary well-known techniques that can be used to identify CDR boundaries include, for example, Kabat definition, Chothia definition, IMGT definition, and AbM definition. See, for example, Kabat, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., Standard conformations for the canonical structures of immunoglobulins., J. Mol. Biol. 273:927-948 (1997); and Martin AC et al., Modeling antibody hypervariable loops: a combined algorithm, Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989); International ImMunoGeneTics database (IMGT) (1999 Nucleic Acids Research, 27, 209-212).
[0744] A "human immunoglobulin" is an immunoglobulin that possesses an amino acid sequence corresponding to an immunoglobulin produced by a human or a human cell or is derived from a non-human source utilizing a human immunoglobulin library or other sequences encoding a human immunoglobulin.
[0745] The term "bivalent antibody" contains two antigen binding sites. In some cases, the two binding sites have the same antigen specificity. However, a bivalent antibody can be bispecific.
[0746] The term "diabody" refers to a small antibody fragment with two antigen binding sites, which comprises a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL or VL-VH). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and generate two antigen binding sites.
[0747] The term "chimeric antibody" is an antibody having the variable domains of a first antibody and the constant domains of a second antibody, wherein the first antibody and the second antibody are from different species. Typically, the variable domains are obtained from antibodies such as rodents ("parent antibodies"), while the constant domain sequences are obtained from human antibodies, such that the resulting chimeric antibodies are less likely to induce adverse immune responses in human subjects than the parent rodent antibodies.
[0748] The term "humanized antibody" refers to an antibody form containing sequences from human and non-human (e.g., mouse, rat) antibodies. In general, a humanized antibody comprises substantially all of at least one, usually two variable domains, wherein all or substantially all of the hypervariable loops correspond to the hypervariable loops of non-human immunoglobulins, and all or substantially all of the framework (FR) regions are framework regions of human immunoglobulin sequences. A humanized antibody may optionally comprise at least a portion of a human immunoglobulin constant region (Fc).
[0749] The term "fully human antibody" refers to an antibody that contains only human immunoglobulin protein sequences. If produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell, a fully human antibody may contain rat sugar chains. Similarly, a "mouse antibody" refers to an antibody that contains only mouse immunoglobulin sequences. Alternatively, if produced in a rat, in a rat cell, or in a hybridoma derived from a rat cell, a fully human antibody may contain rat sugar chains. Similarly, a "rat antibody" refers to an antibody that contains only rat immunoglobulin sequences.
[0750] "PD-L1 antibody" refers to any chemical compound or biological molecule that binds to PD-L1 and blocks the binding of PD-L1 expressed on cancer cells to PD-1 expressed on immune cells (T, B, NK cells). Alternative terms or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279, and SLEB2 for PD-1; PDCD1L1, PD-L1, B7-H1, B7H1, B7-4, CD274, and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, and CD273 for PD-L2. In any of the methods, drugs, and uses of the present invention for treating human subjects, the PD-L1 antibody blocks the binding of human PD-1 to human PD-L1.
[0751] Herein, when referring to an "anti-PD-L1 antibody", unless otherwise indicated or described, the term includes antigen-binding fragments thereof.
[0752] "4-1BB antibody" refers to any chemical compound or biological molecule that specifically binds to 4-1BB. Alternative terms or synonyms for 4-1BB and its ligands include: TNFRSF9 and CD137. In any of the methods, drugs and uses of the present invention for treating human individuals, the 4-1BB antibody can bind to 4-1BB on the cell surface, activate 4-1BB-related downstream pathways, and enhance the body's immune response ability.
[0753] Herein, when referring to an "anti-4-1BB antibody", unless otherwise indicated or described, the term includes antigen-binding fragments thereof.
[0754] An "isotype" antibody refers to the class of antibody provided by the heavy chain constant region genes (e.g., IgM, IgE, IgG such as IgG1, IgG2, or IgG4). Isotypes also include modified forms of one of these classes, where the modifications have been made to alter Fc function, for example to enhance or reduce effector function or binding to Fc receptors.
[0755] The term "epitope" refers to a region of an antigen to which an antibody binds. An epitope can be formed by contiguous amino acids or by non-contiguous amino acids juxtaposed by tertiary folding of a protein.
[0756] "Affinity" or "binding affinity" refers to the intrinsic binding affinity that reflects the interaction between members of a binding pair. The affinity of a molecule X for its partner Y can be generally represented by the equilibrium dissociation constant (KD), which is the ratio of the dissociation rate constant and the association rate constant (kdis and kon, respectively). Affinity can be measured by common methods known in the art. One specific method for measuring affinity is the ForteBio kinetic binding assay herein.
[0757] The term "not binding" to a protein or cell means that it does not bind to the protein or cell, or does not bind to it with high affinity, i.e., the KD of binding to the protein or cell is 1.0×10 -6 M or more, more preferably 1.0×10 -5 M or more, more preferably 1.0×10 -4 M or higher, 1.0×10 -3 M or more, more preferably 1.0×10 -2 M or higher.
[0758] The term "high affinity" for IgG antibodies refers to a KD for the antigen of 1.0 × 10 -6 M or less, preferably 5.0×10 -8 M or less, more preferably 1.0×10 -8 M or less, 5.0×10 -9 M or less, more preferably 1.0×10 -9 M or less. For other antibody subtypes, “high affinity” binding may vary. For example, “high affinity” binding for the IgM subtype is defined as a KD of 10 -6 M or less, preferably 10 -7 M or less, more preferably 10 -8 M or lower.
[0759] The terms "antibody-dependent cellular cytotoxicity," "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refer to a cell-mediated immune defense in which immune system effector cells actively lyse target cells, such as cancer cells, that are bound to cell membrane surface antigens and antibodies, such as Claudin18.2 antibodies.
[0760] The term "complement dependent cytotoxicity" or "CDC" refers to the effector function of IgG and IgM antibodies, which, when bound to surface antigens, initiate the classical complement pathway, including the formation of a membrane attack complex and target cell lysis. The antibodies of the present invention, when bound to Claudin 18.2, initiate CDC against cancer cells.
[0761] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless explicitly limited, the term includes nucleic acids containing analogs of known natural nucleotides that have similar binding properties to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides (see, U.S. Patent No. 8,278,036 to Kariko et al., which discloses mRNA molecules in which uridine is replaced by pseudouridine, methods for synthesizing the mRNA molecules, and methods for delivering therapeutic proteins in vivo). Unless otherwise indicated, a specific nucleic acid sequence also implicitly includes conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as sequences explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985), and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0762] "Construct" refers to any recombinant polynucleotide molecule (such as a plasmid, cosmid, virus, autonomously replicating polynucleotide molecule, bacteriophage, or linear or circular single-stranded or double-stranded DNA or RNA polynucleotide molecule), derived from any source, capable of integrating with a genome or autonomously replicating, constituting a polynucleotide molecule in which one or more polynucleotide molecules have been linked (i.e., operably linked) in a functionally operable manner. Recombinant constructs will typically include a polynucleotide of the invention operably linked to a transcription initiation regulatory sequence that directs transcription of the polynucleotide in a host cell. Both heterologous and non-heterologous (i.e., endogenous) promoters can be used to direct expression of the nucleic acids of the invention.
[0763] "Vector" refers to any recombinant polynucleotide construct that can be used for the purpose of transformation (i.e., introducing heterologous DNA into a host cell). One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments can be connected. Another type of vector is a viral vector, in which additional DNA segments can be connected to the viral genome. Certain vectors are capable of autonomous replication in the host cell into which they are introduced (e.g., bacterial vectors with bacterial replication origins and episomal mammalian vectors). After introduction into the host cell, other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell and are therefore replicated together with the host genome. In addition, certain vectors are capable of directing the expression of operatively connected genes. Such vectors are referred to herein as "expression vectors".
[0764] The term "expression vector" as used herein refers to a nucleic acid molecule that can replicate and express a target gene when transformed, transfected or transduced into a host cell. The expression vector comprises one or more phenotypic selection markers and an origin of replication to ensure maintenance of the vector and to provide amplification in the host when necessary.
[0765] "Activation," "stimulation," and "treatment" as used for a cell or receptor may have the same meaning, e.g., a cell or receptor is activated, stimulated, or treated with a ligand, unless the context otherwise or clearly dictates. "Ligand" includes natural and synthetic ligands, such as cytokines, cytokine variants, analogs, muteins, and binding compounds derived from antibodies. "Ligand" also includes small molecules, such as peptide mimetics of cytokines and peptide mimetics of antibodies. "Activation" may refer to cell activation regulated by internal mechanisms as well as external or environmental factors. "Response / reaction," such as the response of a cell, tissue, organ, or organism, includes changes in biochemical or physiological behavior (e.g., concentration, density, adhesion or migration within a biological compartment, gene expression rate, or differentiation state), where the change is related to activation, stimulation, or treatment, or to internal mechanisms such as genetic programming.
[0766] As used herein, the term "treatment" or "treating" of any disease or condition refers to improving the disease or condition (i.e., slowing down or preventing or reducing the progression of the disease or at least one of its clinical symptoms) in one embodiment. In another embodiment, "treatment" or "treating" refers to alleviating or improving at least one physical parameter, including those physical parameters that may not be discerned by the patient. In another embodiment, "treatment" or "treating" refers to regulating the disease or condition physically (e.g., stabilization of discernible symptoms), physiologically (e.g., stabilization of physical parameters), or in both aspects. Unless explicitly described herein, methods for assessing the treatment and / or prevention of a disease are generally known in the art.
[0767] "Subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. As used herein, the term "cyno" or "cynomolgus monkey" refers to cynomolgus monkeys.
[0768] Administration "in combination with" one or more additional therapeutic agents includes simultaneous (concurrent) administration and consecutive administration in either order.
[0769] "Therapeutically effective amount", "therapeutically effective dose" and "effective amount" refer to an amount of an antibody or antigen-binding fragment thereof or a bispecific antibody of the invention, when administered alone or in combination with other therapeutic agents to a cell, tissue or subject, that is effective to prevent or improve the symptoms of one or more diseases or conditions or the development of the disease or condition. A therapeutically effective dose also refers to an amount of an antibody or antigen-binding fragment thereof sufficient to cause an improvement in symptoms, such as an amount to treat, cure, prevent or improve a related medical condition or to increase the rate of treatment, cure, prevention or improvement of such a condition. When a single active ingredient is administered to an individual, a therapeutically effective dose refers only to that ingredient. When administered in combination, a therapeutically effective dose refers to the combined amount of active ingredients that causes a therapeutic effect, whether administered in combination, sequentially or simultaneously. An effective amount of a therapeutic agent will result in an improvement in a diagnostic criterion or parameter of at least 10%; typically at least 20%; preferably at least about 30%; more preferably at least 40%, and most preferably at least 50%.
[0770] "Cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Included in this definition are benign and malignant cancers as well as dormant tumors or micrometastases. Examples of cancer include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias. More specific examples of such cancers include squamous cell carcinoma, lung cancer (including small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung), peritoneal cancer, hepatocellular carcinoma, gastric cancer or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer or renal cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, and various types of head and neck cancer, as well as B-cell lymphoma (including low-grade / follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-cleaved cell NHL, storage disease (bulky disease) NHL, mantle cell lymphoma, AIDS-related lymphoma, and Waldenstrom's macroglobulinemia), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloblastic leukemia, and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs syndrome.
[0771] Anti-4-1BB antibodies and / or antigen-binding fragments of anti-4-1BB antibodies
[0772] The anti-4-1BB antibody and / or the antigen-binding fragment of the anti-4-1BB antibody of the present invention can specifically bind to 4-1BB; or compete with the complete anti-4-1BB antibody and / or its antigen-binding fragment for binding to 4-1BB.
[0773] The "anti-4-1BB antibody or antigen-binding fragment thereof" described in the present invention may include any anti-4-1BB antibody or antigen-binding fragment thereof described in the art. The anti-4-1BB antibody may be a commercially available 4-1BB antibody or antigen-binding fragment thereof disclosed in the literature. The antibody may be a monoclonal antibody, a chimeric antibody, a humanized antibody or a fully human antibody. The antigen-binding fragment may be a Fab fragment, a Fab' fragment, a F(ab')2 fragment having antigen-binding activity, or an Fv fragment or a ScFv fragment that can bind to the antibody.
[0774] In some embodiments, the anti-4-1BB antibody or antigen-binding fragment thereof of the present invention comprises HCDR1, HCDR2 and HCDR3 which are identical to the amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, or have one mutation selected from deletion, insertion or substitution, and LCDR1, LCDR2 and LCDR3 which are identical to the amino acid sequences shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, or have one mutation selected from deletion, insertion or substitution. In some embodiments, the antigen-binding fragment of the anti-4-1BB antibody of the present invention comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6.
[0775] In some embodiments, the anti-4-1BB antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region identical to the amino acid sequence shown in SEQ ID NO: 7 or having 1, 2 or 3 mutations selected from deletion, insertion or substitution, and a light chain variable region identical to the amino acid sequence shown in SEQ ID NO: 8 or having 1, 2 or 3 mutations selected from deletion, insertion or substitution. In some embodiments, the anti-4-1BB antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 7 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 8.
[0776] In some embodiments, the anti-4-1BB antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, wherein the heavy chain is selected from SEQ ID NO: 18-26 or has 1, 2, 3, 4 or 5 selected from deletion, insertion or substitution mutations. The amino acid sequence, the light chain is selected from SEQ ID NO: 27 or has 1, 2, 3, 4 or 5 selected from deletion, insertion or substitution mutations. In some embodiments, the anti-4-1BB antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, wherein the heavy chain is selected from the amino acid sequence shown in SEQ ID NO: 18-26, and the light chain is the amino acid sequence shown in SEQ ID NO: 27.
[0777] In some embodiments, the anti-4-1BB antibody or antigen-binding fragment thereof of the present invention comprises Fab, Fab', F(ab')2, Fv, scFv or sdAb.
[0778] Anti-PD-L1 antibodies and / or antigen-binding fragments of anti-PD-L1 antibodies
[0779] The anti-PD-L1 antibody and / or the antigen-binding fragment of the anti-PD-L1 antibody of the present invention can specifically bind to PD-L1; or compete with the complete anti-PD-L1 antibody and / or its antigen-binding fragment for binding to PD-L1.
[0780] The "anti-PD-L1 antibody or antigen-binding fragment thereof" described in the present invention may include any anti-PD-L1 antibody or antigen-binding fragment thereof described in the art. The anti-PD-L1 antibody may be a commercially available PD-L1 antibody or antigen-binding fragment thereof disclosed in the literature. The antibody of the present invention may be a monoclonal antibody, a chimeric antibody, a humanized antibody or a fully human antibody. Antigen-binding fragments include Fab fragments, Fab' fragments, F(ab')2 fragments having antigen-binding activity, and Fv fragments and ScFv fragments that bind to the antibody.
[0781] In some embodiments, the antigen-binding fragment of the anti-PD-L1 antibody of the present invention comprises HCDR1, HCDR2 and HCDR3, which are identical to the amino acid sequences shown in SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO: 33, or have one mutation selected from deletion, insertion or substitution, and LCDR1, LCDR2 and LCDR3, which are identical to the amino acid sequences shown in SEQ ID NO: 34, SEQ ID NO: 35 and SEQ ID NO: 36, or have one mutation selected from deletion, insertion or substitution. In some embodiments, the antigen-binding fragment of the anti-PD-L1 antibody of the present invention comprises HCDR1, HCDR2 and HCDR3, which are identical to the amino acid sequences shown in SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO: 33, or have one mutation selected from deletion, insertion or substitution, and LCDR1, LCDR2 and LCDR3, which are identical to the amino acid sequences shown in SEQ ID NO: 34, SEQ ID NO: 35 and SEQ ID NO: 36, or have one mutation selected from deletion, insertion or substitution, respectively.
[0782] In some embodiments, the antigen-binding fragment of the anti-PD-L1 antibody of the present invention comprises a heavy chain variable region that is identical to the amino acid sequence shown in SEQ ID NO: 37 or has 1, 2 or 3 mutations selected from deletion, insertion or substitution, and a light chain variable region that is identical to the amino acid sequence shown in SEQ ID NO: 38 or has 1, 2 or 3 mutations selected from deletion, insertion or substitution. In some embodiments, the antigen-binding fragment of the anti-PD-L1 antibody of the present invention comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 37 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 38.
[0783] Immunoglobulin Fc domain
[0784] The "immunoglobulin Fc domain" in the bispecific antibody of the present invention comprises all the amino acid residues of the naturally occurring immunoglobulin Fc domain or comprises a portion of the amino acid residues of the naturally occurring immunoglobulin Fc domain. The immunoglobulin Fc domain provides favorable pharmacokinetic properties to the bispecific antibody of the present invention, including but not limited to long serum half-life.
[0785] An immunoglobulin Fc domain is typically a dimeric molecule that can be produced by papain digestion or trypsin digestion of an intact (full-length) immunoglobulin or can be produced recombinantly and comprises a CH2 domain, a CH3 domain, and optionally a CH4 domain.
[0786] In some embodiments, the IgG Fc region comprises an IgG CH2 domain and an IgG CH3 domain. In some embodiments, the immunoglobulin Fc domain has an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 9. In some embodiments, the immunoglobulin Fc domain has an amino acid sequence as shown in SEQ ID NO: 9.
[0787] In some embodiments, the immunoglobulin Fc domain of the present invention is the Fc domain of human IgG1, IgG2, IgG3 or IgG4; preferably, it is the Fc domain of human IgG4.
[0788] In some embodiments, the immunoglobulin Fc domain of the present invention further comprises a peptide sequence obtained by subjecting its amino acid sequence to one or more amino acid substitutions, deletions or derivatizations. In some embodiments, the antibody or antigen-binding fragment thereof of the present invention, wherein the immunoglobulin Fc domain is selected from an amino acid sequence identical to SEQ ID NO: 9-17 or having 1, 2, 3, 4 or 5 mutations selected from deletions, insertions or substitutions. In some embodiments, the antibody or antigen-binding fragment thereof of the present invention, wherein the immunoglobulin Fc domain is selected from an amino acid sequence as shown in SEQ ID NO: 9-17.
[0789] Bispecific Antibodies
[0790] The present invention provides a bispecific antibody targeting 4-1BB and PD-L1, which comprises two polypeptide chains, wherein each polypeptide chain comprises
[0791] (a) 4-1BB binding domain;
[0792] (b) an immunoglobulin Fc domain; and
[0793] (c) PD-L1 binding domain.
[0794] The connection order from N-terminus to C-terminus is N'-(a)-(c)-(b)-C', N'(c)-(a)-(b)-C', N'-(b)-(c)-(a)-C' or N'(b)-(a)-(c)-C', and the domains are directly connected, connected through the hinge region, or indirectly connected through a linker. In some embodiments, the connection mode of each domain on the two polypeptide chains is the same or different. In some embodiments, the linker for indirect connection between domains is (GGGGS)n, where n is selected from an integer of 1-10. In some embodiments, the linker for indirect connection between domains is (GGGGS)n, where n is selected from 2 or 4.
[0795] The present invention uses a binding domain targeting PD-L1 as the molecular part of the bispecific antibody that blocks the PD-1 / PD-L1 pathway, which is used to block negative regulatory signals, restore T cell activity, and thus enhance immune response; it can also be used to enrich bispecific antibodies in tissues with high PD-L1 expression abundance, and selectively enhance the activity of the 4-1BB binding domain. The present invention uses the 4-1BB binding domain as the immunomodulatory molecule part in the bispecific antibody, which is used to activate downstream pathways, enhance T cell proliferation activity and immune response ability, and enhance the ability of immune cells to release immune cytokines such as IL-2 and IFNγ, effectively inhibiting tumor occurrence and development.
[0796] In some embodiments, the bispecific antibodies of the invention are present in an amount of 10 -8 M or less, for example, 10 -9 M to 10 -12 The dissociation constant (KD) of 10 -8 M or less, for example, 10 -9 M to 10 -12 The dissociation constant (KD) of M specifically binds to the 4-1BB molecule.
[0797] In some embodiments, the bispecific antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, wherein the heavy chain is selected from SEQ ID NO: 18-26 or has 1, 2, 3, 4 or 5 selected from deletion, insertion or substitution mutations. The amino acid sequence, the light chain is selected from SEQ ID NO: 27 or has 1, 2, 3, 4 or 5 selected from deletion, insertion or substitution mutations. In some embodiments, the antibody or antigen-binding fragment thereof targeting 4-1BB of the present invention comprises a heavy chain and a light chain, wherein the heavy chain is selected from the amino acid sequence shown in SEQ ID NO: 18-26, and the light chain is selected from the amino acid sequence shown in SEQ ID NO: 27.
[0798] In some embodiments, the bispecific antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, wherein the heavy chain is an amino acid sequence identical to SEQ ID NO: 28 or SEQ ID NO: 29 or having 1, 2, 3, 4 or 5 mutations selected from deletion, insertion or substitution, and the light chain is an amino acid sequence identical to SEQ ID NO: 30 or having 1, 2, 3, 4 or 5 mutations selected from deletion, insertion or substitution. In some embodiments, the antibody or antigen-binding fragment thereof targeting 4-1BB of the present invention comprises a heavy chain and a light chain, wherein the heavy chain is an amino acid sequence as shown in SEQ ID NO: 28 or SEQ ID NO: 29, and the light chain is an amino acid sequence as shown in SEQ ID NO: 30.
[0799] In some embodiments, the amino acid changes include amino acid deletions, insertions or substitutions. In some embodiments, the bispecific antibodies of the invention include those having amino acid sequences that have been mutated by amino acid deletions, insertions or substitutions, but still have at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the above-mentioned bispecific antibodies.
[0800] In some embodiments, the polynucleotide encoding the antibody of the present invention includes a polynucleotide that has been mutated by nucleotide deletion, insertion or substitution, but still has at least about 60%, 70%, 80%, 90%, 95% or 100% identity with the CDR corresponding coding region depicted in the sequence described above.
[0801] In some embodiments, the bispecific antibodies provided herein can be further modified to contain other non-protein moieties known in the art and readily available. Suitable moieties for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
[0802] Antibody expression
[0803] Bispecific Antibody K2
[0804] Heavy chain coding sequence (immunoglobulin heavy chain-linker-scFv): (SEQ ID NO: 68)
[0805]
[0806] Light chain coding sequence: (SEQ ID NO: 69)
[0807] Gacatcgtgatgacccagagccccgacagcctggccgtgagcctgggcgagagagccaccatcaactgcaag
[0808] gccagccagaacgtggacaccagcgtggcctggttccagcagaagcccggccagccccccaaggccctgatctaca
[0809] gcgccagcttcagatacagcggcgtgcccgacagattcagcggcagcggcagcggcaccgacttcaccctgaccatc
[0810] agcagcctgcaggccgaggacgtggccgtgtacttctgccagcagtactacggctaccccttcaccttcggccagggc
[0811] accaagctggagatcaagcgaactgtggctgcaccatctgtcttcatcttcccgccatctgatgagcagttgaaatctgg
[0812] aactgcctctgttgtgtgcctgctgaataacttctatcccagagaggccaaagtacagtggaaggtggataacgccctcc
[0813] aatcgggtaactcccaggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagcagcaccctgac
[0814] gctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgcccgtca
[0815] caaagagcttcaacaggggagagtgttag
[0816] Bispecific antibody KF2:
[0817] Heavy chain coding sequence (heavy chain of immunoglobulin - linker - scFv): (SEQ ID NO:70)
[0818] CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGC
[0819] CTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACTGGCTACT
[0820] ATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGG
[0821] ATGGATCAACCCTCAGAGTGGTGGCACAAACTATGCACAGAAGTTTCAGG
[0822] GCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCCTACATGGA
[0823] GCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAG
[0824] AGGGGGGGGAGTGGCTGGCCATCCCGTTTGACTACTGGGGCCAGGGAAC
[0825] CCTGGTCACCGTCTCCTCAgctagcaccaagggccccagcgtgttccccctggccccttgcagcaga
[0826] agcaccagcgagagcacagccgccctgggctgcctggtgaaggactacttccccgagcccgtgaccgtgtcctggaa
[0827] cagcggcgctctgaccagcggcgtgcataccttccccgccgtgctccagagcagcggactgtactccctgagcagcg
[0828] tggtgaccgtgccttccagcagcctgggcaccaagacctacacctgcaacgtggaccacaagcccagcaacaccaag
[0829] gtggacaagagagtggagagcaagtacggccctccctgccccccttgccctgcccccgagttcctgggcggacctag
[0830] cgtgttcctgttcccccccaagcccaaggacaccctgatgatcagcagaacccccgaggtgacctgcgtggtggtgga
[0831] cgtgTGCcaggagTGCcccgaggtccagtttaattggtacgtggacggcgtggaagtgcataacgccaagacca
[0832] agcccagagaggagcagttcaacagcacctacagagtggtgtccgtgctgaccgtgctgcaccaggactggctgaac
[0833] ggcaaggaatacaagtgcaaggtctccaacaagggcGCtcctagcagcatcgagaagaccatcagcaaggccaag
[0834] ggccagccacgggagccccaggtctacaccctgccacctagccaagaggagatgaccaagaaccaggtgtccctga
[0835] cctgtctggtgaaaggcttctatcccagcgatatcgccgtggagtgggagagcaacggccagcccgagaacaactac
[0836] aagaccaccccccctgtgctggacagcgacggcagcttcttcctgtactccagactgaccgtggacaagtccagatgg
[0837] caggagggcaacgtcttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgagcct
[0838] gagcctgGGAGGCGGAGGCAGCGGCGGAGGCGGATCCGAGGTGCAGCTGCT
[0839] GGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGACTGAGC
[0840] TGCGCCGCCAGCGGCGCCGCCCCCTGCATGGCCTGGTTCAGACAGGCCCC
[0841] CGGCAAGGGCCTGGAGGGCGTGGCCGCCAGCGTGAGAGGCGGCCTGAGC
[0842] CCCTACTACGCCGACAGCGTGAAGGGCAGATTCACCATCAGCCACGACAT
[0843] CCCCAAGAACACCATGTACCTGCAGATGAACAGCCTGAGAGCCGAGGAC
[0844] ACCGCCGTGTACTACTGCGCCGCCAGAGCCACCTTCTACAGATGCGAGGG
[0845] CGACGCCAGCAGCTACACCTACTGGGGCCAGGGCACCCTGGTGACCGTG
[0846] AGCAGCTGA
[0847] Light chain coding sequence: (SEQ ID NO:71)
[0848] Gacatcgtgatgacccagagccccgacagcctggccgtgagcctgggcgagagagccaccatcaactgcaaggccagccagaacgtggacaccagcgtggcctggttccagcagaagcccggccagcccccccaaggccctgatctacagcgccagcttcag atacagcggcgtgcccgacagattcagcggcagcggcagcggcaccgacttcaccctgaccatcagcagcctgcaggccgaggacgtggccgtgtacttctgccagcagtactacggctaccccttcaccttcggccagggcaccaagctggagatcaagc gaactgtggctgcaccatctgtcttcatcttcccgccatctgatgagcagttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccagagaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactcccaggag agtgtcacagagcaggacagcaaggacagcacctacagcctcagcagcaccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggggagagtgttag
[0849] In another aspect, the present invention provides a polynucleotide encoding a bispecific antibody as described herein. The polynucleotide may comprise a polynucleotide encoding an amino acid sequence of a heavy chain variable region and / or a light chain variable region of an antibody, or a polynucleotide comprising an amino acid sequence encoding a heavy chain and / or a light chain of a bispecific antibody. In some embodiments, the polynucleotide of the present invention comprises a nucleotide sequence encoding a heavy chain as shown in SEQ ID NO: 28 and / or a nucleotide sequence encoding a light chain as shown in SEQ ID NO: 30. In some embodiments, the polynucleotide of the present invention comprises a nucleotide sequence encoding a heavy chain as shown in SEQ ID NO: 29 and / or a nucleotide sequence encoding a light chain as shown in SEQ ID NO: 30.
[0850] The heavy chain encoding nucleotide sequence of the bispecific antibody K2 of the present invention is shown in SEQ ID NO:68; the light chain encoding nucleotide sequence of the bispecific antibody K2 of the present invention is shown in SEQ ID NO:69; the heavy chain encoding nucleotide sequence of the bispecific antibody K2F of the present invention is shown in SEQ ID NO:70; the light chain encoding nucleotide sequence of the bispecific antibody K2F of the present invention is shown in SEQ ID NO:71.
[0851] In another aspect, the present invention provides an expression vector comprising a polynucleotide as described herein, preferably, the vector is a eukaryotic expression vector. In some embodiments, the polynucleotide as described herein is contained in one or more expression vectors.
[0852] In another aspect, the present invention provides a host cell comprising the polynucleotide as described herein or the expression vector as described herein. Preferably, the host cell is a eukaryotic cell, more preferably a mammalian cell.
[0853] In another aspect, the present invention provides a method for preparing a bispecific antibody as described herein, the method comprising expressing the antibody in a host cell as described herein under conditions suitable for expression of the antibody, and recovering the expressed bispecific antibody from the host cell.
[0854] The present invention provides mammalian host cells for expressing the recombinant antibodies of the present invention, including many immortalized cell lines available from the American Type Culture Collection (ATCC). These include Chinese hamster ovary (CHO) cells, NS0, SP2 / 0 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells, A549 cells, 293T cells and many other cell lines. Mammalian host cells include humans, mice, rats, dogs, monkeys, pigs, goats, cattle, horses and hamster cells. Particularly preferred cell lines are selected by determining which cell line has a high expression level.
[0855] In one embodiment, the present invention provides a method for preparing a bispecific antibody of the present invention, wherein the method comprises, when the expression vector is introduced into a mammalian host cell, producing the bispecific antibody by culturing the host cell for a sufficient period of time to allow the bispecific antibody to be expressed in the host cell, or more preferably, the bispecific antibody to be secreted into the culture medium in which the host cell is grown. The bispecific antibody can be recovered from the culture medium using standard protein purification methods.
[0856] It is likely that bispecific antibodies expressed by different cell lines or in transgenic animals have different glycosylation from each other. However, all bispecific antibodies encoded by the nucleic acid molecules provided herein or comprising the amino acid sequences provided herein are part of the present invention, regardless of the glycosylation of the antibodies. Likewise, in certain embodiments, non-fucosylated antibodies are advantageous because they generally have more potent efficacy than their fucosylated counterparts in vitro and in vivo, and are not immunogenic because their sugar structures are normal components of natural human serum IgG.
[0857] Pharmaceutical compositions and pharmaceutical preparations
[0858] In another aspect, the present invention provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof as described herein, the polynucleotide as described herein, the expression vector as described herein or the host cell as described herein, and a pharmaceutically acceptable carrier or excipient.
[0859] It should be understood that the antibodies or antigen-binding fragments thereof or pharmaceutical compositions provided by the present invention can be integrated with suitable carriers, excipients and other agents in the formulation for combined administration, thereby providing improved transfer, delivery, tolerance and the like.
[0860] The term "pharmaceutical composition" refers to a preparation which permits the active ingredient contained therein to exist in biologically effective form, and which contains no additional ingredients that are unacceptably toxic to a subject to which the preparation would be administered.
[0861] Pharmaceutical preparations containing the antibodies or antigen-binding fragments thereof described herein can be prepared by mixing the antibodies or antigen-binding fragments thereof of the present invention having the desired degree of purity with one or more optional pharmaceutical excipients (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980)), preferably in the form of aqueous solutions or lyophilized preparations.
[0862] The pharmaceutical composition or preparation of the present invention may also include one or more other active ingredients, which are required for the specific indications to be treated, preferably those active ingredients with complementary activities that do not adversely affect each other. In some embodiments, other active ingredients are chemotherapeutic agents, immune checkpoint inhibitors, growth inhibitors, antibiotics or various known anti-tumor or anti-cancer agents, and the active ingredients are appropriately combined in an amount effective for the intended use.
[0863] In some embodiments, the pharmaceutical composition of the present invention further comprises a composition of polynucleotides encoding antibodies or antigen-binding fragments thereof.
[0864] In another aspect, the present invention provides a pharmaceutical combination comprising the antibody or antigen-binding fragment thereof as described herein, the polynucleotide as described herein, the expression vector as described herein, the host cell as described herein, or the pharmaceutical composition as described herein, and one or more additional therapeutic agents.
[0865] In another aspect, the present invention provides a kit comprising an antibody or antigen-binding fragment thereof targeting 4-1BB as described herein, a polynucleotide as described herein, an expression vector as described herein, a host cell as described herein, or a pharmaceutical composition as described herein.
[0866] Medical Uses
[0867] In another aspect, the present invention provides the use of the antibody or antigen-binding fragment thereof, polynucleotide, expression vector, host cell, or pharmaceutical composition as described above in the preparation of a medicament for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity; preferably, the disease or condition is cancer; more preferably, the cancer is selected from lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, pancreatic cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer, and blood cancer.
[0868] In another aspect, the present invention provides an antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, or a pharmaceutical composition as described above, for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity, preferably the disease or condition is cancer; preferably, the disease or condition is cancer; more preferably, the cancer is selected from lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer, and blood cancer.
[0869] In another aspect, the present invention provides a method for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity, comprising administering to a subject in need thereof an antibody or antigen-binding fragment thereof, a polynucleotide, an expression vector, a host cell, or a pharmaceutical composition as described above; preferably, the disease or condition is cancer; more preferably, the cancer is selected from lymphoma, myeloma, ovarian cancer, breast cancer, urothelial carcinoma, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer, and blood cancer.
[0870] In some embodiments, the cancer or tumor described herein can be selected from lymphoma, myeloma, ovarian cancer, breast cancer, urothelial cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer, blood cancer.
[0871] In some embodiments, the administration of the present invention includes, but is not limited to, oral, intravenous, subcutaneous, intramuscular, intraarterial, intraarticular (e.g., in arthritic joints), by inhalation, aerosol delivery, or intratumoral administration, etc.
[0872] In some embodiments, the invention provides for co-administering to a subject a therapeutically effective amount of one or more therapies (eg, treatment modalities and / or other therapeutic agents). In some embodiments, the therapy comprises surgery and / or radiation therapy.
[0873] In some embodiments, the methods or uses provided by the present invention also include administering one or more therapies (e.g., treatment modalities and / or other therapeutic agents) to an individual. The antibodies of the present invention may be used alone or in combination with other therapeutic agents in a therapy. For example, they may be co-administered with at least one additional therapeutic agent.
[0874] Methods for diagnosis and detection
[0875] In another aspect, the present invention provides a method for detecting the presence of 4-1BB or PD-L1 in a sample using an antibody or antigen-binding fragment thereof as described herein. The term "detection" as used herein includes quantitative or qualitative detection. In some embodiments, the sample is a biological sample. In certain embodiments, the biological sample is blood, serum or other liquid samples of biological origin. In certain embodiments, the biological sample comprises cells or tissues.
[0876] The present invention includes all combinations of the described specific embodiments. Further embodiments of the present invention and the full scope of applicability will become apparent from the detailed description provided below. However, it should be understood that although the detailed description and specific embodiments indicate preferred embodiments of the present invention, these descriptions and embodiments are provided only by way of illustration, because various changes and modifications within the spirit and scope of the present invention will become apparent to those familiar with the art from this detailed description. For all purposes, all publications, patents and patent applications cited herein, including citations, will be incorporated herein by reference in their entirety. The relevant sequences of the 4-1BB antibody or antigen-binding fragment used in the present invention are non-limiting examples, cited from the invention patent of application number PCT / CN2022 / 135784. The relevant sequences of the PD-L1 antibody or antigen-binding fragment used in the present invention are non-limiting examples, cited from the invention patent of application number PCT / CN2018 / 076669 or PCT / CN2022 / 089289.
[0877] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention.
[0878] Example
[0879] The present invention is illustrated by the following examples, but is not intended to limit the present invention in any way. The present invention has been described in detail herein, and specific embodiments thereof are disclosed therein. It will be apparent to those skilled in the art that various changes and modifications will be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.
[0880] In liquid pharmaceutical compositions, the buffer system and pH closely affect the stability of the antibody, and each antibody with unique physicochemical properties has the most suitable type of buffer and pH. This embodiment aims to preliminarily screen out the best buffer system and stabilizer so that the bispecific antibody targeting 4-1BB and PD-L1 disclosed in the present invention has the best stability to be suitable for clinical application.
[0881] The present invention uses the following abbreviations:
[0882] hr means hours;
[0883] D represents day, for example, 3D in Table 15 represents shaking for 3 days;
[0884] W stands for week;
[0885] M stands for month;
[0886] C represents the number of freeze-thaw cycles, for example, 3C in Table 15 represents 3 freeze-thaw cycles;
[0887] FT indicates freeze-thaw cycle;
[0888] RT means room temperature;
[0889] T0 represents the initial test of the prescription sample before the sample is placed;
[0890] MFI indicates microfluidics imaging analysis. (one)
[0892] Example 1: Construction of 4-1BB monoclonal antibody IgG4Fc mutant monoclonal antibody expression vector
[0893] In order to construct the mutation required for the invention, the Fc mutation was first introduced from the 4-1BB monoclonal antibody for testing. GenScript was commissioned to synthesize JS011-3LC, which was digested by SapI and connected to the HXT2 vector to obtain the expression vector HXT2-JS011-3LC. GenScript was commissioned to synthesize JS011-3HC, which was digested by SapI and connected to the HXT4S vector to obtain the expression vector HXT4S-JS011-3HC. Design point mutation primers for PCR amplification to obtain each IgG4-Fc mutant fragment, which was digested and recovered with NheI and NotI, and HXT4S-JS011-3HC was digested with NheI and NotI at the same time and recovered to obtain the vector, which was connected with T4DNA ligase to obtain the IgG4Fc mutant heavy chain. The heavy chain and light chain expression plasmids of various monoclonal antibodies were mixed and paired to transfect expression cells (CHOK1 18, Suzhou Junmeng) to obtain 8 monoclonal antibodies, the monoclonal antibody variable region sequences are shown in Table 1, and the full-length sequences of the heavy chain and light chain are shown in Table 2.
[0894] Unless otherwise specified, the 4-1BB monoclonal antibody in the subsequent examples is obtained by the method in this example.
[0895] Table 1: Variable regions and CDR sequences of 4-1BB antibodies or antigen-binding fragments thereof
[0896] Heavy chain variable region Light chain variable region HCDR1 (SEQ ID NO: 1) LCDR1 (SEQ ID NO:4) HCDR2 (SEQ ID NO: 2) LCDR2 (SEQ ID NO:5) HCDR3 (SEQ ID NO: 3) LCDR3 (SEQ ID NO:6) VH (SEQ ID NO:7) VL (SEQ ID NO: 8)
[0897] Table 2: 4-1BB antibody heavy and light chain sequences containing Fc mutations
[0898]
[0899]
[0900] Example 2: Mutation and construction of bispecific antibody molecule expression vector
[0901] In order to test the effect of the Fc mutation in Example 1, the Fc mutation contained in mAb 8 was further introduced into the bispecific antibody to construct a bispecific antibody molecule containing the mutation.
[0902] The coding sequences of the heavy chain constant region IgG4 and the light chain constant region κ were cloned from human B lymphocytes (from Beijing Institute of Hematology) and introduced into the pTT5 plasmid to form vectors HXT4S and HXT2, respectively.
[0903] 2.1 Construction of anti-4-1BB control antibody expression vector
[0904] Light chain of anti-4-1BB antibody: We commissioned GenScript Biotech Co., Ltd. (hereinafter referred to as GenScript) to synthesize the DNA sequence encoding JS011-3LC, which was digested with BSPQI and ligated to the HXT2 vector (Junshi Biosciences' self-modified vector, derived from pTT5) to obtain the expression vector HXT2-JS011-3LC;
[0905] Heavy chain of anti-4-1BB antibody: GenScript was commissioned to synthesize the DNA sequence encoding JS011-Ref HC, which was digested with BSPQI and connected to the HXT4s vector (Junshi Biosciences' self-modified vector, derived from pTT5) to obtain the expression vector HXT4s-JS011-Ref HC.
[0906] The heavy and light chain sequences of the anti-4-1BB antibody are the same as those in Example 1.
[0907] 2.2 Construction of anti-PD-L1 control antibody expression vector
[0908] Light chain of anti-PD-L1 antibody: We commissioned GenScript to synthesize the DNA sequence encoding JS003-Ref, which was digested with BSPQI and ligated to the HXT2 vector (Junshi Biosciences' self-modified vector, derived from pTT5) to obtain the expression vector HXT2-9B1-LC3;
[0909] Heavy chain of anti-PD-L1 antibody: GeneScript was commissioned to synthesize the DNA sequence encoding JS003-Ref, which was digested with BSPQI and connected to the HXT4s vector (Junshi Biosciences' independently modified vector, derived from pTT5) to obtain the expression vector HXT4s-9B1-HC2.
[0910] Table 3: Variable regions and CDR sequences of PD-L1 antibodies or antigen-binding fragments
[0911] Heavy chain variable region Light chain variable region HCDR1 (SEQ ID NO:31) LCDR1 (SEQ ID NO:34) HCDR2 (SEQ ID NO:32) LCDR2 (SEQ ID NO:35) HCDR3 (SEQ ID NO:33) LCDR3 (SEQ ID NO:36) VH (SEQ ID NO:37) VL (SEQ ID NO:38)
[0912] 2.4 Construction of bispecific antibody molecule expression vector
[0913] Bispecific antibody molecule JS211 402 (K2):
[0914] GenScript was commissioned to synthesize the DNA sequence encoding IgG4-JS011-3ScFv, which was digested with NheI / NotI and ligated into the HXT4s-9B1-HC2 vector (same as in 2.2 above) to obtain the first expression vector HXT4s-JS003-G4HC-011-3ScFv. The second expression vector HXT2-JS011-3LC was the same as in Example 1.
[0915] Bispecific antibody molecule JS211 402FCS (K2F):
[0916] GenScript was commissioned to synthesize the DNA sequence encoding IgG4-M-JS011-3ScFv, which was digested with NheI / NotI and ligated into the HXT4s-9B1-HC2 vector (same as in 2.2 above) to obtain the first expression vector HXT4s-JS003-M-G4HC-011-3ScFv. The second expression vector HXT2-JS011-3LC was the same as in Example 1.
[0917] The structure of JS211-402(K2) and JS211-402FCS(K2F) is as follows Figure 1 shown.
[0918] Bispecific antibody molecule JS211ref (Genmab):
[0919] GenScript was commissioned to synthesize the DNA sequence encoding PD-L1-Ref-LC1, which was digested with SaptI and connected to the HXT3 vector to obtain the first expression vector HXT3-PD-L1-Ref-LC1 (Genmab). GenScript was commissioned to synthesize the DNA sequence encoding IgG1-PD-L1-Ref-HC1, which was digested with EcoRI / NotI and connected to HXT1S to obtain the second expression vector HXT1s-PD-L1-Ref-HC1 (Genmab). GenScript was commissioned to synthesize the DNA sequence encoding CD137-Ref-LC2, which was digested with SaptI and connected to the HXT3 vector to obtain the third expression vector HXT3-CD137-Ref-LC2 (Genmab). GenScript was commissioned to synthesize the DNA sequence encoding IgG1-P CD137-Ref-HC2, which was digested with EcoRI / NotI and connected to HXT1S to obtain the fourth expression vector HXT1s-CD137-Ref-HC2 (Genmab).
[0920] Unless otherwise specified, the bispecific antibodies in the subsequent examples are obtained by the method in this example.
[0921] Table 4: Bispecific antibody heavy and light chain sequences
[0922]
[0923] Example 3: Expression and purification of mutant monoclonal antibodies and bispecific antibody molecules
[0924] 3.1 Expression of bispecific antibody molecules
[0925] Transient expression and purification of bispecific antibody molecules JS211-402, JS211-402FCS and ref Genmab: The plasmids constructed above were extracted using an endotoxin-controlled kit for subsequent mammalian cell expression. The CHO-K1 cells in culture (which have been modified at the genome level to make them suitable for transient expression) were counted. When the cell density was between 2-6*10 6 / mL, use CD CHO medium for subculture and amplification. Dilute the cell density to 1.5-2.0*10 one day before transfection. 6 / mL, the next day when the cell density reached about 3.5*10 6 / mL for transfection. First add one-tenth of the transfection volume of culture medium, then add 1-2ug / mL of plasmid, and finally add 3-14ug / mL of PEI, mix well and incubate at room temperature for no more than 5 minutes, and finally slowly add the transfection mixture to the pre-treated cells, mixing while adding. The transfected mixture is placed in a shaker for culture at 36.5°C, 120rpm, and 7% CO2. The culture cycle is 6-10 days after transfection, and feed is added once at D1, D3, D5, D7, and D9 respectively.
[0926] 3.2 Purification of bispecific antibody molecules
[0927] After the above transfection mixture was cultured, the cell supernatant was collected by centrifugation at 8000rpm for 15min and sterile filtration was performed. Purification was performed using an AKTA Avant purifier. The column filled with Mabselect SURE LX affinity filler was first CIPed for 30min with 0.1M NaOH, then equilibrated with PBS buffer for 3-5CV before loading. After loading, the affinity chromatography elution buffer was used for elution, and finally the target protein was eluted with acetic acid-sodium acetate buffer at pH 3.6. The sample was neutralized with 1MTris buffer, adjusted to pH 5.5, and the sample was sent to SEC-HPLC for testing the purity of the sample. The remaining samples were subjected to the next step of purification; cationic fillers ESHMUNO CPX and Capto MMC ImpRes fillers were selected for purification, the equilibrium solution was pH5.5 50mM acetic acid-sodium acetate system, the eluent was pH5.5 50mM acetic acid-sodium acetate + 1M NaCl buffer system, and a linear elution method was used to collect the target protein. The final SEC-HPLC monomer purity could reach more than 95%, and the purified bispecific antibody molecule was obtained.
[0928] Example 4: Activity study of antibodies containing Fc mutations
[0929] 4.1 Binding activity of human IgG4Fc mutant mAb to human CD32B
[0930] To study the binding activity of human IgG4Fc mutant 4-1BB antibody to human CD32B, the Fortebio octetRed96e (Sartorius) instrument was used to detect the affinity of human IgG4Fc mutant monoclonal antibody to human CD32B protein.
[0931] The method for determining the binding affinity of human IgG4Fc mutant monoclonal antibody to human CD32B protein is as follows: CD32B-his at a concentration of 1.5 μg / ml is bound to the HIS1K probe (Cat No: 18-5120; Lot: 2105017411). Human IgG4Fc mutant monoclonal antibody is diluted 2 times from 12000nM with 1X Fortebio working solution (1X PBS+0.05% P20+500nM NaCl) to set 4 concentration gradients to bind to CD32B-his, dissociate in 1X Fortebio working solution, and use Fortebio octet Red96e (Sartorius) to measure the binding and dissociation signals. The affinity KD value is determined using software fitting.
[0932] As shown in Table 5, mAb 3, mAb 5, mAb 6, mAb 7 and mAb 8 did not bind to human CD32B, while other human IgG4Fc mutant mAbs all significantly bound to human CD32B.
[0933] Table 5: Binding affinity of 4-1BB antibodies containing Fc mutations to human CD32B
[0934]
[0935]
[0936] In Table 5, N / A indicates no significant binding to CD32b.
[0937] 4.2 Study on disulfide bond formation before and after human IgG4 Fc mutation
[0938] Disulfide bonds play an important role in building and maintaining the three-dimensional structure of proteins and exerting biological functions. Using specific protein endonucleases to hydrolyze proteins under non-reducing conditions can obtain peptides containing disulfide bonds. Using LC-MS to separate and detect the enzyme digestion products of the sample, combined with software analysis and manual spectrum confirmation, and comparing the precise molecular weight of the sample and theoretical peptides, it can be confirmed whether the disulfide bond connection of the sample is consistent with the theory.
[0939] After the JS011-BS3-402FCS and JS011-BS3-402 samples were concentrated and dried by vacuum centrifugation, protein denaturation reduction solution was added (non-reduced samples were not added with DTT, but ultrapure water was used instead), and placed at 37°C for 1 hour. IAM (iodoacetamide) was added to the above samples and placed at room temperature in the dark for 0.5 hours for alkylation treatment, and then diluted with 50mM Tris-HCl solution, 100μL of the diluted samples were digested with 1mg / mL Glu-C for 4 hours, and finally 2μL FA was added to terminate the reaction. The generated samples were analyzed by LC-MS at the same time, and the generated peptides were separated by reverse phase chromatography, and the chromatographic column was ACQUITY UPLC peptide CSH C18 (specification: 2.1×150mm, 1.7μm), and entered the Agilent Q-TOF high-resolution mass spectrometer for mass spectrometry full molecular weight and secondary fragment ion scanning. According to the results collected by the mass spectrometer, the correctness of the disulfide bond pairing of the JS011 sample was determined by combining the non-reduced and reduced peptide UV comparison spectra. The disulfide bond pairing results introduced by the JS211-402 FCS design are detailed in Table 6, and the typical confirmation results of disulfide bonds are shown in Figure 2 .
[0940] The results showed that there was a designed disulfide bond pairing HC:C265=HC:C268 in JS211-402FCS, and the normal pairing was a two-chain symmetrical bispecific antibody structure, while the disulfide bond did not exist in JS211-402.
[0941] Table 6: Confirmation results of disulfide bond pairing of bispecific antibodies
[0942]
[0943]
[0944] 4.3 Activity detection of human IgG4Fc mutated 4-1BB antibody in luciferase reporter gene system (CHO FcGR2B4G6 / JurkatNFKB 4-1BB dual cells)
[0945] To further confirm that the 4-1BB antibody with a CD32B-free binding activity mutation (CD32B silencing) introduced into the Fc region cannot transmit related signaling pathways through CD32B, its activity was detected using the luciferase reporter gene system.
[0946] CHO FcGR2B 4G6 (stable expression of CD32B) was added at 3×10 4 The cells were added to a 96-well flat-bottom white plate (Corning, Cat#3917) and incubated overnight at 37°C. The next day, effector cells Jurkat NFKB 4-1BB (stable expression of NlucP / NFKB-RE and 4-1BB) were added at 1×10 per well. 5 The number of cells was added to the cell plate. Then, the anti-4-1BB monoclonal antibody JS011-phage3 and the anti-4-1BB monoclonal antibody (CD32B Silence) JS011-3HC-S267C-D270C-L328NST, JS011-3HC-S267C-D270C-L328N, JS011-3HC-S267C-D270C-L328A (starting concentration of 10 μg / ml, 3-fold dilution, a total of 10 concentration gradients) were added to the cell plate using an experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell antibody mixture system and the chemiluminescent signal was detected using a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted using GraphPad prism software, and the EC50 value was calculated.
[0947] like Figure 3 As shown, JS011-phage3 has a strong activity in activating T cells in the luciferase reporter gene system composed of CHO FcGR2B 4G6 cells and effector cells Jurkat NFKB 4-1BB. Samples of monoclonal antibody 6, monoclonal antibody 7 and monoclonal antibody 8 with CD32B silencing mutation based on JS011-phage3 are inactive, proving that the mutation leads to the loss of activity of CD32B-dependent anti-4-1BB monoclonal antibodies.
[0948] 4.4 Activity detection of anti-4-1BB / PD-L1 bispecific antibody in luciferase reporter gene system (CHO FcGR2B4G6 / Jurkat NFKB 4-1BB dual cells)
[0949] To further confirm that the 4-1BB / PD-L1 bispecific antibody with a CD32B-free binding activity mutation (CD32B silencing) introduced into the Fc is unable to transmit related signaling pathways through CD32B, its activity was detected using the luciferase reporter gene system.
[0950] CHO FcGR2B 4G6 (stable expression of CD32B) was added at 3×10 4 The cells were added to a 96-well flat-bottom white plate (Corning, Cat#3917) and incubated overnight at 37°C. The next day, effector cells Jurkat NFKB 4-1BB (stable expression of NlucP / NFKB-RE and 4-1BB) were added at 1×10 per well. 5 The number of cells was added to the cell plate. Then, the anti-4-1BB / PD-L1 bispecific antibodies JS211-K2 and JS211-K2F (starting concentration of 667nM, 4-fold dilution, a total of 10 concentration gradients) were added to the cell plate with experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixture system and the chemiluminescent signal was detected with a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted by GraphPad prism software, and the EC50 value was calculated. The positive control was JS011-phage3; the negative control was anti-KLH hu-IgG4 antibody.
[0951] Depend on Figure 4 It can be seen that the EC50 value of JS211-K2 is 15nM, and its activity is significantly weaker than that of JS011-phage3, indicating that placing the 4-1BB binding domain in the form of scFv at the C-terminus of the Fc domain will lead to a significant weakening of the CD32B-related cross link; and JS211-K2F containing CD32silence has no obvious activity relative to JS011-phage3 or JS211-K2, which also shows that the cross link caused by CD32B disappears after the dual antibody mutation.
[0952] Example 5: Anti-4-1BB / PD-L1 bispecific antibody in luciferase reporter gene system (CHO PD-L1 / Activity detection in Jurkat NFKB 4-1BB cells
[0953] To further confirm that the 4-1BB / PD-L1 bispecific antibody with a CD32B-free binding activity mutation (CD32B silencing) introduced into the Fc cannot transmit related signal pathways through CD32B, but does not affect the signal transmission of the PD-L1 end, its activity was detected using the luciferase reporter gene system.
[0954] The bispecific antibody in this example was obtained by the methods in Examples 2 and 3. CHO PD-L1 (stable expression of human PD-L1) was added at 5×10 4 The cells were added to a 96-well flat-bottom white plate (Corning, Cat#3917) and incubated overnight at 37°C. The next day, effector cells Jurkat NFKB 4-1BB (stable expression of NlucP / NFKB-RE and 4-1BB) were added at 1×10 per well. 5 The number of cells was added to the cell plate. Then, the anti-4-1BB / PD-L1 bispecific antibodies JS211-K2 and JS211-K2F (starting concentration of 167nM, 4-fold dilution, a total of 9 concentration gradients) were added to the cell plate with experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixture system and the chemiluminescent signal was detected with a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted by GraphPad prism software to calculate the EC50 value. The negative controls were anti-KLH hu-IgG4 antibody and JS011-phage3.
[0955] like Figure 5 As shown, JS211-K2 and JS211-K2F both have strong T cell activation activity in the luciferase reporter gene system composed of CHO PD-L1 cells and effector cells Jurkat NFKB 4-1BB, with EC50 of 88.9pM and 92.8pM, respectively; this proves that the mutation only weakens the cross link formed by CD32B and has no effect on the PD-L1-dependent cross link4-1BB activity.
[0956] The activities of JS211-K2 and JS211-K2F (CD32B silencing mutation) are comparable, proving that this mutation places 4-1BB at the C-terminus to weaken the cross link formed by CD32B, but has no effect on the PD-L1-dependent cross link 4-1BB activity.
[0957] Example 6: Cellular detection of the binding of bispecific antibodies to human 4-1BB and human PD-L1
[0958] 6.1: Cell-based detection of the binding of bispecific antibodies to human 4-1BB
[0959] To detect the binding ability of bispecific antibodies to human 4-1BB, Jurkat NFKB 4-1BB cells overexpressing human 4-1BB (stable expression of NlucP / NFKB-RE and 4-1BB) were incubated with different concentrations of anti-4-1BB / PD-L1 bispecific antibodies (starting concentration of 667nM, 3-fold dilution, a total of 12 concentration gradients) at 4°C for 30min, and then unbound antibodies were washed with staining buffer (PBS+1% FBS) and incubated with 1% (v / v) fluorescent secondary antibody goatanti-human IgG PE (SouthernBiotech, Cat#2040-09) prepared in staining buffer at 4°C for 30 minutes in the dark. Finally, cells were collected using a flow cytometer (BD, CantoⅡ model) to detect fluorescent antibodies bound to the cell surface. The raw data were analyzed using FlowJo to obtain the MFI value, and the antibody dose-dependent binding curve was fitted by GraphPad and the EC was calculated. 50 The positive controls were JS011-phage3 and JS211-Ref (Genmab); the negative control was anti-KLH hu-IgG4 antibody.
[0960] like Figure 6 As shown, the EC of JS211-K2F and JS011-phage3 50 The peak value of JS011-phage3 binding activity was higher than that of JS211-K2F within the dosage range.
[0961] 6.2: Cell-based detection of binding of bispecific antibodies to human PD-L1
[0962] To detect the binding ability of bispecific antibodies to human PD-L1, CHO-PD-L1 cells overexpressing human PD-L1 (CHO-K1 cells were purchased from ATCC cell bank, numbered CCL-61, and a stable cell line overexpressing PD-L1 was independently constructed based on this cell) were incubated with different concentrations of anti-4-1BB / PD-L1 bispecific antibody JS211-K2F (starting concentration of 25nM, 3-fold dilution, a total of 9 concentration gradients) at 4°C for 30min, and then unbound antibodies were washed with staining buffer (PBS+1% FBS) and incubated with 1% (v / v) fluorescent secondary antibody goat anti-human IgG PE (SouthernBiotech, Cat#2040-09) prepared in staining buffer at 4°C for 30min in the dark. Finally, cells were collected using a flow cytometer (BD, CantoⅡ model) to detect fluorescent antibodies bound to the cell surface. The raw data were analyzed by FlowJo to obtain the MFI value, and the antibody dose-dependent binding curve was fitted by GraphPad and the EC50 was calculated. The positive controls were JS011-phage3 and JS211-Ref (Genmab).
[0963] like Figure 7 As shown, the EC50 of JS211-K2F and JS003-Ref are 0.6 nM and 0.4 nM, respectively, and the binding activities of JS211-K2F and JS003-Ref are equivalent.
[0964] Example 7: Study on the activity of bispecific antibodies in blocking PD-1 / PD-L1 interaction
[0965] To determine the activity of bispecific antibodies in blocking PD-1 / PD-L1, target CHO PD-L1 cells (stable expression of human PD-L1 and CD3 scFv) were plated in 96-well white flat-bottom plates at 5 × 10 4 The cells were plated overnight; the next day, the medium in the cell wells was aspirated, and different concentrations of JS211-K2F (starting concentration was 67nM, 3-fold dilution, a total of 10 concentration gradients) were added to the target cells with experimental buffer (RPMI 1640 (1×) + 1% FBS) and incubated at 37°C for 30 minutes. Then, effector cells Jurkat PD-1 (stable expression of human PD-1 and luc2P / NFAT-RE) were added at 1×10 per well. 5The number of cells was added to the cell plate and incubated in a 37°C incubator for 6 hours; finally, ONE-Lite luciferase detection reagent (Vazyme, Cat#1203-03) was added to the cell antibody mixture system and the chemiluminescent signal was detected by a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted by GraphPad prism software and the EC50 value was calculated. The positive controls were JS003-Ref, JS211-Ref (Genmab), and JS211-Ref (FS), and the negative control was anti-KLH hu-IgG4 antibody.
[0966] like Figure 8 As shown, the EC50 values of JS211-K2F, JS211-Ref (Genmab), JS211-Ref (FS), and JS003-Ref were 0.4 nM, 0.7 nM, 0.3 nM, and 0.4 nM, respectively.
[0967] All of the above antibodies can effectively block the PD-1 / PD-L1 interaction, and there is no significant difference in their activity.
[0968] Example 8: Study on PD-L1-dependent 4-1BB activity of bispecific antibodies (luciferase reporter gene)
[0969] To determine the PD-L1-dependent 4-1BB activity of the bispecific antibody, CHO PD-L1 cells (highly expressing human PD-L1), MC38PD-L1 cells (moderately expressing human PD-L1), HCC827PD-L1 cells (lowly expressing human PD-L1), and MDA-MB-231 cells (no human PD-L1) were cultured at 5×10 4 The cells were added to a 96-well flat-bottom white plate (Corning, Cat#3917) and incubated overnight at 37°C. The next day, effector cells Jurkat NFKB 4-1BB (stable expression of NlucP / NFKB-RE and 4-1BB) were added at 1×10 per well. 5 The number of cells was added to the cell plate. Then, the anti-4-1BB / PD-L1 bispecific antibody JS211-K2F (starting concentration of 10 μg / ml, 4-fold dilution, a total of 10 concentration gradients) was added to the cell plate using an experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixture system and the chemiluminescent signal was detected using a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the EC50 value.
[0970] like Fig. 9As shown in the figure, in the reporter gene systems with CHO PD-L1, MC38PD-L1, and HCC827 as target cells, the upper platform signal values decreased in turn, and there was no T cell activation effect in the reporter gene system with MDA-MB-231 as target cells. This shows that the degree of T cell activation by bispecific antibodies is positively correlated with the abundance of PD-L1 expression in the target cells in the environment.
[0971] Example 9: Bispecific Antibodies in Luciferase Reporter Gene Systems in Different Abundances of PD-L1 and 4-1BB Activity detection
[0972] To determine the 4-1BB activity of the bispecific antibody in environments with different abundances of PD-L1 and 4-1BB, CHO PD-L1 cells (highly expressing human PD-L1) and MC38PD-L1 cells (moderately expressing human PD-L1) were incubated with 5 × 10 4 The cells were added to a 96-well flat-bottom white plate (Corning, Cat#3917) and incubated overnight at 37°C. The next day, effector cells Jurkat NFKB 4-1BB (stable expression of NlucP / NFKB-RE and high expression of human 4-1BB) and Jurkat NFKB 4-1BB SP (stable expression of NlucP / NFKB-RE and low expression of human 4-1BB) were added at 1×10 per well. 5 The number of cells was added to the cell plate. Then, the anti-4-1BB / PD-L1 bispecific antibody JS211-K2F (starting concentration of 2054nM, 4-fold dilution, a total of 12 concentration gradients) was added to the cell plate using experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixture system and the chemiluminescent signal was detected using a multi-function microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the EC 50 The positive control was JS211-Ref (Genmab).
[0973] HCC827 cells (low expression of human PD-L1) were cultured at 5×10 4 The cells were added to a 96-well flat-bottom white plate (Corning, Cat#3917) and incubated overnight at 37°C. The next day, effector cells Jurkat NFKB 4-1BB (stable expression of NlucP / NFKB-RE and high expression of human 4-1BB) and Jurkat NFKB 4-1BB SP (stable expression of NlucP / NFKB-RE and low expression of human 4-1BB) were added at 1×10 per well. 5The number of cells was added to the cell plate. Then, the anti-4-1BB / PD-L1 bispecific antibody JS211-K2F (starting concentration of 205nM, 5-fold dilution, a total of 12 concentration gradients) was added to the cell plate using an experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixture system and the chemiluminescent signal was detected using a multi-function microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the EC 50 The positive control was JS211-Ref (Genmab).
[0974] like FIG. 10A to FIG. 10F As shown in the figure, in the reporter gene system with CHO PD-L1 (highly expressed human PD-L1) as the target cell, JS211-Ref (Genmab) showed an obvious bell-shaped curve, and the activation effect on T cells was significantly reduced in some ranges of higher concentrations (≥100nM) and lower concentrations (≤1nM), while JS211-K2F was able to maintain a high level of T cell activation in the corresponding range ( Fig. 10A , Fig. 10D ); In the reporter gene system with MC38PD-L1 (human PD-L1 expressed in the medium) as the target cell, JS211-K2F and JS211-Ref (Genmab) both showed a bell-shaped curve ( Fig. 10B , Fig. 10E ), but JS211-K2F has a more obvious advantage in the concentration range in which it can maintain high activity; in the reporter gene system with HCC827 cells (low expression of human PD-L1) as target cells, JS211-K2F and JS211-Ref (Genmab) also showed a bell-shaped curve ( Fig. 10C , Fig.10F ); In the high 4-1BB environment, the concentration range in which JS211-K2F can maintain high activity is also significantly better than JS211-Ref (Genmab), while in the low-high 4-1BB environment, the peak activity of JS211-K2F is slightly inferior to JS211-Ref (Genmab), but there is no significant difference in the concentration range in which high activity is maintained.
[0975] Example 10: Bispecific antibodies promote the secretion of cytokines IFN-γ and IL-2 in mixed lymphocyte reactions
[0976] To determine the promoting effect of the bispecific antibody on the secretion of IFN-γ and IL-2 by lymphocytes, CD14 cells were obtained by purifying commercial human PBMCs using CD14 MicroBeads, Human (Miltenyi Biotec, cat#130-050-201). Then, adherent cells were stimulated with 10 ng / ml GM-CSF (Sino Biological, cat#GMP-11846-HNAE) and 10 ng / ml IL-4 (Sino Biological, cat#GMP-10015-HNAH) for 5 days, followed by 5 ng / ml IL-1β (Sino Biological, cat#10139-HNAE), 10 ng / ml IL-6 (Sino Biological, cat#GMP-10395-HNAE), 10 ng / ml TNF-α (Sino Biological, cat#GMP-10602-HNAE) and 1 μmol / L PGE2 for 2 days to induce mature dendritic cells (mDC). CD4 T cells were obtained by purifying commercial human PBMCs with CD4 T MicroBeads, Human (Miltenyi Biotec, cat#130-045-101).
[0977] In a 96-well round-bottom plate, different concentrations of the test antibody (starting concentration of 150 nM, 10-fold dilution, a total of 5 concentration gradients) and mDC cells (10,000 cells per well) and the above-purified CD4 T cells (100,000 cells per well) were co-incubated in a CO2 incubator at 37°C for 5 days. On the third day of co-incubation, part of the reaction supernatant was collected from each well of the 96-well plate and IL-2 release was detected using BDCBA human IL-2Flex set (BD, cat#558270), and IFNγ content in the supernatant was detected using BD CBAhuman IFNγFlex set (BD, cat#558269) on the fifth day of co-incubation. The positive control was JS211-Ref (Genmab).
[0978] from FIG. 11A to FIG. 11D It can be seen that in the mixed lymphocyte reaction, both JS211-K2F and JS211-Ref (Genmab) can promote the release of IL-2 and IFNγ and activate T cells, and there is no significant difference in the promotion effect. There is no significant difference in the efficacy of JS211-K2F and the single drug combination group, but the combination can significantly reduce the amount of antibody used compared to the single drug.
[0979] Example 11: Inhibitory effect of dual antibodies on the growth of MC3-B7H1 tumors transplanted into humanized mice
[0980] Purpose of test: To evaluate the anti-tumor effect of the anti-4-1BB / PD-L1 dual antibody of the present application in the subcutaneous tumor model of mouse colon cancer MC38-B7H1 (MCB high-expressing B7H1 cell line) transplanted with h4-1BB-PD-L1 humanized mice.
[0981] Test process: 6-8 week old female h4-1BB humanized mice (purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.) were inoculated subcutaneously on the right back with 1×10 6 MC38 cells. The average tumor volume is about 90mm 3 When the tumor volume was quantified, appropriate animals were selected and randomly divided into 5 groups, with 6 animals in each group.
[0982] 1. Normal saline control group (solvent control group);
[0983] Treatment Group:
[0984] 2. JS003 (1 mg / kg body weight) group;
[0985] 3. JS011 (1 mg / kg body weight) group;
[0986] 4. JS003+JS011 (1+1 mg / kg body weight) group;
[0987] 6. JS211K2F (1.31 mg / kg body weight) group;
[0988] 8. JS211K2 (1.31 mg / kg body weight) group;
[0989] The single-use dose of JS003 / JS011 is 1 mg, and the dose of JS211K2 (K2F) is 1.13 mg. After conversion, the molar dose of the antibody per kg body weight is basically the same.
[0990] Intraperitoneal injection, twice a week, for 3 consecutive weeks, the experiment was terminated 4 days after the last administration. Tumor volume and body weight were measured twice a week, and the mouse weight and tumor volume were recorded. At the end of the experiment, the mice were euthanized, and the tumor inhibition rate TGI (%) was calculated = [1-(Ti-T0) / (Vi-V0)] × 100%. (Ti: mean tumor volume of the treatment group on the i-th day of administration, T0: mean tumor volume of the treatment group on the 0th day of administration; Vi: mean tumor volume of the solvent control group on the i-th day of administration, V0: mean tumor volume of the solvent control group on the 0th day of administration).
[0991] like Fig.12 As shown in Figure 2, on day 21 after administration, the average tumor volume of the saline control group was 1749 mm 3All drug-treated groups could significantly inhibit tumor growth. Compared with the saline control group, the tumor inhibition rate of the JS003 (1 mg / kg body weight) group was 57.0%; the average tumor volume of the JS011 (1 mg / kg body weight) group was 301 mm 3 The tumor inhibition rate was 89.2%; the average tumor volume of the JS003+JS011 (1+1 mg / kg body weight) group was 21 mm 3 The tumor inhibition rate was 106.5%; the average tumor volume of the JS211K2F (1.31 mg / kg body weight) group was 147 mm 3 The tumor inhibition rate was 98.8%; the average tumor volume of the JS211K2 (1.31 mg / kg body weight) group was 182 mm 3 The tumor inhibition rate was 96.6%. All the results showed that in the h4-1BB-PD-L1 humanized mouse transplanted MC38B7H1 model, at a dose level of 1 mg / kg of the analog monoclonal antibody, JS211K2 and JS211K2F showed significantly better tumor inhibition than single-target antibodies alone, and also showed comparable tumor inhibition compared to the monoclonal antibody combination group.
[0992] Example 12: Inhibitory effect of dual antibodies on the growth of MC3-B7H1 tumors transplanted into humanized mice (reduced dose)
[0993] Purpose of test: To evaluate the anti-tumor effect of the anti-4-1BB-PD-L1 dual antibody of the present application in the subcutaneous tumor model of mouse colon cancer MC38-B7H1 (MCB high-expressing B7H1 cell line) transplanted with h4-1BB-PD-L1 humanized mice.
[0994] Test process: 6-8 week old female h4-1BB humanized mice (purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.) were inoculated subcutaneously on the right back with 1×10 6 MC38 cells. The average tumor volume is about 90mm 3 When the tumor volume was quantified, appropriate animals were selected and randomly divided into 5 groups, with 6 animals in each group.
[0995] KLH antibody (control group);
[0996] JS011 (0.37 mg / kg body weight) group;
[0997] JS211ref (0.5 mg / kg body weight) group; and
[0998] JS211K2F (0.5 mg / kg body weight) group.
[0999] After conversion, the molar dose per kg body weight of JS211K2 (K2F) 0.5 mg and JS211ref 0.5 mg are basically the same.
[1000] Intraperitoneal injection, twice a week, for 3 consecutive weeks, the experiment was terminated 4 days after the last administration. Tumor volume and body weight were measured twice a week, and the mouse weight and tumor volume were recorded. At the end of the experiment, the mice were euthanized, and the tumor inhibition rate TGI (%) was calculated = [1-(Ti-T0) / (Vi-V0)] × 100%. (Ti: mean tumor volume of the treatment group on the i-th day of administration, T0: mean tumor volume of the treatment group on the 0th day of administration; Vi: mean tumor volume of the solvent control group on the i-th day of administration, V0: mean tumor volume of the solvent control group on the 0th day of administration).
[1001] like Fig.13 As shown, on day 21 after administration, the average tumor volume of the saline control group was 752 mm 3 The average tumor volume of the JS211ref (0.5 mg / kg body weight) group was 439 mm 3 The tumor inhibition rate was 49.8%; the average tumor volume of the JS211K2F (0.5 mg / kg body weight) group was 308 mm 3 The tumor inhibition rate was 70.6%. The results showed that in the h4-1BB-PD-L1 humanized mouse transplanted MC38B7H1 model, JS211-K2F showed a significant tumor inhibition activity advantage over JS211ref.
[1002] Example 13: In vitro CRS study of bispecific antibodies
[1003] In this experiment, JS211-K2F, JS011-phage3 and control antibodies were incubated with PBMC in vitro. This experiment was incubated under 1640 complete medium (1640RPMI+10% AB serum), and 50μl PBMC (3.0×105 cells / well) was added. The study was carried out in PBMC of 2 different volunteers. The antibody detection concentration was 10μg / ml, 50μl antibody per well, and 3 replicates were set for each condition. The cells and antibodies were incubated at 37℃, 5% CO2 for 24h, and the supernatant was collected by centrifugation on the second day. The cytokine release was detected using BD CBAhuman Th1 / Th2cytokine kitⅡ. The positive control was OKT3 and the negative control was Anti-KLH IgG4.
[1004] like Fig.14 As shown in the figure, JS211-K2F and JS011-phage3 did not cause CRS effect at a concentration of 10 μg / ml. The results show that JS211-K2F has a high safety in CRS.
[1005] Example 14: Bispecific Antibody Toxicity Study in Cynomolgus Monkeys
[1006] This experimental study was conducted on the toxicity of repeated administration of JS211K2F to crab-eating macaques. The dose was designed to be 10 mg / kg or 30 mg / kg (1 male and 1 female high-dose and low-dose groups, a total of 4 monkeys), with infusion for 30 minutes, once a week (4 times in total), and planned euthanasia on D30. The toxicological indicators included general toxicity: death, clinical observation, body weight and weight gain, food intake, and body temperature; clinical pathology: blood cell count, coagulation function, blood biochemistry, and urine analysis; toxicometabolism: before and after the first and last doses; safety pharmacology: blood pressure, electrocardiogram; pathology: gross pathology, organ weight, and tissue pathology (liver, kidney, and spleen).
[1007] Main results: No product-related death, dying, body weight, food intake, or changes in blood routine were observed in each dose group. The histopathological results after autopsy are as follows:
[1008] Lung: Gross observation of male animals in the low-dose group showed dark discoloration in the right middle lobe of the lung, and moderate granulomatous inflammation under the microscope. Since a comprehensive pathological examination of the lung tissue was not performed, the correlation between this change and the test article cannot be ruled out. Moderate granulomatous inflammation is a chronic inflammation that occasionally occurs in normal animals.
[1009] Kidney: Slight mononuclear cell infiltration was observed in the kidneys of the animals in the low-dose group. Microscopic observation of the kidneys of female animals in the high-dose group revealed slight glomerular hemorrhage. The above changes were of low severity and no obvious dose-dependency was observed. It is considered that the background lesions may be unrelated to the test article.
[1010] Liver: Blood biochemistry: On the second day of administration, ALT and AST of cynomolgus monkeys 2, 3, and 4 increased slightly transiently, but were within the background range. Slight mononuclear cell infiltration was observed in the liver of cynomolgus monkey 1, and slight sinusoidal cell increase was observed in the liver of cynomolgus monkey 2. The above changes were of low degree and no obvious dose-dependent relationship was observed. It is considered that the background lesions may be unrelated to the test article.
[1011] Spleen: No test article-related abnormalities were observed.
[1012] In summary, no product-related toxicity, especially liver-related toxicity, was found in JS211K2F 30 mg / kg, indicating that JS211K2F has good safety. (two)
[1014] Example 15: Preliminary screening experiment of buffer system
[1015] 15.1 Experimental Methods
[1016] The JS211(K2F) storage samples were used in Millipore 3 0.11m 2Ultrafiltration concentration (UF / DF) was performed until the concentration of JS211 was 15 mg / mL, and then dialyzed into the corresponding buffer containing a stabilizer. The concentration of JS211 was measured respectively, and the corresponding buffer containing a stabilizer and a surfactant were added according to the measured concentration, and the final concentration of JS211 was adjusted to 10 mg / mL, and the contents of other components were respectively as shown in Table 7, to obtain the drug compositions numbered FS1-1 to FS1-9 to be tested, and the corresponding dosage forms were water injections. The above-mentioned newly prepared different drug compositions to be tested were aseptically filled into 2R cillin bottles, and then stability sampling and testing were performed according to the stability investigation conditions.
[1017] Stability test conditions include:
[1018] (1) Placed in an environment at 5±3℃ for 2 weeks, 4 weeks or 3 months, hereinafter referred to as “long-term (5±3℃)”;
[1019] (2) Placed in an environment of 40±2℃ for 2W or 4W, hereinafter referred to as "high temperature (40±2℃)";
[1020] (3) Placed in an environment at 25±2℃ for 2W or 4W, hereinafter referred to as "accelerated (25±2℃)".
[1021] Table 7: Buffer system preliminary screening experimental plan
[1022]
[1023] Appearance test
[1024] Test method: Use visual inspection to inspect the appearance of each pharmaceutical composition (sample). During the inspection, ensure that the light intensity of the clarity detector is maintained between 1000 and 1500 lux. Keep the sample at the same level as the eye, and gently shake or turn it upside down to avoid bubbles; perform visual inspection in front of a black background and a white background respectively. Record the visual inspection results in terms of color, opalescence, and visible foreign matter.
[1025] SEC-HPLC (Size Exclusion High Performance Liquid Chromatography) Purity Test
[1026] Test method: Using a SEC column ( BEH SEC purity was detected by HPLC (Waters instrument) with a diameter of 7.8 mm × 30 cm, 3.5 μm. Each drug composition (sample) was diluted to 1.0 mg / mL with the mobile phase, mixed and added to the inner liner tube, and directly injected for analysis; the mobile phase composition was 50 mM phosphate solution, 300 mM sodium chloride solution, pH 6.8 ± 0.2. The relative percentages of the main peak, polymers and oligomers were calculated by the area normalization method. The components of the reference product used in the test include: 50 mM phosphate, 300 mM sodium chloride, pH 6.8 ± 0.2; the pretreatment method and test method of the reference product were the same as those of the sample. The test parameters are shown in Table 8 below.
[1027] Table 8: SEC-HPLC purity test parameters
[1028] icIEF purity test
[1029] Test method: Take 20.00μL sample solution (1.0mg / mL) and ultrapure water (blank sample) and mix them with 80.0μL icIEF Master Mix respectively, centrifuge at 10000rpm for 5min, take 75.0μL supernatant and add it to a 96-well plate, be careful to avoid bubbles, and then centrifuge the 96-well plate at 1000g for 5min to remove bubbles. The components of the reference product used in the test include: 50mM phosphate, 300mM sodium chloride, 300mM L-arginine hydrochloride, pH6.8±0.2; the pretreatment method and test method of the reference product are the same as those of the sample. The preparation method of polymer icIEF Master Mix and the parameters of the sample operation method are shown in Tables 9 and 10.
[1030] Table 9: icIEF Master Mix Preparation
[1031]
[1032]
[1033] Table 10: icIEF sample run method parameters
[1034]
[1035] CEX-HPLC purity test
[1036] The CEX-HPLC purity was tested by HPLC (Waters E2695 instrument) equipped with a cation chromatography column (ProPacTM WCX-10, 4×250 mm). The mobile phase composition was phase A: 20 mM MES solution (pH 6.50±0.02); phase B: 20 mM MES + 100 mM NaCl solution (pH 6.50±0.02). The peak area normalization method was used to calculate the percentage of the main peak, acidic peak, and basic peak. If the automatic integration could not obtain a reasonable integration result, manual integration was used. The CEX operation method parameters are shown in Table 11.
[1037] Table 11: CEX sample run method parameters
[1038]
[1039] rCE-SDS purity test
[1040] Test method: Use a capillary electrophoresis instrument (Maurice instrument) for rCE-SDS purity detection. Take a diluent (1wt% SDS + 40mM phosphate buffer, pH 6.5) to dilute each JS211 (sample) to 1mg / mL, then take 95μL of the diluted sample and mix it evenly with 5μL 2-mercaptoethanol, centrifuge at 3000rpm at room temperature for 30s, and then incubate at 70°C for 15min. After incubation, cool to room temperature and centrifuge at 12000rpm at room temperature for 5min. Take out 75μL of sample solution from the sample tube to a 96-well plate to avoid bubbles, centrifuge at 1000g at room temperature for 10min, and detect using a capillary electrophoresis instrument (Maurice). The ingredients of the reference product used in the test include: citric acid 0.56 mg / mL, sodium citrate 2.16 mg / mL, sucrose 78.73 mg / mL and polysorbate 800.2 mg / mL; the pretreatment method and test method of the reference product are the same as those of the sample.
[1041] nrCE-SDS purity test
[1042] Test method: Use a capillary electrophoresis instrument (Maurice Instrument) for nrCE-SDS purity detection. Calculate the diluent and sample volume required to dilute JS211 (sample) to 1 mg / mL according to the final volume of 100 μL, then add the diluent (0.01g / mL SDS + 40mM phosphate buffer, pH6.5), 5.0μL 0.25M NEM (ethylmaleimide), and sample to a 1.5mL EP tube and mix well; ultrapure water is used as a blank control, and the dilution ratio is consistent with the reference product (the dilution multiple is at least 2 times). Centrifuge at 3000rpm at room temperature for 30s, then incubate at 70℃ for 5min. After incubation, cool to room temperature and centrifuge at 12000rpm at room temperature for 5min. Take out 75μL of sample solution from the sample tube to a 96-well plate to avoid bubbles, centrifuge at 1000g at room temperature for 10min, and detect using a capillary electrophoresis instrument (Maurice). The ingredients of the reference product used in the test include: citric acid 0.56 mg / mL, sodium citrate 2.16 mg / mL, sucrose 78.73 mg / mL and polysorbate 80 0.2 mg / mL; the pretreatment method and test method of the reference product are the same as those of the sample.
[1043] Binding activity test
[1044] Test method: This method adopts the indirect method, using human PD-L1 and human 4-1BB as antigens to coat a 96-well plate. JS211 can bind to human PD-L1 and human 4-1BB, and mouse anti-human IgG4Fc-HRP can specifically bind to JS211 bound to the solid phase antigen (human PD-L1, human 4-1BB. Under the action of hydrogen peroxide, it can catalyze TMB to develop a blue color. The depth of blue is positively correlated with the amount of mouse anti-human IgG4Fc-HRP binding, and it turns yellow after termination with 2M hydrochloric acid. The absorbance (OD value) is measured at a wavelength of 450nm / 620nm using an enzyme reader, and the ability of JS211 bispecific antibodies to bind to human PD-L1 and human 4-1BB is examined by the effective binding activity (EC50) of the standard curve.
[1045] Table 12: JS211 binding PD-L1 ELISA experimental method
[1046]
[1047] Table 13: JS211 binding to 4-1BB ELISA experimental method
[1048]
[1049] Insoluble particle test
[1050] Test method: HIAC insoluble particle counter was used as the detection instrument, and the insoluble particles in each pharmaceutical composition (sample) were statistically determined by the light obscuration method. The operation mode used was Run counter, and the setting parameters were shown in Table 14 below.
[1051] Table 14: Insoluble Particle Test Parameters
[1052] parameter Settings Number of runs 4 Dilution Factor 1 First run flush volume (mL) 0 Whether to discard the first run result yes
[1053] 15.2 Experimental Results
[1054] 15.2.1 Appearance test results
[1055] According to the results in Table 15, no obvious visible foreign matter was found in all samples at T0, and no obvious opalescence was found; after being placed under different conditions for 2 weeks and 4 weeks, the opalescence intensity of sample FS1-8 was relatively strong; the appearance of other samples did not show obvious changes, that is, no obvious visible foreign matter was found, no obvious opalescence was found, and no color was found; after samples FS1-1 to FS1-9 were placed under long-term conditions for 3 months, the appearance showed obvious opalescence
[1056] Table 15: First round of prescription screening - appearance test
[1057]
[1058]
[1059] 15.2.2SEC-HPLC Purity Results
[1060] From the results in Table 16 above, it can be seen that the monomer purity of all water injection samples decreased after being placed under high temperature conditions for 4 weeks, which was mainly manifested by the increase of aggregates. The aggregates of FS1-8 and FS1-9 increased significantly, followed by FS1-7, and there was no significant difference between the other samples.
[1061] Table 16: First round of prescription screening - SEC-HPLC test
[1062]
[1063] 15.2.3 icIEF Purity Results
[1064] From the results in Table 17 below, it can be seen that after being placed under high temperature conditions, accelerated conditions or long-term conditions for 4 weeks, the icIEF purity of all samples decreased, the acidic peak and the alkaline peak increased, the purity of the main peaks of FS1-8 and FS1-9 decreased significantly compared with the T0 condition, and the degree of decrease of FS1-6 and FS1-7 was also significant, but less than that of FS1-8 and FS1-9. There was no significant difference among the other samples.
[1065] Table 17: First round of prescription screening—R-CE-SDS test
[1066] Sample No. type T0 High temperature (40±2℃) 4W Acceleration (25±2℃) 4W Long term (5±3℃) 4W Long term (5±3℃) 4W FS1-1 Acid peak% 30.6 34.4 30.9 30.4 31.0 FS1-1 Main peak% 68.5 46.8 65.4 68.5 67.4 FS1-1 Alkali peak% 0.8 18.8 3.7 1.1 1.6 FS1-2 Acid peak% 31.1 37.2 30.8 31 31.1 FS1-2 Main peak% 68.2 49.1 66.2 68.0 67.6 FS1-2 Alkali peak% 0.7 13.7 3.0 1.0 1.3 FS1-3 Acid peak% 31.1 47.0 32.3 31.4 32.0 FS1-3 Main peak% 68.2 35.5 63.6 67.5 66.2 FS1-3 Alkali peak% 0.8 17.5 4.1 1.1 1.8 FS1-4 Acid peak% 31.2 43.2 31.5 30.7 31.2 FS1-4 Main peak% 68.1 43.9 65.2 68.4 67.3 FS1-4 Alkali peak% 0.7 12.9 3.3 0.9 1.5 FS1-5 Acid peak% 31.3 42.8 30.9 31.6 31.3 FS1-5 Main peak% 68.0 50.7 66.5 67.5 67.5 FS1-5 Alkali peak% 0.7 6.5 2.6 0.9 1.2 FS1-6 Acid peak% 32.6 45.1 33.5 32.8 32.8 FS1-6 Main peak% 66.7 39.3 63.4 66.2 65.8 FS1-6 Alkali peak% 0.7 15.6 3.1 1.0 1.4 FS1-7 Acid peak% 33.2 54.6 34.5 33.1 33.2 FS1-7 Main peak% 65.9 38.2 63.1 66.1 65.7 FS1-7 Alkali peak% 0.9 7.2 2.4 0.8 1.1 FS1-8 Acid peak% 33.4 66.5 35.4 33.6 33.6 FS1-8 Main peak% 66.1 30.2 62.9 65.6 65.5 FS1-8 Alkali peak% 0.5 3.3 1.7 0.8 0.9 FS1-9 Acid peak% 32.1 63.9 39.9 32.3 32.2 FS1-9 Main peak% 67.2 20.4 59.5 67.1 67.1 FS1-9 Alkali peak% 0.7 15.7 0.6 0.6 0.7
[1067] 15.2.4 R-CE-SDS Purity Results
[1068] From the results in Table 18 below, it can be seen that after being placed under high temperature conditions for 4 weeks, the purity of all samples decreased significantly, with FS1-7, FS1-8 and FS1-9 showing the most significant decreases, and there were no significant differences among the other samples; after being placed under accelerated conditions for 4 weeks, the purity of all samples showed a slight downward trend; after being placed under long-term conditions for 3 months, the rCE-SDS purity did not show significant changes; after all samples were placed under long-term conditions for 3 months, the rCE-SDS purity did not show significant changes.
[1069] Table 18: First round of prescription screening—R-CE-SDS test
[1070]
[1071]
[1072] 15.2.5 NR-CE-SDS Purity Results
[1073] From the results in Table 19 below, it can be seen that after being placed under high temperature conditions for 4 weeks, the nrCE-SDS purity of all samples showed a significant downward trend, the purity of FS1-7, FS1-8, and FS1-9 decreased significantly, and there was no significant difference between the other samples; after being placed under accelerated conditions for 4 weeks, the nrCE-SDS purity of all samples showed no significant change; after being placed under long-term conditions for 3 months, the nrCE-SDS purity of all samples showed no significant change.
[1074] Table 19: First round of formulation screening - combined activity results
[1075]
[1076] 15.2.6 Binding Activity Results
[1077] According to the cell activity results in Table 20 below, after 4 weeks of high temperature conditions, the 4-1BB binding activity and PD-L1 binding activity of all samples were within the normal range. In terms of 4-1BB binding activity, FS1-2 and FS1-9 decreased relatively less and performed better; in terms of PD-L1 binding activity, FS1-1 to FS1-4, FS1-6, and FS1-9 performed relatively well; after 4 weeks of accelerated conditions or 3 months of long-term conditions, the 4-1BB binding activity and PD-L1 binding activity of all samples were within the normal range and did not decrease significantly.
[1078] Table 20: First round of prescription screening - cell activity results
[1079]
[1080]
[1081] 15.2.7 Insoluble Particle Results
[1082] Test results: The test results of insoluble particles are shown in Table 21. 10μm≤X<25μm means that the particle size is between 10 and 25μm, and X≥25μm means that the particle size is greater than 25μm. Under high temperature conditions for 4 weeks and accelerated conditions for 4 weeks, the insoluble particles of FS1-8 sample with a particle size of 10 to 25μm increased significantly, and the other samples increased slightly or did not increase significantly. Under long-term conditions for 3 months, the insoluble particles of all samples increased slightly or did not increase significantly.
[1083] Table 21: First round of prescription screening - insoluble particulate results
[1084]
[1085] 15.3 Conclusion of the First Round of Prescription Screening
[1086] From the appearance results, except for FS1-8, no obvious abnormalities were observed in all other samples under high temperature for 4 weeks, accelerated for 4 weeks or long-term for 4 weeks. From the SEC-HPLC results, the monomer purity of FS1-7 to FS1-9 decreased significantly to varying degrees under high temperature for 4 weeks, accelerated for 4 weeks or long-term for 4 weeks. From the ic-IEF results, the main peak purity of FS1-6 to FS1-9 decreased significantly to varying degrees under high temperature for 4 weeks, accelerated for 4 weeks or long-term for 4 weeks. From the rCE-SDS According to the results, under high temperature conditions for 4 weeks, the purity of FS1-7 to FS1-9 decreased significantly to varying degrees; from the nrCE-SDS results, under high temperature conditions for 4 weeks, the purity of FS1-7 to FS1-9 decreased significantly to varying degrees; from the binding activity results, under high temperature conditions for 4 weeks, FS1-2 and FS1-9 performed better in terms of 4-1BB binding activity, and FS1-1 to FS1-4, FS1-6, and FS1-9 performed relatively well in terms of PD-L1 binding activity.
[1087] In summary, FS1-1 to FS1-4 showed good stability in all aspects, so 20 mM acetate buffer and citric acid buffer with a relatively low pH (5.0-5.5) were selected as the buffer system for the next round of screening experiments.
[1088] Example 16: Second round of prescription screening - screening of stabilizers and surfactants
[1089] 16.1 Experimental Methods
[1090] The preparation methods of samples FS2-1 to FS2-9 refer to Example 15. The performance test methods of each sample refer to Example 15.
[1091] Table 22: Second round of prescription screening experimental plan
[1092]
[1093] 16.2 Experimental Results
[1094] 16.2.1 Appearance and concentration results
[1095] Test results: No obvious foreign matter was found in all samples at T0, and no obvious opalescence; after being placed under different conditions for 2 weeks and 4 weeks, there was no obvious change in the appearance of all samples.
[1096] Table 23: Second round of prescription screening - appearance data
[1097]
[1098]
[1099] 16.2.2SEC-HPLC Purity Results
[1100] From the results in Table 24 below, it can be seen that the monomer purity of all water injection samples decreased after being placed under high temperature conditions for 4 weeks, while there was no significant decrease in all powder injection samples. Among the water injection samples, the degree of monomer decrease of FS2-5 and FS2-8 was relatively large, and there was no significant difference between other water injection samples. All water injection samples were placed under accelerated conditions for 4 weeks, and the SEC-HPLC purity did not show significant changes; all samples were placed under long-term conditions for 3 months, and the SEC-HPLC purity did not show significant changes.
[1101] Table 24: High concentration pharmaceutical composition prescription screening - SEC-HPLC results
[1102]
[1103] 16.2.3 CEX-HPLC Purity Results
[1104] From the results in Table 25 below, it can be seen that the main peak purity of all samples decreased to varying degrees after being placed under high temperature conditions for 4 weeks, mainly due to the increase in the alkaline peak. After being placed under accelerated conditions for 4 weeks, the CEX main peak of all samples decreased, and there was no significant difference between the samples. After all samples were placed under long-term conditions for 3 months, the main peak purity did not change significantly.
[1105] Table 25: Second round of formulation screening - CEX-HPLC results
[1106]
[1107] 16.2.4R-CE-SDS Purity Results
[1108] From the results in Table 26 below, it can be seen that after being placed under high temperature conditions for 4 weeks, the purity of all samples decreased significantly, and there was no significant difference between the samples; after being placed under accelerated conditions for 4 weeks, the purity of all samples decreased slightly, and there was no significant difference between the samples; after being placed under long-term conditions for 3 months, the purity of all samples did not show any significant change.
[1109] Table 26: Second round of prescription screening—R-CE-SDS results
[1110]
[1111]
[1112] 16.2.5 NR-CE-SDS Purity Results
[1113] From the results in Table 27 below, it can be seen that after being placed under high temperature conditions for 2 weeks, the purity of all water injection samples decreased to varying degrees, with FS2-4, FS2-5 and FS2-8 decreasing more significantly; after being placed under high temperature conditions for 4 weeks, the purity of all water injection samples showed a significant downward trend, with FS2-8 decreasing most significantly; after the samples were placed under accelerated conditions for 4 weeks, there was no significant change in purity; after all samples were placed under long-term conditions for 3 months, there was no significant change in nrCE-SDS purity.
[1114] Table 27: Second round of prescription screening - NR-CE-SDS results
[1115]
[1116] 16.2.6 Binding Activity Results
[1117] As shown in Table 28 below, after 4 weeks of high temperature conditions, the 4-1BB binding ability of all samples decreased to varying degrees, with FS2-1, FS2-2, FS2-3 and FS2-7 decreasing to a higher degree, but all within the normal range, while the PD-L1 binding ability did not change significantly. After 4 weeks of long-term conditions, the 4-1BB binding ability and PD-L1 binding ability of all samples did not change significantly.
[1118] Table 28: Formulation Optimization—Binding Activity Results
[1119]
[1120]
[1121] 16.2.7 Insoluble Particle Results
[1122] According to Table 29 below, after 4 weeks of high temperature treatment, the insoluble particles of 10 μm or more of FS2-5 increased significantly, while the other samples did not show significant changes. After 4 weeks of accelerated treatment or 3 months of long-term treatment, the insoluble particles of 10 μm or more of each sample did not show significant changes.
[1123] Table 29: Second round of prescription screening - insoluble particulate results
[1124]
[1125] 16.3 Conclusion of the Second Round of Prescription Screening
[1126] Judging from the appearance test and rCE-SDS results, there were no significant differences among all the prescriptions. In the SEC-HPLC results, the monomer decrease of FS2-5 and FS2-8 was relatively high after 4 weeks of high temperature treatment. In the CEX-HPLC results, the main peak decrease of FS2-4, FS2-8 and FS2-9 was relatively small after 4 weeks of high temperature treatment. In the nrCE-SDS results, the purity of FS2-4, FS2-5, FS2-8 and FS2-9 decreased to a high degree after 2 weeks of high temperature; the purity of FS2-7 decreased to a high degree after 4 weeks of high temperature treatment. In the binding activity results, the 4-1BB binding activity of FS2-1, FS2-2, FS2-3 and FS2-7 decreased to a high degree after 4 weeks of high temperature treatment. Overall, FS2-6 can maintain a relatively high stability of bispecific antibodies in each performance test of the second round of prescription screening.
[1127] Example 17: Formulation Optimization
[1128] 17.1 Experimental Methods
[1129] Since the purity of the monomer or the main peak in the second round of screening in Example 16 still decreased significantly to varying degrees, the prescription was further optimized to prepare a lyophilized preparation with higher stability performance. The optimized sample selection was an acetate buffer and a citric acid buffer system containing 230 mM sucrose and 0.02% polysorbate 80, and the concentration of the antibody was further increased. The sample preparation methods of the high-concentration liquid prescriptions FS2-1-20, FS2-6-20 and the lyophilized prescriptions FS2-Lyo-1, FS2-Lyo-2, and FS2-Lyo-3 are as follows.
[1130] JS211 storage samples were used in Millipore 3 0.11m2 was ultrafiltered and concentrated (UF / DF) to a concentration of JS211 of 22mg / mL, and then dialyzed into a corresponding buffer solution containing a stabilizer. The concentration of JS211 was determined respectively, and the corresponding buffer solution and surfactant containing a stabilizer were added according to the determined concentration, and the final concentration of JS211 was adjusted to 20mg / mL, and the contents of other components were shown in Table 30; the drug compositions to be tested were numbered FS2-1-20 and FS2-6-20, and the corresponding dosage forms were water injections. Part of the newly prepared drug compositions to be tested were aseptically filled into 2R vials, and then stability sampling and testing were performed according to the stability investigation conditions; part of the drug compositions to be tested were freeze-dried and stability sampling was performed according to the stability investigation conditions. After sampling, the JS211 concentration was reconstituted with water for injection to a concentration of 20mg / mL, and the drug compositions to be tested were numbered FS2-Lyo-1 to FS2-Lyo-3, and the corresponding dosage forms were freeze-dried powder injections.
[1131] For the performance testing methods of each sample, please refer to Example 15.
[1132] Table 30: Formulation optimization plan
[1133]
[1134] 17.2 Experimental Results
[1135] 17.2.1 Appearance test results
[1136] Test results: No obvious foreign matter was found in all samples at T0, and no obvious opalescence; after being placed under different conditions for 2 weeks and 4 weeks, there was no obvious change in the appearance of all samples.
[1137] Table 31: Formulation Optimization - Appearance Data
[1138]
[1139] 17.2.2SEC-HPLC Purity Results
[1140] From the results in Table 32 below, it can be seen that the purity of the monomers of the water injection samples decreased after being placed under high temperature conditions for 4 weeks, while the purity of FS2-Lyo-3 in the powder injection samples decreased slightly, and the purity of the other powder injection samples did not decrease significantly. The purity of the water injection samples did not change significantly after being placed under accelerated conditions for 4 weeks; all samples did not change significantly after being placed under long-term conditions for 3 months.
[1141] Table 32: Formulation Optimization—SEC-HPLC Results
[1142]
[1143] “ / ” means the data has not been detected.
[1144] 17.2.3 CEX-HPLC Purity Results
[1145] From the results in Table 33 below, it can be seen that the main peak purity of all samples decreased to varying degrees after being placed under high temperature conditions for 4 weeks. The main reason was the increase in alkaline peaks. The degree of decrease in the main peak purity of the powder injection samples was significantly less than that of the water injection samples. Among the powder injection samples, FS2-Lyo-1 and FS2-Lyo-2 performed significantly better than FS2-Lyo-3. The water injection samples were placed under accelerated conditions for 4 weeks, and the main peak purity did not change significantly. All samples were placed under long-term conditions for 3 months, and the main peak purity did not change significantly.
[1146] Table 33: Formulation Optimization—CEX-HPLC Results
[1147]
[1148] “ / ” means the data has not been detected.
[1149] 17.2.4 R-CE-SDS Purity Results
[1150] From the results in Table 34 below, it can be seen that after being placed under high temperature conditions for 4 weeks, the purity of the water injection sample decreased significantly, while the purity of the powder injection sample did not decrease significantly; after being placed under accelerated conditions for 4 weeks, the purity of the water injection sample decreased slightly; after being placed under long-term conditions for 3 months, the purity of all samples did not show significant changes.
[1151] Table 34: Formulation Optimization—R-CE-SDS Results
[1152]
[1153] 17.2.5 NR-CE-SDS Purity Results
[1154] From the results in Table 35 below, it can be seen that the purity of the water injection samples decreased significantly after being placed under high temperature conditions for 4 weeks, while among the powder injection samples, except for a slight decrease in FS2-Lyo-3, there was no significant decrease; the purity of the water injection samples did not change significantly after being placed under accelerated conditions for 4 weeks; all samples had no significant change in nrCE-SDS purity after being placed under long-term conditions for 3 months.
[1155] Table 35: Second round of prescription screening - NR-CE-SDS results
[1156]
[1157] 17.2.6 Binding Activity Results
[1158] As can be seen from Table 36 below, after 4 weeks of high temperature conditions, the 4-1BB binding ability of the water injection samples decreased significantly, but it was all within the normal range. For the 4-1BB binding ability of the powder injection samples, except for a slight decrease in FS2-Lyo-3, there was no significant decrease; the PD-L1 binding ability of all samples did not change significantly. After 4 weeks of accelerated conditions, the 4-1BB binding ability and PD-L1 binding ability of all powder injection samples did not change significantly. After 4 weeks of long-term conditions, the 4-1BB binding ability and PD-L1 binding ability of all samples did not change significantly.
[1159] Table 36: Formulation Optimization—Binding Activity Results
[1160]
[1161] “ / ” means the data has not been detected.
[1162] 17.2.7 Insoluble Particle Results
[1163] According to Table 37 below, after 4 weeks of treatment under high temperature conditions, 4 weeks of treatment under accelerated conditions, or 3 months of treatment under long-term conditions, there was no significant change in the insoluble particles ≥10 μm in each sample.
[1164] Table 37: Formulation Optimization - Insoluble Microparticles Results
[1165]
[1166]
[1167] 17.3 Conclusion of formulation optimization
[1168] In the second round of prescription screening, FS2-6 performed significantly better than FS2-1, but after the development of freeze-dried preparations, the stability performance of the corresponding freeze-dried preparations FS2-Lyo-1 and FS2-Lyo-2 in all aspects increased significantly, with no significant difference, and both were better than FS2-Lyo-3. The above results show that the optimized freeze-dried preparations FS2-Lyo-1 and FS2-Lyo-2 can provide excellent stability performance for bispecific antibodies.
[1169] Example 18: Antigen Binding Activity of Pharmaceutical Compositions
[1170] 18.1 Experimental Methods
[1171] 18.1.1 Human 4-1BB Binding Activity
[1172] This experiment uses a Thermo Scientific or Molecular Devices microplate reader. The plate is coated with 1.0 μg / mL human 4-1BB (His tag), blocked with 2% BSA, and then a gradient dilution of JS211 antibody (starting at 10.0 μg / mL, 2.5-fold gradient dilution for a total of 12 concentrations) is added. Mouse anti-human IgG4Fc-HRP is diluted 5000 times as a detection antibody for detection, and then 0.1 mg / mL TMB is used for color development. Finally, the reaction is terminated with 2M HCl and the plate is read at 450nm / 620nm. The four-parameter logarithmic regression (4PL) model is used to fit the EC 50 .
[1173] 18.1.2 Human PD-L1 Binding Activity
[1174] This experiment uses a Thermo Scientific or Molecular Devices microplate reader. The plate is coated with 2.0 μg / mL human PD-L1 (His tag), blocked with 2% BSA, and then a gradient dilution of JS211 antibody (starting at 1.0 μg / mL, 2.5-fold gradient dilution for a total of 12 concentrations) is added. Mouse anti-human IgG4Fc-HRP is diluted 5000 times as a detection antibody for detection, and then 0.1 mg / mL TMB is used for color development. Finally, the reaction is terminated with 2M HCl and the plate is read at 450nm / 620nm. The four-parameter logarithmic regression (4PL) model is used to fit the EC 50 .
[1175] 18.2 Experimental Results
[1176] The experimental results are shown in Table 38 and Fig.15 , Fig.16 As shown, the binding curves of the drug composition to human 4-1BB and human PD-L1his are both "S" shaped, which shows the specific binding characteristics to the two antigens. 50 The value is 65.4ng / mL, binding to human PD-L1 (His tag) EC 50 The value is 8.4ng / mL.
[1177] Table 38: ELISA results of the binding activity of the drug composition to human 4-1BB and human PD-L1 proteins
[1178]
[1179] Example 19: Cellular activity of pharmaceutical compositions
[1180] 19.1 Experimental Methods
[1181] When JS211 binds to PD-L1 on target cells and 4-1BB on effector cells at the same time, it can activate T cells, leading to upregulation of NFKB expression and upregulation of the luciferase reporter gene coupled thereto. The cellular biological activity of the pharmaceutical composition is reflected by detecting the fluorescent signal released by luciferase. Target cells CHO PDL1 2E6 (human PDL1 stably expressed on CHO-K1 cells) were inoculated into 96-well flat-bottom white plates (CORNING, CAT#3917) at 50,000 cells per well and cultured overnight, then the supernatant was discarded and the gradient dilution of the test antibody (JS211-K2F batch number: 20220326) and 100,000 effector cells Jurkat NFKB 4-1BB 1D5 (human 4-1BB stably expressed on Jurkat cells and luciferase reporter gene coupled to NFKB) were added per well and incubated at 37°C for 4-6h. Finally, the luciferase substrate Nano-Glo (Promega, cat# N1120) was added and chemiluminescence was detected.
[1182] 19.2 Experimental Results
[1183] The results are as follows Fig.17 As shown, from Fig.17 It can be seen that the pharmaceutical composition exhibits significant T cell activation activity, EC 50 The value was 23.63 ng / mL, and the negative control Anti-KLH hIgG4 had no T cell activation effect. (three)
[1185] Experimental Example 1: Screening of anti-4-1BB antibodies
[1186] 1.1 Establishment of phage library
[1187] 50mL of peripheral blood from 40 different individuals were mixed together, peripheral blood mononuclear cells (PBMC) were separated, total RNA was extracted with Trizol, and the first chain of cDNA was synthesized using a reverse transcription kit (Thermo, 18080051). The variable region VH of the antibody heavy chain, and the variable regions Vκ and Vλ of the antibody light chain κ chain and λ chain were amplified by PCR using the synthesized cDNA as a template. VH-CH1, Vκ-CK, and Vλ-Cλ were assembled by the first round of overlap PCR, and then Fab was assembled by the second round of overlap PCR. The Fab fragments were digested and recovered and connected to the phagemid vector. The constructed plasmid vector was electroporated into TG1 competent cells to obtain a phage display library.
[1188] 1.2 Phage library screening
[1189] The constructed phage display library was packaged into phage. 13 -10 14 The phages were added to biotinylated 4-1BB for incubation and binding, and then streptavidin-coupled magnetic beads were added to bind to 4-1BB. The unbound phages were first washed off with PBST, and then the phages bound to 4-1BB were eluted with glycine at pH 2.0 to infect TG1, and the phages were amplified and packaged for the second round of panning. After four rounds of panning, the phages in the fourth round infected TG1 and plated into monoclones. Monoclones were picked in 96 deep-well plates and induced to express with IPTG (isopropylthiogalactoside). The next day, the periplasmic supernatant was extracted for 4-1BB binding enzyme-linked immunosorbent assay (ELISA) analysis. The sequences of the positive clones were obtained by sequencing. Finally, two groups of phages were obtained, named phage3 and phage6 for further analysis, among which the antibody expressed by phage phage3 was named JS011-phage3; the antibody expressed by phage phage6 was named JS011-phage6.
[1190] Experimental Example 2: Molecular Construction and Production of Anti-4-1BB Antibodies
[1191] The coding sequences of the IgG4 heavy chain constant region (hIgG4CH1-CH3) and kappa light chain constant region (human Kappa LC) were cloned from human B lymphocytes (from Beijing Institute of Hematology) and introduced into the pTT5 plasmid to form vectors HXT4S and HXT2, respectively.
[1192] The main elements of the vector HXT4S include: BSPQI restriction site, CMV Promoter (promoter of target gene expression), AmpR (ampicin resistance gene), pMB1ori (replication initiator), ori p, signal peptide (signal peptide of target gene expression) and target gene hIgG4CH1-CH3.
[1193] The main elements of the vector HXT2 include: BSPQI restriction site, CMV Promoter (promoter of target gene expression), AmpR (ampicin resistance gene), pMB1ori (replication initiator), ori p, signal peptide (signal peptide of target gene expression) and target gene human Kappa LC.
[1194] 2.1 Construction of JS011-phage3 light chain expression vector
[1195] The TG1 strain was infected with phage3, and the plasmid extracted after shaking was used as a template to synthesize the first and last primers as shown in SEQ ID No: 21 and SEQ ID No: 22 in Table A below, and PCR was performed. The obtained PCR product was digested with SapI and ligated to the HXT2 vector to obtain the expression vector HXT2-JS011-3-LC.
[1196] 2.2 Construction of JS011-phage3 heavy chain expression vector
[1197] The TG1 strain was infected with phage3, and the plasmid extracted after shaking was used as a template to synthesize the first and last primers as shown in SEQ ID No: 23 and SEQ ID No: 24 in Table A below, and PCR was performed. The obtained PCR product was digested with SapI and ligated to the HXT4S vector to obtain the expression vector HXT4S-JS011-3-HC.
[1198] 2.3 Construction of JS011-phage6 light chain expression vector
[1199] The TG1 strain was infected with phage6, and the plasmid extracted after shaking was used as a template to synthesize the first and last primers as shown in SEQ ID No: 25 and SEQ ID No: 26 in Table A below, and PCR was performed. The obtained PCR product was digested with SapI and ligated to the HXT2 vector to obtain the expression vector HXT2-JS011-6-LC.
[1200] 2.4 Construction of JS011-phage6 heavy chain expression vector
[1201] The TG1 strain was infected with phage6, and the plasmid extracted after shaking was used as a template to synthesize the first and last primers as shown in SEQ ID No: 23 and SEQ ID No: 24 in Table A below, and PCR was performed. The obtained PCR product was digested with SapI and ligated to the HXT4S vector to obtain the expression vector HXT4S-JS011-6-HC.
[1202] Table A
[1203] Primer name Primer sequences JS011-3VL F BSPQI: gatcgctcttcatgtgagctcgagctgactcagccaccctca(SEQ ID NO:49) JS011-3VL R BSPQI: gatcgctcttcttcgtaggacggtcagtctggtccctccgccga(SEQ ID NO:50) JS011-3 / 6VH F BSPQI gatcgctcttcatctcaggtgcagctggtgcagtctggggct(SEQ ID NO:51) JS011-3 / 6VH R BSPQI atgcgctcttctagctgaggagacggtgaccagggttccctgg(SEQ ID NO:52) JS011-6VL F BSPQI: atgcgctcttcatgtgagctcgccctgactcagcctccctccg(SEQ ID NO:53) JS011-6VL R BSPQI: atgcgctcttcttcgtaggacggtcagcttggtccctccgccg(SEQ ID NO:54)
[1204] 2.5 Expression and purification of JS011-phage3 and JS011-phage6 antibodies
[1205] CHO-K1 cells (ATCC, CCL-61) were cultured in suspension serum-free medium (Gibco) at 36.5°C, 120 rpm, and 7% CO2. When the cell density reached (2-6)×106 / mL, use CD CHO medium for subculture expansion. One day before transfection, dilute the CHO-18 cell density to (1.5-2.0)×10 6 / mL, placed in a shaker (culture conditions: 36.5°C, 120 rpm, 7% CO2) for culture, and when the cell density reached about 3.5×10 6 / mL for transfection. During transfection, first add one-tenth of the transfection volume of CD CHO culture medium to the reactor, then add 1-2ug / mL of the above expression vectors HXT2-JS011-3-LC and HXT4S-JS011-3-HC, or HXT4S-JS011-3-HC and HXT4S-JS011-6-HC, 3-14ug / mL of PEI (polyethyleneimine), mix well and incubate at room temperature for 20-30min, then slowly add the obtained mixture to the pre-treated CHO-18 cells to form a transfection mixture, while adding and mixing. The transfection mixture is placed in a shaker for culture, and the culture conditions are 36.5°C, 120rmp, and 7% CO2. The culture period is 6-10 days after transfection, and the feed is supplemented every two days.
[1206] After the above transfection mixture was cultured, the mixture was centrifuged at 1000 rpm for 10 min to discard the precipitate, and then centrifuged at 12000 rpm for 30 min to collect the cell supernatant and perform sterile filtration. In the first step, purification was performed using an AKTA Avant purifier. The mabselect sure LX column was first disinfected with 0.1M NaOH for 15-20 minutes, and then equilibrated with PBS buffer for 3-5 column volumes before loading. After loading, the column was eluted with pH 5.5 sodium acetate buffer, and finally the target protein was eluted with pH 3.6 acetic acid-sodium acetate buffer. In the second step, purification was performed using Eshmuno CPX. The equilibration solution was pH 5.5, 50mM acetic acid-sodium acetate system, and the elution solution was pH 5.5, 50mM acetic acid-sodium acetate + 1M NaCl buffer system. The target protein was collected in a linear elution mode. The monomer purity was determined by SEC-HPLC to be more than 95%, thereby obtaining monoclonal antibodies JS011-phage3 and JS011-phage6.
[1207] The gene sequences of antibodies JS011-phage3 and JS011-phage6 were obtained by gene sequencing, and then the amino acid sequences of the antibodies of the present application were obtained.
[1208] The amino acid sequence of antibody JS011-phage3 is as follows:
[1209] Heavy chain (JS011-phage3-HC, italics represent VH, underlines represent HCDR1, HCDR2 and HCDR3 in sequence):
[1210] QVQLVQSGAEVKKPGASVKVSCKASGYTFT G JZ WVRQAPGQGLEWMG WINPQSGGTNYAQKFQG RVTMTRDTSISTAYMELSRLRSDDTAVYYCAR EGGEWLAIPFDY WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVD GVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:55);
[1211] This includes the heavy chain variable region JS011-phage3-VH:
[1212] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPQSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGEWLAIPFDYWGQGTLVTVSS(SEQ ID NO:7);
[1213] According to the Kabat numbering system, they include:
[1214] HCDR1: GYYMH (SEQ ID NO: 1);
[1215] HCDR2:WINPQSGGTNYAQKFQG(SEQ ID NO:2);
[1216] HCDR3:EGGEWLAIPFDY(SEQ ID NO:3);
[1217] Light chain (JS011-phage3-LC, italics represent VL, underlines represent LCDR1, LCDR2 and LCDR3 in sequence):
[1218] ELELTQPPSVSVSPGQTASITC SADKLGDKYAS WYQQKPGQSPVLVLY EDSKRPS GIPERISGSNSGNTATLTIRGTQPMDEADYYC QTWDTNTVL FGGGTRLTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:56);
[1219] This includes the light chain variable region JS011-phage3-VL:
[1220] ELELTQPPSVSVSPGQTASITCSADKLGDKYASWYQQKPGQSPVLVLYEDSKRPSGIPERISGSNSGNTATLTIRGTQPMDEADYYCQTWDTNTVLFGGGTRLTVL(SEQ ID NO:8);
[1221] According to the Kabat numbering system, they include:
[1222] LCDR1:SADKLGDKYAS(SEQ ID NO:4);
[1223] LCDR2: EDSKRPS (SEQ ID NO: 5);
[1224] LCDR3: QTWDTNTVL (SEQ ID NO: 6).
[1225] The amino acid sequence of antibody JS011-phage6 is as follows:
[1226] Heavy chain (JS011-phage6-HC, italics represent VH, underlines represent HCDR1, HCDR2 and HCDR3 in sequence):
[1227] QVQLVQSGAEVKKPGASVKVSCKASGYTFT QUR WARQAPGQGLEWMG WINPNSGGTNYAQKFQG RVTMTRDTSISTAYMELSRLRSDDTAVYYCAR DKAGADYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQID NO:57);
[1228] This includes the heavy chain variable region JS011-phage6-VH:
[1229] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGQYIHWARQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDKAGADYWGQGTLVTVSS (SEQ ID NO: 58);
[1230] According to the Kabat numbering system, they include:
[1231] HCDR1: GQYIH (SEQ ID NO: 59);
[1232] HCDR2:WINPNSGGTNYAQKFQG(SEQ ID NO:60);
[1233] HCDR3:DKAGADY(SEQ ID NO:61);
[1234] Light chain (JS011-phage6-LC, italics represent VL, underlines represent LCDR1, LCDR2 and LCDR3 in sequence):
[1235] ELALTQPPSVSGSPGQSITISC TGTSSDIGGYDYVS WYQQYPGKAPKLMIS GVSNRPS GVSNRFSGSSKSGNTASLIISGLQAEDEGDYYC SSYTSRSTRWVFGGGTKLTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:62);
[1236] This includes the light chain variable region JS011-phage6-VL:
[1237] ELALTQPPSVSGSPGQSITISCTGTSSDIGGYDYVSWYQQYPGKAPKLMISGVSNRPSGVSNRFSGSSKSGNTASLIISGLQAEDEGDYYCSSYTSRSTRWVFGGGTKLTVL(SEQ ID NO:63);
[1238] According to the Kabat numbering system, they include:
[1239] LCDR1:TGTSSDIGGYDYVS(SEQ ID NO:64);
[1240] LCDR2:GVSNRPS(SEQ ID NO:65);
[1241] LCDR3: SSYTSRSTRWV (SEQ ID NO: 66).
[1242] Experimental Example 3: Binding ability detection of anti-4-1BB antibody
[1243] Elisa detects the ability of candidate antibodies to bind to 4-1BB protein.
[1244] Thermo Scientific microplate reader was used to coat the plate with a fixed concentration of human 4-1BB containing a His tag (the 4-1BB extracellular domain sequence was fused to a His tag to construct an expression plasmid, and the expression was purified by transient transfection of 293 cells) or mouse 4-1BB containing a His tag (manufacturer Sino Biological, catalog number 50811-M08H) antigen (1.0 μg / mL). After blocking with 2% BSA, gradient dilutions of JS011 antibodies JS011-phage3 and JS011-phage6 were added (binding to human 4-1BB: 1 μg / ml starting, 3-fold gradient dilution, a total of 12 concentrations; binding to mouse 4-1BB: 1 μg / ml starting, 2.5-fold gradient dilution, a total of 12 concentrations); mouse anti-human IgG4Fc HRP (Southern Biotech, 9200-05) was diluted 5000 times as the detection antibody for detection, and then 0.1 mg / ml TMB (3,3',5,5'-tetramethylbenzidine) was used for color development, and the reaction was terminated with 2M HCl. The plate was read at 450nm / 620nm. The half-maximal effect concentration (EC) was fitted using a four-parameter logistic regression (4PL) model. 50 Anti-KLH-IgG4 (CB25772663, or constructing expression plasmids with the heavy and light gene sequences encoding anti-hemocyanin KLH human IgG4 antibodies, and expressing and purifying them by transient transfection of CHO-18 cells) was used as a negative control.
[1245] The binding curves of JS011-phage3 and JS011-phage6 with human 4-1BB are shown in Figure 2. Fig.18 The binding curves of JS011-phage3 and JS011-phage6 with mouse 4-1BB are shown in Fig.19 As shown. Fig.18 It can be seen that JS011-phage3 and JS011-phage6 can bind to human 4-1BB with similar binding activity. 50 1.5ng / ml and 1.6ng / ml respectively; Fig.19 As can be seen, JS011-phage3 can bind to mouse 4-1BB, EC 50 At 6.1 ng / ml, JS011-phage6 does not bind to mouse 4-1BB.
[1246] Experimental Example 4: Binding of anti-4-1BB antibody to Jurkat NFKB 4-1BB cells
[1247] Jurkat NFKB 4-1BB cells (stable expression of 4-1BB, NFKB fused to luciferase reporter gene to construct expression plasmid, and electro-transfected into Jurkat cells, pressure screening to obtain Jurkat cells stably expressing NFKB, named Jurkat NFKB cells. Then the full-length 4-1BB gene was constructed into expression plasmid, electro-transfected into Jurkat NFKB cells, and pressure screening to obtain Jurkat NFKB 4-1BB stably expressing 4-1BB) were incubated with different concentrations of anti-4-1BB monoclonal antibodies JS011-phage3 and JS011-phage6 (starting concentration of 100 μg / ml, 3-fold dilution, a total of 12 concentration gradients) at 4°C for 30 minutes, then washed and incubated with fluorescein PE-labeled anti-human IgG secondary antibody (SouthernBiotech, Cat#2040-09) at 4°C in the dark for 30 minutes. Finally, the cells were collected by flow cytometry (BD CantoⅡ) to detect the fluorescent antibodies bound to the cell surface. The raw data were analyzed by FlowJo to obtain the MFI value (denoted as MFI-PE), and the antibody dose-dependent binding curve was fitted by GraphPad. The results are shown in Fig. 20 As shown, and calculate EC 50 The positive controls were Urelumab (BMS control antibody, see patent CN1867585B) and Utomilumab (Pfizer control antibody, see patent CN103221428B) antibodies; the negative control was Anti-KLH-IgG4.
[1248] like Fig. 20 As shown in Figure 2, JS011-phage3, JS011-phage6, Urelumab, and Utomilumab antibodies can bind to 4-1BB on the surface of Jurkat NFKB 4-1BB cells with high affinity. 50 They were 3.442 μg / mL, 6.961 μg / mL, 1.532 μg / mL and 0.01656 μg / mL respectively.
[1249] Experimental Example 5: Anti-4-1BB antibody blocks the binding of 4-1BB ligand (4-1BBL) to Jurkat NFKB 4-1BB cells
[1250] Jurkat NFKB 4-1BB cells were incubated with different concentrations of anti-4-1BB monoclonal antibodies JS011-phage3 and JS011-phage6 (starting concentration of 100 μg / ml, 3-fold dilution, a total of 12 concentration gradients) and 2 μg / ml biotin-labeled 4-1BBL-hFc (4-1BB ligand, 4-1BBL extracellular domain sequence fused to human FC (hFC) sequence to construct expression plasmid, and then transiently transfected CHO-18 cells to express and purify) at 4°C for 30 minutes, then washed and incubated with fluorescein FITC-labeled secondary antibody (BioLegend, Cat#405202) at 4°C in the dark for 30 minutes. Finally, cells were collected by flow cytometry (BD CantoⅡ) to detect fluorescent antibodies bound to the cell surface. The raw data were analyzed by FlowJo to obtain the MFI value (denoted as MFI-FITC), and the antibody dose-dependent inhibition curve was fitted by GraphPad and the IC was calculated. 50 , the results are as follows Fig.21 As shown, the positive controls are Urelumab (BMS control antibody, see patent CN1867585B) and Utomilumab (Pfizer control antibody, see patent CN103221428B); the negative control is Anti-KLH-IgG4.
[1251] like Fig.21 As shown in the figure, JS011-phage3, JS011-phage6, and Urelumab antibodies cannot block the binding of 4-1BBL to 4-1BB on the surface of Jurkat NFKB 4-1BB cells, while Utomilumab can effectively block the binding of 4-1BBL to 4-1BB on the surface of Jurkat NFKB 4-1BB cells. 50 It is 0.3431μg / ml.
[1252] Experimental Example 6: Anti-4-1BB antibody in luciferase reporter gene system (CHO FCGR2B 4G6 / Jurkat NFKB Activity detection in 4-1BB double cells
[1253] CHO FCGR2B 4G6 cells (human CD32B is stably expressed, and the CD32B gene is constructed into an expression plasmid and electroporated into CHO-K1 cells. Monoclonal cells that stably express CD32B are obtained by pressure screening and named CHO FCGR2B 4G6 cells) were plated at 3×10 4 The cells were added to a 96-well flat-bottom white plate (Corning, Cat#3917) and incubated overnight at 37°C. The next day, effector cells Jurkat NFKB 4-1BB (stable expression of NlucP / NFKB-RE and 4-1BB) were added at 1×10 per well. 5The number of cells was added to the cell plate. Then, the anti-4-1BB monoclonal antibodies JS011-phage3 and JS011-phage6 (starting concentration of 25 μg / ml, 4-fold dilution, a total of 9 concentration gradients) were added to the cell plate using experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixture system and the chemiluminescent signal (denoted as RLU) was detected using a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the EC 50 Value, the result is Fig. 22 The positive controls are Urelumab (BMS control antibody, see patent CN1867585B) and Utomilumab (Pfizer control antibody, see patent CN103221428B).
[1254] like Fig. 22 As shown in Figure 2, JS011-phage3, JS011-phage6, Urelumab and Utomilumab have strong T cell activation activity in the luciferase reporter gene system composed of CHOFCGR2B4G6 cells and effector cells Jurkat NFKB 4-1BB. 50 The concentrations of JS011-phage3 and Utomilumab were 0.03888μg / mL, 0.4499μg / mL, 1.038μg / mL and 0.02391μg / mL, respectively. The activity of JS011-phage3 was comparable to that of Utomilumab. The activity of JS011-phage6 was comparable to that of Urelumab, and the ability of JS011-phage3 to activate T cells was stronger than that of JS011-phage6.
[1255] Experimental Example 7: Anti-4-1BB antibody in luciferase reporter gene system (THP-1 / Jurkat NFKB 4-1BB double cell Activity detection in cells
[1256] THP-1 cells (a human myeloid leukemia mononuclear cell, CD32B positive) and effector Jurkat NFKB4-1BB (stable expression of NlucP / NFKB-RE and 4-1BB) were respectively cultured at 5×10 4 The number of cells per well was 1×10 5The number of cells was added to a 96-well flat-bottom white plate (Corning, Cat#3917). Then, the anti-4-1BB monoclonal antibodies JS011-phage3 and JS011-phage6 (starting concentration of 100 μg / ml, 4-fold dilution, a total of 10 concentration gradients) were added to the cell plate using an experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixed system and the chemiluminescent signal (denoted as RLU) was detected using a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the EC 50 Value, the result is Fig.23 The positive controls are Urelumab (BMS control antibody, see patent CN1867585B) and Utomilumab (Pfizer control antibody, see patent CN103221428B).
[1257] like Fig.23 As shown in Figure 2, JS011-phage3, JS011-phage6, Urelumab, and Utomilumab have strong T cell activation activity in the luciferase reporter gene system composed of THP-1 cells and effector cells Jurkat NFKB 4-1BB. 50 They were 0.006642 μg / mL, 0.2826 μg / mL, 218.6 μg / mL and 0.04173 μg / mL respectively.
[1258] Experimental Example 8: Anti-4-1BB antibody in luciferase reporter gene system (Raji / JurkatNFKB4-1BB dual cell line Activity detection in Raji / Jurkat NFKB cells
[1259] Raji cells (a type of human myeloid leukemia mononuclear cell, CD32B positive, 4-1BBL positive) were cultured at 5×10 4 1×10 cells were added into 96-well flat-bottom white plates (Corning, Cat#3917). Jurkat NFKB 4-1BB cells (stable expression of NlucP / NFKB-RE and 4-1BB) or Jurkat NFKB cells (stable expression of NlucP / NFKB-RE) were added into each well at 1×10 5The number of cells was added to the cell plate. Then, the anti-4-1BB monoclonal antibodies JS011-phage3 and JS011-phage6 (starting concentration of 100 μg / ml, 4-fold dilution, a total of 10 concentration gradients) were added to the cell plate using experimental buffer (RPMI 1640 (1×) + 2% FBS) and incubated in a 37°C incubator for 4-6 hours. Finally, Nano-Glo luciferase detection reagent (Promega) was added to the cell-antibody mixture system and the chemiluminescent signal (denoted as RLU) was detected using a multifunctional microplate reader (TECAN M1000pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the EC 50 The results are as follows Fig.24 and Fig.25 Among them, the positive controls are Urelumab (BMS control antibody, see patent CN1867585B) and Utomilumab (Pfizer control antibody, see patent CN103221428B).
[1260] like Fig.24 As shown in the figure, JS011-phage3, JS011-phage6 and Urelumab have the activity of activating T cells in the luciferase reporter gene system composed of Raji cells and effector cells Jurkat NFKB 4-1BB (4-1BB high expression), EC 50 They were 9.446 μg / mL, 2.713 μg / mL and 7.240 μg / mL respectively. Utomilumab blocked the 4-1BBL binding effect in this system, resulting in decreased activity.
[1261] like Fig.25 As shown, in the luciferase reporter gene system composed of Raji cells and effector cells Jurkat NFKB (4-1BB low expression), JS011-phage3 and Urelumab respectively synergized with 4-1BBL on the surface of Raji cells to activate T cells, EC 50 The concentrations of JS011-phage6 and Utomilumab were 9.450 μg / mL and 86.01 μg / mL, respectively. JS011-phage6 and Utomilumab were inactive in this system.
[1262] Experimental Example 9: Study on cytokine storm caused by anti-4-1BB antibody
[1263] PBMCs from two different volunteers (volunteer 1 ID#: LP191225, volunteer 2 ID#: LP190812) were plated at 3×10 5The number of cells was added to a 96-well round-bottom plate, and then the anti-4-1BB monoclonal antibodies JS011-phage3, JS011-phage6, Urelumab and Utomilumab were added to the cell plate at a concentration of 10 μg / mL. After incubation at 37°C, 5% CO2 for 24 hours, the supernatant was collected by centrifugation and the release of IL-2, IL-4, IL-6, IL-10, TNFα and IFNγ cytokines was detected using BD CBA human Th1 / Th2cytokine kitⅡ. The results are shown in FIG. 26A to FIG. 26F The positive control was OKT3 antibody (obtained from a hybridoma deposited in the American Type Culture Collection under accession number ATCC CRL 8001); the negative control was Anti-KLH-IgG4.
[1264] like FIG. 26A to FIG. 26F As shown, at a concentration of 10 μg / mL, JS011-phage3, JS011-phage6, Urelumab and Utomilumab did not cause cytokine storm.
[1265] Experimental Example 10: Inhibitory effect of anti-4-1BB antibody on the growth of MC38 tumors transplanted into h41BB humanized mice
[1266] 1. Test Purpose
[1267] The anti-tumor effect of the anti-4-1BB monoclonal antibody of the present application was evaluated in the h41BB humanized mouse transplanted mouse colon cancer MC38 subcutaneous tumor model.
[1268] 2. Testing process
[1269] Female h41BB humanized mice aged 6-8 weeks (purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.) were inoculated subcutaneously on the right back with 1×10 6 MC38 cells. The average tumor volume is about 90mm 3 When the tumor volume was quantified, appropriate animals were selected and randomly divided into 5 groups, with 6 animals in each group.
[1270] 1. Normal saline control group (solvent control group);
[1271] Treatment Group:
[1272] 2. Urelumab (1 mg / kg body weight) group;
[1273] 3. Utomilumab (1 mg / kg body weight) group;
[1274] 4. JS011-phage3 (1 mg / kg body weight) group and
[1275] 5. JS011-phage6 (1 mg / kg body weight) group.
[1276] Intraperitoneal injection, twice a week, for 3 consecutive weeks, the experiment was terminated 4 days after the last administration. Tumor volume and body weight were measured twice a week, and the mouse weight and tumor volume were recorded. At the end of the experiment, the mice were euthanized, and the tumor inhibition rate TGI (%) was calculated = [1-(Ti-T0) / (Vi-V0)] × 100%. (Ti: mean tumor volume of the treatment group on the i-th day of administration, T0: mean tumor volume of the treatment group on the 0th day of administration; Vi: mean tumor volume of the solvent control group on the i-th day of administration, V0: mean tumor volume of the solvent control group on the 0th day of administration).
[1277] like Fig. 27 As shown in Figure 2, on day 20 after administration, the average tumor volume in the saline control group was 2213 mm 3 The average tumor volume of the Urelumab (BMS, see patent CN1867585B) group was 430 mm 3 Compared with the saline control group, the tumor growth was significantly inhibited, with a tumor inhibition rate of 83.9%; the average tumor volume of the Utomilumab (Pfizer, see patent CN103221428B) group was 1937mm 3 No significant tumor inhibition was observed, with a tumor inhibition rate of 13.0%; the average tumor volume of the JS011-phage3 group was 506 mm 3 , significantly inhibited tumor growth, with a tumor inhibition rate of 64.7%; the average tumor volume of the JS011-phage6 group was 674mm 3 , significantly inhibited tumor growth, with a tumor inhibition rate of 50.6%. The results showed that in the h41BB humanized mouse transplanted MC38WT model, at a dose level of 1 mg / kg, both JS011-phage3 and JS011-phage6 showed significant tumor inhibition effects.
[1278] Experimental Example 11: Study on the toxicity of anti-4-1BB antibody to h41BB humanized mice transplanted with MC38 tumors
[1279] 1. Test Purpose
[1280] The toxicity of the anti-4-1BB monoclonal antibody of the present application was evaluated in h41BB humanized mice transplanted with subcutaneous tumors of mouse colon cancer MC38 cells.
[1281] 2. Testing process
[1282] Female h41BB humanized mice aged 6-8 weeks (purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.) were inoculated subcutaneously on the right back with 1×10 6MC38 cells. The average tumor volume is about 115mm 3 When the tumor volume was quantified, appropriate animals were selected and randomly divided into 5 groups, with 6 animals in each group.
[1283] 1. Anti-KLH-IgG4 (labeled as Anti KLH hIgG4 in the figure, negative control group);
[1284] Treatment Group:
[1285] 2. JS011-phage3 (10 mg / kg body weight) group;
[1286] 3. JS011-phage6 (10 mg / kg body weight) group;
[1287] 4. Urelumab (10 mg / kg body weight) group and
[1288] 5. Utomilumab (10 mg / kg body weight) group.
[1289] Intraperitoneal injection, twice a week, three times in a row, euthanasia 7 days after the last administration. Weigh the spleen of mice. Collect the liver of mice, and detect the CD3 + 、CD3 + CD4 + 、CD3 + CD8 + 、CD3 + CD8 + CD11c + and CD3 - NK1.1 + Cell ratio to observe the in vivo toxicity of anti-4-1BB monoclonal antibody.
[1290] like Fig.28 As shown, on the 14th day after administration, compared with the Anti KLH hIgG4 negative control group, the spleen weight of mice in the Urelumab (BMS, see patent CN1867585B) group increased significantly, while the spleen weight of mice in the JS011-phage3 group, JS011-phage6 group and Utomilumab (Pfizer, see patent CN103221428B) group did not change significantly. This shows that 10 mg / kg of Urelumab can cause splenomegaly in mice, while JS011-phage3 and JS011-phage6 will not cause splenomegaly in animals. This result suggests that JS011-phage3 and JS011-phage 6 of the present application will not cause excessive activation of immune cells in the spleen, and may have better safety in clinical practice.
[1291] like Fig.29A As shown, the number of lymphocytes per unit weight of the liver was analyzed on the 14th day after administration. Compared with the AntiKLH hIgG4 negative control group, the number of lymphocytes in the liver of mice in the JS011-phage3 group, JS011-phage6 group, Utomilumab group and Urelumab group increased, and the number of lymphocytes in the liver of mice in the Urelumab group was significantly higher than that in the JS011-phage3 group, JS011-phage6 group and Utomilumab group, indicating that 10 mg / kg of Urelumab will lead to a significant increase in the number of lymphocytes in the liver of mice. FIG. 29B to FIG. 29E As shown, the changes in the proportions of different hepatic lymphocyte subsets were analyzed on the 14th day after administration. Compared with the Anti KLH hIgG4 negative control group, the CD3 + CD4 + The proportion of T cells decreased, CD3 + CD8 + The proportion of T cells increased and CD3 + CD8 + The proportion of T cells in the liver of mice in the Urelumab group was significantly higher than that in the JS011-phage3 group, JS011-phage6 group, and Utomilumab group. + CD8 + CD11c + The proportion of T cells increased significantly, indicating that there was over-activated CD3 in the liver of mice in the Urelumab group. + CD8 + The proportion of T cells increased significantly, while the CD3 - NK1.1 + The proportion of NK cells in the liver of mice was reduced, indicating that 10 mg / kg Urelumab would cause CD3 + CD8 + The proportion of T cells increased significantly. The increase in the number of lymphocytes in the mouse liver is due to CD3 + CD8 + The absolute number of T cells increased significantly, and CD3 + CD4 + The absolute number of T and NK cells increased, but due to CD3 + CD8 + The proportion of T cells increased significantly, leading to CD3 + CD4 +The proportion of T and NK cells decreased. + CD8 + Judging from the absolute and relative values of T cells in the liver, JS011-phage3 and JS011-phage6 are significantly better than Urelumab, suggesting that they may have lower liver toxicity in clinical practice.
Claims
1. A bispecific antibody comprising a first protein functional region and a second protein functional region, wherein: The first protein functional region is an anti-4-1BB antibody or an antigen-binding fragment thereof, The second protein functional region is an antibody or an antigen-binding fragment thereof that targets a target different from 4-1BB, Wherein, the anti-4-1BB antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 with an amino acid sequence as shown in SEQ ID NO: 1, HCDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and HCDR3 with an amino acid sequence as shown in SEQ ID NO: 3, and the light chain variable region comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 4, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 5, and LCDR3 with an amino acid sequence as shown in SEQ ID NO:
6.
2. The bispecific antibody according to claim 1, wherein The amino acid sequence of the heavy chain variable region of the anti-4-1BB antibody is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
8.
3. The bispecific antibody according to any one of claims 1 to 2, wherein: The second protein functional region is an anti-PD-L1 antibody or an antigen-binding fragment thereof, or an anti-PD-1 antibody or an antigen-binding fragment thereof.
4. The bispecific antibody according to claim 3, wherein the anti-PD-L1 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising HCDR1 with an amino acid sequence as shown in SEQ ID NO: 31, HCDR2 with an amino acid sequence as shown in SEQ ID NO: 32, and HCDR3 with an amino acid sequence as shown in SEQ ID NO: 33, and the light chain variable region comprises LCDR1 with an amino acid sequence as shown in SEQ ID NO: 34, LCDR2 with an amino acid sequence as shown in SEQ ID NO: 35, and LCDR3 with an amino acid sequence as shown in SEQ ID NO:
36.
5. The bispecific antibody according to any one of claims 3 to 4, wherein: The amino acid sequence of the heavy chain variable region of the anti-PD-L1 antibody is shown in SEQ ID NO:37, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
38.
6. The bispecific antibody according to any one of claims 1 to 5, wherein: The anti-4-1BB antibody and / or the antibody targeting a target different from 4-1BB further independently comprises a human heavy chain constant region and a human light chain constant region, and the human heavy chain constant region is independently selected from the heavy chain constant region of human IgG1, human IgG2, human IgG3 or human IgG4; Preferably, the human light chain constant region is independently selected from the light chain constant region of a lambda light chain or a kappa light chain; Preferably, the human heavy chain constant region is the heavy chain constant region of human IgG4 and has the following mutations: (1) S267A or S267C; and (2) L328A or L328N; Preferably, it also has any one, two or three mutations selected from the following (3): (3) S268A, S268Q, D270C, P329S and S330T.
7. The bispecific antibody according to any one of claims 1 to 6, wherein: The anti-4-1BB antibody and / or the antibody targeting a target other than 4-1BB further independently comprises an Fc domain of human IgG1, human IgG2, human IgG3 or human IgG4.
8. The bispecific antibody according to claim 7, wherein The amino acid sequence of the Fc domain is shown in any one of SEQ ID NO: 9 to SEQ ID NO: 17, and SEQ ID NO: 67 to SEQ ID NO: 75; Preferably, the amino acid sequence of the heavy chain of the anti-4-1BB antibody is as shown in any one of SEQ ID NO: 18 to SEQ ID NO: 26, and SEQ ID NO: 76 to SEQ ID NO:
84.
9. The bispecific antibody according to any one of claims 1 to 8, wherein: The antigen binding fragment is independently selected from VHH, Fab, scFv and sdAb.
10. The bispecific antibody according to any one of claims 1 to 9, wherein: The first protein functional region and the second protein functional region are directly connected or connected through a connecting fragment; Preferably, the linker fragment is (GGGGS)n, where n is 1, 2, 3, 4 or 5.
11. The bispecific antibody according to any one of claims 1 to 10, wherein: Among them, The first protein functional region and the second protein functional region are independently 1, 2 or more than 2.
12. The bispecific antibody according to any one of claims 1 to 11, wherein: The first protein functional region is an anti-4-1BB antibody, and the second protein functional region is a VHH, Fab, scFv or sdAb targeting PD-L1; or The first protein functional region is a VHH, Fab, scFv or sdAb targeting 4-1BB, and the second protein functional region is an anti-PD-L1 antibody.
13. The bispecific antibody according to any one of claims 1 to 12, wherein: The bispecific antibody is in the form of IgG-scFv.
14. The bispecific antibody according to any one of claims 1 to 13, wherein: The first protein functional region is a scFv targeting 4-1BB, and the second protein functional region is an anti-PD-L1 antibody. The number of the first protein functional regions is 2, and the number of the second protein functional region is 1; The scFv comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, and HCDR3 as shown in SEQ ID NO: 3, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; The anti-PD-L1 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO:31, HCDR2 as shown in SEQ ID NO:32, and HCDR3 as shown in SEQ ID NO:33, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO:34, LCDR2 as shown in SEQ ID NO:35, and LCDR3 as shown in SEQ ID NO:36; The scFvs are respectively connected to the C-termini of the two heavy chains of the anti-PD-L1 antibody.
15. The bispecific antibody according to any one of claims 1 to 14, wherein: The first protein functional region is a scFv targeting 4-1BB, and the second protein functional region is an anti-PD-L1 antibody. The number of the first protein functional regions is 2, and the number of the second protein functional region is 1; The amino acid sequence of the heavy chain variable region of the scFv is shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region of the scFv is shown in SEQ ID NO: 8; The amino acid sequence of the heavy chain variable region of the anti-PD-L1 antibody is shown in SEQ ID NO: 37, and the amino acid sequence of the light chain variable region thereof is shown in SEQ ID NO: 38; The scFvs are respectively connected to the C-termini of the two heavy chains of the anti-PD-L1 antibody.
16. An isolated polynucleotide encoding the bispecific antibody of any one of claims 1 to 15.
17. A recombinant expression vector comprising the isolated polynucleotide according to claim 16; preferably, the recombinant expression vector is a recombinant eukaryotic expression vector.
18. A recombinant host cell comprising the isolated polynucleotide of claim 16 or the recombinant expression vector of claim 17; preferably, the recombinant host cell is a recombinant mammalian cell.
19. Use of the bispecific antibody according to any one of claims 1 to 15 in the preparation of a medicament for treating and / or preventing a disease or condition associated with 4-1BB and / or PD-L1 activity; preferably, the disease or condition is cancer.
20. The use according to claim 19, wherein The cancer is selected from one or more of lymphoma, myeloma, ovarian cancer, breast cancer, urothelial cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer and blood cancer.
21. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 1 to 15, and a pharmaceutically acceptable carrier or excipient.
22. The pharmaceutical composition according to claim 21, wherein the concentration of the bispecific antibody is 0.1-100 mg / mL, preferably 0.2-50 mg / mL, more preferably 0.5-30 mg / mL, more preferably 5-25 mg / mL, more preferably 10-20 mg / mL.
23. The pharmaceutical composition according to any one of claims 21 to 22, wherein the pH of the pharmaceutical composition is 4.5 to 7.5, preferably 4.8 to 6.0, and more preferably 5.0 to 5.
5.
24. The pharmaceutical composition according to any one of claims 21 to 23, wherein the osmotic pressure of the pharmaceutical composition is in the range of 250 to 350 mOsm / kg; preferably in the range of 260 to 320 mOsm / kg, more preferably in the range of 290 to 310 mOsm / kg.
25. The pharmaceutical composition according to any one of claims 21 to 24, comprising a buffer, the buffer being selected from one or more of an acetate buffer, a histidine buffer, a citrate buffer and a phosphate buffer; preferably, the buffer is an acetate buffer or a citrate buffer; preferably, the buffer is a citrate buffer; preferably, the concentration of the buffer is 5 to 50 mM; more preferably, the concentration of the buffer is 10 to 30 mM; preferably, the pH of the buffer is 4.5 to 7.5, preferably 4.8 to 6.0, more preferably 5.0 to 5.8, more preferably 5.2 to 5.
5.
26. The pharmaceutical composition according to any one of claims 21 to 25, wherein the pharmaceutical composition further comprises a stabilizer, wherein the stabilizer is any one of sodium chloride, arginine hydrochloride, mannitol, sucrose and trehalose, or the stabilizer is a combination of multiple thereof; preferably, the concentration of the stabilizer is 10-300 mM, preferably 20-295 mM, 50-290 mM, 80-285 mM or 120-280 mM, more preferably 20-280 mM or 120-250 mM.
27. The pharmaceutical composition according to claim 26, wherein the stabilizer is selected from any one of the following (1) to (8): (1) sodium chloride, at a concentration of 120 to 280 mM, preferably at a concentration of 120 to 160 mM; (2) arginine hydrochloride at a concentration of 120 to 280 mM, preferably 120 to 160 mM; (3) mannitol, at a concentration of 120 to 280 mM, preferably at a concentration of 200 to 250 mM; (4) sucrose, at a concentration of 120 to 280 mM, preferably, at a concentration of 200 to 250 mM; (5) trehalose, at a concentration of 120 to 280 mM, preferably, at a concentration of 200 to 250 mM; (6) A combination of sucrose and mannitol, wherein the concentration of sucrose is 100-180 mM, and the concentration of mannitol is 60-120 mM; preferably, wherein the concentration of sodium chloride is 120-160 mM, and the concentration of mannitol is 80-100 mM.
28. A pharmaceutical composition according to any one of claims 21 to 27, wherein the pharmaceutical composition further comprises a surfactant selected from one or more of polysorbate 80, polysorbate 20 and poloxamer 188; preferably, calculated on a w / v basis, the concentration of the surfactant is 0.005% to 0.1%, more preferably, the concentration of the surfactant is 0.01% to 0.08%, more preferably, the concentration of the surfactant is 0.01% to 0.04%.
29. The pharmaceutical composition according to any one of claims 21 to 28, comprising the components as shown in any one of the following (1) to (25): (1) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or (2) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or (3) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM histidine buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or (4) (a) 0.2-50 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM phosphate buffer, pH 4.5-7.5; (c) 120-280 mM sucrose; and (d) 0.01%-0.08% polysorbate 80; or (5) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 200-250 mM sucrose; and (d) 0.01%-0.04% polysorbate 80; or (6) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 200-250 mM trehalose; and (d) 0.01%-0.04% polysorbate 80; or (7) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 120-200 mM sodium chloride; and (d) 0.01%-0.04% polysorbate 80; or (8) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM acetate buffer, pH 4.8-6.0; (c) 120-200 mM arginine hydrochloride; and (d) 0.01%-0.04% polysorbate 80; or (9) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 200-250 mM sucrose; and (d) 0.01%-0.04% polysorbate 80; or (10) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 200-250 mM trehalose; and (d) 0.01%-0.04% polysorbate 80; or (11) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 120-200 mM sodium chloride; and (d) 0.01%-0.04% polysorbate 80; or (12) (a) 0.5-30 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10-30 mM citric acid buffer, pH 4.8-6.0; (c) 120-200 mM arginine hydrochloride; and (d) 0.01%-0.04% polysorbate 80; or (13) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or (14) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM sucrose; and (d) 0.04% polysorbate 80; or (15) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM trehalose; and (d) 0.02% polysorbate 80; or (16) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 150 mM sodium chloride; and (d) 0.02% polysorbate 80; or (17) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 150 mM arginine hydrochloride; and (d) 0.02% polysorbate 80; or (18) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or (19) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM trehalose; and (d) 0.02% polysorbate 80; or (20) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 150 mM sodium chloride; and (d) 0.02% polysorbate 80; or (21) (a) 10 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 150 mM arginine hydrochloride; and (d) 0.02% polysorbate 80; or (22) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM acetate buffer, pH 5.1-5.3; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or (23) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 20 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or (24) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10 mM citric acid buffer, pH 5.3-5.7; (c) 230 mM sucrose; and (d) 0.02% polysorbate 80; or (25) (a) 20 mg / mL of the bispecific antibody targeting 4-1BB and PD-L1; (b) 10 mM citric acid buffer, pH 5.3-5.7; (c) 140 mM sucrose; (d) 90 mM mannitol; and (e) 0.02% polysorbate 80.
30. A lyophilized formulation of the pharmaceutical composition of any one of claims 21 to 29.
31. A reconstituted preparation obtained by reconstitution of the lyophilized preparation according to claim 30.
32. A liquid preparation, characterized in that The liquid preparation contains the pharmaceutical composition according to any one of claims 21 to 29, or contains a glucose solution or a sodium chloride solution and the reconstituted preparation according to claim 31; preferably, the concentration of the sodium chloride solution is 0.85-0.9% (w / v), and the concentration of the glucose solution is 5-25% (w / v); preferably, in the liquid preparation, the concentration of the bispecific antibody is 0.1-50 mg / mL, more preferably 0.2-20 mg / mL; more preferably 0.2-5 mg / mL; preferably, the pH of the liquid preparation is 5.0-7.0; preferably, the liquid preparation is an injection.
33. An anti-4-1BB antibody or an antigen-binding fragment thereof, wherein: The anti-4-1BB antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, and HCDR3 as shown in SEQ ID NO: 3, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; The anti-4-1BB antibody comprises a human heavy chain constant region and a human light chain constant region, wherein the human heavy chain constant region is selected from the heavy chain constant region of human IgG1, human IgG2, human IgG3 or human IgG4; Preferably, the human light chain constant region is independently selected from the light chain constant region of a lambda light chain or a kappa light chain; Preferably, the human heavy chain constant region is the heavy chain constant region of human IgG4 and has the following mutations: (1) S267A or S267C; and (2) L328A or L328N; Preferably, it also has any one, two or three mutations selected from the following (3): (3) S268A, S268Q, D270C, P329S and S330T.
34. The anti-4-1BB antibody or antigen-binding fragment thereof according to claim 33, wherein The amino acid sequence of the heavy chain variable region of the anti-4-1BB antibody is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
8.
35. The anti-4-1BB antibody or antigen-binding fragment thereof according to any one of claims 33 to 34, wherein The anti-4-1BB antibody comprises the Fc domain of human IgG1, human IgG2, human IgG3 or human IgG4; The amino acid sequence of the Fc domain is shown in any one of SEQ ID NO: 9 to SEQ ID NO: 17, and SEQ ID NO: 67 to SEQ ID NO:
75.
36. The anti-4-1BB antibody or antigen-binding fragment thereof according to any one of claims 33 to 35, wherein The amino acid sequence of the heavy chain of the anti-4-1BB antibody is shown in any one of SEQ ID NO: 18 to SEQ ID NO: 26, and SEQ ID NO: 76 to SEQ ID NO:
84.
37. The anti-4-1BB antibody or antigen-binding fragment thereof according to any one of claims 33 to 36, wherein The antigen binding fragment is independently selected from VHH, Fab, scFv and sdAb.
38. An isolated polynucleotide encoding the anti-4-1BB antibody or antigen-binding fragment thereof according to any one of claims 33 to 37.
39. A recombinant expression vector comprising the isolated polynucleotide according to claim 38; preferably, the recombinant expression vector is a recombinant eukaryotic expression vector.
40. A recombinant host cell comprising the isolated polynucleotide of claim 38 or the recombinant expression vector of claim 39; preferably, the recombinant host cell is a recombinant mammalian cell.
41. Use of the anti-4-1BB antibody or antigen-binding fragment thereof according to any one of claims 33 to 37 in the preparation of a medicament for treating and / or preventing a disease or condition associated with 4-1BB activity; preferably, the disease or condition is cancer.
42. The use according to claim 41, wherein The cancer is selected from one or more of lymphoma, myeloma, ovarian cancer, breast cancer, urothelial cancer, lung cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, cervical cancer, bladder cancer, thyroid cancer, endometrial cancer, melanoma, esophageal cancer and blood cancer.
43. A pharmaceutical composition comprising the anti-4-1BB antibody or antigen-binding fragment thereof according to any one of claims 33 to 37, and a pharmaceutically acceptable carrier or excipient.
